RUXOLITINIB FORMULATION FOR THE REDUCTION OF ICE IN ATOPIC DERMATITIS

Abstract

This invention relates to methods for reducing itching in patients with atopic dermatitis and to the treatment of patients with atopic dermatitis by administering a topical ruxolitinib cream at 0.75% or 1.5% twice a day.

Description

FORMULATION OF RUXOLITINIB FOR THE REDUCTION OF ITCH IN ATOPIC DERMATITIS FIELD OF THE INVENTION This invention relates to methods of reducing itching in patients with atopic dermatitis and to the treatment of patients with atopic dermatitis by administering topical ruxolitinib cream, including 0.75% or 1.5% ruxolitinib cream twice daily. . BACKGROUND OF THE INVENTION Atopic dermatitis affects approximately 10% of adults (Silverberg JI, Hanifin JM. J Allergy Clin Immunol 2013;132:1132-1138), is increasing in incidence, and costs $3.8 billion annually in direct medical costs alone (Ellis CN, et al. J Am Acad Dermatol 2 0 02; 46:361-370). According to the recent Global Burden of Disease project, atopic dermatitis (AD) worldwide is one of the 50 most prevalent diseases and has the second highest disability range of all non-malignant skin diseases (There is RJ, et al. J Invest Dermatol 2014;134:1527-1534). Despite advances in numerous targeted biologic treatments for psoriasis, there is currently only one such therapy for AD (Dupixent®). α^αζηη / ζζηζ / Β / γίΛΐ Ref. 332105 One of the main characteristics and diagnostic criteria of AD is pruritus (itching or stinging). Itching causes scratching, which in turn further damages the AD skin, aggravates the disease, and can lead to secondary infections. Furthermore, nighttime itching and scratching can lead to loss of sleep and impaired quality of life for patients and their immediate family members, for example, parents of a child with AD. Topical therapies for AD are limited to topical spheroids, topical calcineurin inhibitors, and more recently, a PDE4 inhibitor (Eucrisa®). These medications have any limitations related to their levels of efficacy, safety (particularly long-term use), or tolerability issues. The use of topical spheroids may also be associated with irreversible side effects, such as skin atrophy or striae distensae. The use of systemic glucocorticoids and calcineurin inhibitors is also limited due to their adverse event (AE) profiles. If current topical therapies fail, systemic immunosuppressive agents (e.g., cyclosporine, methotrexate) are occasionally used with highly variable efficacy and / or high risk of AD. It is important to note that none of the drugs Qfraznn / zznz / E / YiAi currently available exerts a direct effect on relieving itching. Therefore, new approaches are needed to quickly and effectively control pruritus in patients with AD. As mentioned, itch is the cardinal feature of AD and the symptom that directly leads to a high disease burden (quality of life) in this condition. This invention addresses this need and others. BRIEF DESCRIPTION OF THE INVENTION The present invention provides, among others, methods for reducing itch and treating human patients having atopic dermatitis using ruxolitinib. Ruxolitinib is a potent JAK1 / JAK2 inhibitor, (R)-3-(4(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-IH-pyrazol-l-yl)-3cyclopentylpropanenitrile (INCB018424; ruxolitinib ; active ingredient in JAKAFI®), and its pharmaceutically acceptable salts, has been previously described in US Patent No. 7,598,257, which is incorporated herein by reference in its entirety. Ruxolitinib phosphate was previously described in US Patent Publication No. 2008 / 0312259, which is incorporated herein by reference in its entirety. α^αζηη / ζζηζ / Β / γΐΛ ruxolitinib For example, methods are provided for treating atopic dermatitis in a human patient, wherein the method comprises administering to the skin of the human patient in need thereof, a cream formulation comprising ruxolitinib or a pharmaceutically acceptable salt thereof. In other examples, methods are provided for reducing itching in a human patient with atopic dermatitis, wherein the method comprises administering to the skin of the human patient in need thereof, a cream formulation comprising ruxolitinib or a pharmaceutically acceptable salt thereof, wherein the patient achieves a reduction in the itch Numerical Rating Scale score from baseline. The present invention also provides methods for reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation comprises 1.5% ( p / p) on a free base basis of ruxolitinib, or one of its pharmaceutically acceptable salts, where the patient achieves a reduction in the itch Numerical Rating Scale score from baseline. The present invention also provides methods of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation comprises 0.75% ( p / p) on a free base basis of ruxolitinib, or one of its pharmaceutically acceptable salts, where the patient achieves a reduction in the itch Numerical Rating Scale score from baseline. The present invention further provides methods for reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a twice daily (BID) cream formulation, wherein the cream formulation comprises 1.5% (w / w) on a ruxolitinib phosphate free base basis, where the patient achieved a reduction in the itch Numerical Rating Scale score from baseline. The present invention also provides methods for reducing itching in a human patient with dermatitis. atopic Qfraznn / zznz / E / YiAi, which comprise administering to the skin of the human patient in need, a cream formulation twice daily (BID), wherein the cream formulation comprises 0.75% (w / w) on a ruxolitinib phosphate free base base, wherein the patient achieves a reduction in the itch Numerical Rating Scale score from baseline. The present invention also provides methods of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice daily (BID), wherein the cream formulation comprises 0.75% (w / w) on a ruxolitinib phosphate free base basis, where the patient achieved a reduction in the itch Numerical Rating Scale score from baseline. The present invention further provides methods for treating atopic dermatitis in a human patient, comprising administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation comprises 0.75% (w / p) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. α^αζηη / ζζηζ / Β / γίΛΐ The present invention further provides methods for treating atopic dermatitis in a human patient, comprising administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation comprises 0.75% (w / p) on a ruxolitinib phosphate free base basis. The present invention also provides methods of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation is an emulsion of oil-in-water, comprising 1.5% (w / w) on a phosphate free base basis of ruxolitinib, wherein dosing is sustained for at least 8 weeks (e.g., for 12 weeks), wherein the patient achieves at minus a 4-point reduction in itch Numerical Rating Scale score from baseline at week 8 of dosing. The present invention also provides methods of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation is an emulsion of oil in water, comprising 0.75% (w / w) on an α^αζηη / ζζηζ / Β / γίΛΐ basis of ruxolitinib phosphate free base, wherein dosing is sustained for at least 8 weeks (eg, for 12 weeks), wherein the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of dosing. The present invention further provides methods for reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation is an emulsion of oil in water, comprising 1.5% (w / w) on a phosphate free base basis of ruxolitinib, where dosing is sustained for at least 8 weeks, where the patient achieves at least a 4-point reduction in Itch Numerical Rating Scale score from baseline at week 8 of dosing, and where the patient: are between the ages of 18 and 70, have been diagnosed with atopic dermatitis for at least 2 years, have a Global Assessment of QbQZnn / 77nZ / E / YIAI Investigator 2 to 3 at assessment and baseline, and has a Body Surface Area affected by atopic dermatitis (excluding face and intertriginous areas) of 3% to 20% at baseline. The present invention further provides methods for reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation is an emulsion of oil in water, comprising 0.75% (w / w) or 1.5% (w / w) on a phosphate free base basis of ruxolitinib, wherein dosing is sustained for at least 8 weeks, wherein the patient achieves at minus a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of dosing, and where the patient: is an adolescent > 12 to 17 years of age inclusive, or a male or female 1 to 18 years of age; have a history of AD for at least 2 years; has an Investigator Global Assessment score of 2 to 3 at baseline; and has a % BSA of AD involvement, excluding Qfraznn / zznz / E / YiAi the scalp, from 3% to 20% at the beginning of the study. The present invention also provides methods of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation is an emulsion of oil in water, comprising 1.5% (w / w) on a phosphate free base basis of ruxolitinib, where dosing is sustained for at least 8 weeks, where the patient achieves at least a 4-point reduction in Itch Numerical Rating Scale score from baseline at week 8 of administration, and where the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline. initial value 8 weeks after administration. The present invention also provides methods of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation is an emulsion of oil in water, comprising 0.75% (w / w) on a phosphate free base basis of ruxolitinib, where dosing is sustained for at least 8 weeks, α^αζηη / ζζηζ / Β / γίΛΐ where the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of dosing, and where the patient achieves an Investigator's Global Assessment score of 0 or 1 with a improvement of at least 2 points from baseline at 8 weeks after administration. The present invention further provides methods for reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation is an emulsion of oil in water, comprising 1.5% (w / w) on a phosphate free base basis of ruxolitinib, where dosing is sustained for at least 8 weeks, where the patient achieves at least a 4-point reduction in Itch Numerical Rating Scale score from baseline at week 8 of administration, where the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline initial at 8 weeks of administration, and Qfraznn / zznz / E / YiAi where the patient: is between the ages of 18 and 70, has been diagnosed with atopic dermatitis for at least 2 years, has an Investigator Global Assessment score of 2 to 3 at assessment and at baseline study, and has a Body Surface Area affected by atopic dermatitis (excluding face and intertriginous areas) of 3% to 20% at baseline. The present invention further provides methods for reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation is an emulsion of oil in water, comprising 0.75% (w / w) or 1.5% (w / w) on a phosphate free base basis of ruxolitinib, wherein dosing is sustained for at least 8 weeks, wherein the patient achieves at minus a 4-point reduction in itch Numerical Rating Scale score from baseline at week 8 of dosing, where the patient achieves an Investigator's Global Assessment score of 0 or 1 with improvement Qfraznn / zznz / E / YiAi of at least 2 points from baseline at 8 weeks after administration, and where the patient: is an adolescent between 12 and 17 years of age inclusive, or a man or woman > 18 years of age; have a history of AD for at least 2 years; has an Investigator Global Assessment score of 2 to 3 at baseline; and has a BSA % of AD involvement, excluding the scalp, of 3% to 20% at baseline. The present invention also provides methods for treating moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice a day, wherein the topical formulation comprises 0.75% (w / w) or 1.5% (w / w) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. The present invention also provides methods for treating moderate to severe atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice daily, wherein the topical formulation comprises 0.75% (w / p) or 1.5% (w / w) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. QbQZnn / 77nZ / E / YIAI The present invention also provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice a day, wherein the topical formulation comprises 0.75% (w / w) or 1.5 % (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof, where the patient has: an Eczema Area and Severity Index score of > 16 at baseline; and a Body Surface Area affected by atopic dermatitis of > 10% at the beginning of the study. The present invention further provides a topical formulation (e.g., a cream formulation) comprising 0.75% (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof, for use in any of the methods. described in this document. The present invention also provides a topical formulation (e.g., a cream formulation) comprising 1.5% (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof, for use in any of the methods. described in this document. The present invention further provides the use of a topical formulation (e.g., a cream formulation) comprising 0.75% (w / w) on a free base basis of ruxolitinib, or one of their pharmaceutically acceptable salts, for the manufacture of a medicament for use in any of the methods described herein. The present invention further provides the use of a topical formulation (e.g., a cream formulation) comprising 1.5% (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof, for the manufacture of a medication for use in any of the methods described herein. BRIEF DESCRIPTION OF THE FIGURES RUX in the figures is ruxolitinib phosphate. TAC in the figures is triamcinolone. Figure 1 shows a plot of the mean percent improvement from baseline in EASI scores for vehicle (BID), triamcinolone (0.1% BID), and ruxolitinib cream (0.15% QD, 0.5% QD, 1.5% QD, and 1.5% % BID) in week 2 (first bar graph of each set), week 4 (second bar graph of each set) and week 8 (third bar graph of each set). The 0.1% TAC does not show a bar because the TAC was only given for 4 weeks. Figure 2 shows a graph of the average percentage improvement from baseline in the Qfraznn / zznz / E / YiAi EASI scores for vehicle (BID), triamcinolone (0.1% BID), and ruxolitinib cream (1.5% BID) at week 2 (first bar of graph of each set), week 4 (second bar of graph of each series) and week 8 (third graphic bar of each series). The 0.1% TAC does not show a bar because the TAC was only given for 4 weeks. Figure 3 shows a graph of the percentage of EASI-75 responders (at least a 75% improvement in EASI from baseline) for vehicle (BID), triamcinolone (0.1% BID), and ruxolitinib cream (0.15% QD, 0.5% QD, 1.5% QD and 1.5% BID) in week 2 (first bar graph of each set), week 4 (second bar graph of each set) and week 8 (third bar graph of each set). The 0.1% TAC does not show a bar because the TAC was only given for 4 weeks. Figure 4 shows a graph of the IGA response proportion (a responder was a patient achieving an IGA score of 0-1 with an improvement of h 2 points from baseline) for vehicle (BID), triamcinolone (0.1% BID) and ruxolitinib cream (0.15% QD, 0.5% QD, 1.5% QD and 1.5% BID) at week 2 (first bar of graph of each set), week 4 (second bar of graph of each set) and week 8 (third bar graph of each set). The 0.1% TAC does not show a bar because the TAC alone was administered for 4 weeks. Figure 5 shows a plot of the mean percent improvement from baseline in EASI scores for vehicle, triamcinolone, and ruxolitinib cream at 12 weeks. The open-label period was from week 8 to week 12, where 1.5% ruxolitinib cream was administered. Figure 6 shows a plot of the IGA response ratio for vehicle, triamcinolone, and ruxolitinib cream at 12 weeks. The open label period was from week 8 to week 12, where 1.5% ruxolitinib cream was administered. Figure 7 shows a plot of the mean change from baseline in daily NRS itch scores (NRS score has a range of 0 to 10, where 0 is no itch and 10 is the worst possible itch) for the vehicle. (BID), triamcinolone (0.1% BID) and ruxolitinib cream (0.15% QD, 0.5% QD, 1.5% QD and 1.5% BID) in 28 days. Figure 8 shows a plot of the mean change from baseline in daily itch NRS scores for vehicle (BID), triamcinolone (01% BID), and ruxolitinib cream (15% BID) over 28 days. Figure 9 shows a plot of the mean NRS itch scores for vehicle, triamcinolone, and Qfraznn / zznz / E / YiAi ruxolitinib cream in 12 weeks. The open-label period was from week 8 to week 12, where ruxolitinib 1.5% cream was administered. Figure 10 shows a plot of the mean percent improvement from baseline in Skindex-16 overall score for vehicle (BID), triamcinolone (0.1% BID), and ruxolitinib cream (0.15% QD, 0.5% QD, 1.5 % QD and 1.5% BID) in week 2 (first bar graph of each set), week 4 (second bar graph of each set) and week 8 (third bar graph of each set). The 0.1% TAC does not show a bar because the TAC was only given for 4 weeks. ** indicates P<0.01 versus vehicle; *** indicates P<0.001 vs. vehicle, t indicates that the TAC group received 0.1% TAC cream until week 4 and vehicle thereafter. Figure 11 shows the proportion of participants achieving IGA-TS in the vehicle control period at Week 2, Week 4, and Week 8 for TRuE-ADl (Study 303) (solid bars) and TRuE-AD2 (Study 304) (hatched bars) for vehicle, ruxolitinib cream 0.75% BID and ruxolitinib cream 1.5% BID (the first bar in each set is vehicle; the second bar in each set is ruxolitinib cream 0.75% BID; and the third bar in each set is ruxolitinib cream 1.5%). QbQZnn / 77nZ / E / YIAI Figure 12 shows the proportion of participants achieving EASI75 in the vehicle control period at Week 2, Week 4 and Week 8 for TRuE-ADl (Study 303) (filled bars) and TRuE-AD2 (Study 304) (hatched bars) for vehicle, ruxolitinib cream 0.75% BID, and ruxolitinib cream 1.5% BID (the first bar in each set is vehicle; the second bar in each set is ruxolitinib cream 0.75% BID; and The third bar in each set is ruxolitinib cream 1.5%). Figure 13 shows the proportion of participants who achieved an h 4-point improvement in NRS itch score in the vehicle control period at Week 2, Week 4, and Week 8 for TRuE-ADl (Study 303) ( solid bars) and TRuE-AD2 (Study 304) (hatched bars) for vehicle, ruxolitinib cream 0.75% twice daily and ruxolitinib cream 1.5% twice daily for patients with baseline itch NRS > 4 (the first bar of each set is vehicle; second bar of each set is ruxolitinib 0.75% twice daily) cream; and the third bar in each set is 1.5% ruxolitinib cream. Figure 14 shows the mean change from baseline in daily NRS itch score from day 1 to day 28 for TRuE-ADl (study 303) for vehicle (top line), ruxolitinib cream 0.75% two Qfraznn / zznz / E / YiAi times daily (middle line) and ruxolitinib cream 1.5% twice daily (bottom line) for patients with baseline itch NRS > 4. Figure 15 shows the mean change from baseline in daily NRS itch score from day 1 to day 28 for TRuE-AD2 (study 304) for vehicle (top line), ruxolitinib cream 0.75% twice daily (middle line) and ruxolitinib cream 1.5% twice daily (bottom line) for patients with initial itch NRS > 4. Figure 16 shows the proportion of participants who achieved an improvement of > 6 points in the PROMIS sleep disturbance score (8b) in the vehicle control period at Week 2, Week 4 and Week 8 for TRuE-ADl (Study 303) (filled bars) and TRuE-AD2 (Study 304) (hatched bars) for vehicle, ruxolitinib cream 0.75% twice daily and ruxolitinib 1.5% cream twice daily (first bar). each set is the vehicle; the second bar of each set is ruxolitinib cream 0.75% twice daily; and third bar of each set is ruxolitinib cream 1.5%). Figure 17 shows the proportion of participants who achieved a b 6-point improvement in the PROMIS Sleep Impairment Score (8a) in the vehicle control period at week 2, week 4, and week 8 for Qfraznn / zznz / E / YiAi TRuE-ADl (Study 303) (filled bars) and TRuE-AD2 (Study 304) (hatched bars) for vehicle, ruxolitinib cream 0.75% twice daily and ruxolitinib 1.5% cream twice daily (the First bar of each set is vehicle; second bar of each set is 0.75% ruxolitinib cream twice daily; and third bar of each set is 1.5% ruxolitinib cream. Figure 18 shows a box plot of the change from baseline in hemoglobin (g / L) in the vehicle control period at Week 2, Week 4, and Week 8 for TRuE-ADl (Study 303) for vehicle, ruxolitinib cream 0.75% twice daily and ruxolitinib 1.5% cream twice daily (the first bar in each set is vehicle; the second bar in each set is ruxolitinib cream 0.75% twice a day; and the third bar in each set is ruxolitinib cream 1.5%). Figure 19 shows a box plot of the change from baseline in platelets (109 / L) in the vehicle control period at Week 2, Week 4, and Week 8 for TRuE-ADl (Study 303). for vehicle, ruxolitinib cream 0.75% twice daily and ruxolitinib 1.5% cream twice daily (the first bar in each set is vehicle; the second bar in each set is ruxolitinib cream 0.75% twice a Qfraznn / zznz / E / YiAi day; and the third bar in each set is ruxolitinib cream 1.5%). Figure 20 shows a box plot of the change from baseline in hemoglobin (g / L) in the vehicle control period at Week 2, Week 4, and Week 8 for TRuE-AD2 (Study 304) for vehicle, ruxolitinib cream 0.75% twice daily and ruxolitinib 1.5% cream twice daily (the first bar in each set is vehicle; the second bar in each set is ruxolitinib cream 0.75% twice a day; and the third bar in each set is ruxolitinib cream 1.5%) Figure 21 shows a box plot of the change from baseline in platelets (109 / L) in the vehicle control period at Week 2, Week 4 and Week 8 for TRuE-AD2 (Study 304) for vehicle, ruxolitinib cream 0.75% twice daily and ruxolitinib 1.5% cream twice daily (the first bar in each set is vehicle; the second bar in each set is ruxolitinib cream 0.75% twice a day; and the third bar in each set is ruxolitinib cream 1.5%). Figure 22 shows the proportion of participants who achieved IGA-TS in the vehicle control period at Week 2, Week 4, and Week 8 for patients who Qfraznn / zznz / E / YiAi have a Body Surface Area of ​​involved atopic dermatitis involvement of > 10% at baseline and an Eczema Area and Severity Index score of % 16 at baseline in both TRuE-ADl (Study 303) as in TRuE-AD2 (Study 304) for vehicle, ruxolitinib cream 0.75% twice daily and ruxolitinib cream 1.5% twice daily (the first bar of each set is the vehicle; the second bar of each set is 0.75% ruxolitinib cream twice daily, and the third stick of each set is 1.5% ruxolitinib cream). Figure 23 shows the proportion of participants who achieved EASI-75 in the vehicle control period at week 2, week 4, and week 8 for patients who had an involved atopic dermatitis Body Surface Area of ​​> 10% at baseline and an Eczema Area and Severity Index score of %16 at baseline in both TRuE-ADl (Study 303) and TRuE-AD2 (Study 304) for vehicle, ruxolitinib cream 0.75% twice daily day and ruxolitinib 1.5% cream twice daily (the first bar of each set is vehicle; the second bar of each set is ruxolitinib 0.75% cream twice daily, and the third bar of each set It is a 1.5% ruxolitinib cream. Figure 24 shows the proportion of participants who achieved an improvement of h 4 points in the NRS itch score in the vehicle control period at week 2, week 4 and week 8 for patients with a Body Surface Area of involved atopic dermatitis involvement of > 10% at baseline, an Eczema Area and Severity Index score of > 16 at baseline, and an Itch Numerical Rating Scale score of b 4 at baseline in both TRuE-ADl ( study 303) as in TRuE-AD2 (study 304) for vehicle, ruxolitinib cream 0.75% twice daily and ruxolitinib cream 1.5% twice daily for patients with initial itch NRS > 4 (the first bar of each set is the vehicle; the second bar in each set is ruxolitinib cream 0.75% twice daily; and the third bar in each set is ruxolitinib cream 1.5%). Figure 25 shows the mean change from baseline in daily NRS itch scores from day 1 to day 28 (patients with a baseline NRS itch score of ¿ 4) for the combined TRuE-ADl studies (Study 303 ) and TRuE-AD2 (Study 304) (top line (vehicle), midline (0.75% ruxolitinib cream twice daily), and bottom line (1.5% ruxolitinib cream twice daily). Figure 26 shows the proportion of patients who achieved an NRS itch score of b 4 points improvement in NRS itch score from day 1 to day 7 (patients who had a baseline NRS itch score of > 4) for the TRuE -Combined ADl (Study 303) and TRuE-AD2 Studies (Study 304) (first bar (vehicle), second bar (0.75% ruxolitinib cream twice daily), and third bar (1.5% ruxolitinib cream twice daily) day) . Figure 27 shows the proportion of participants achieving IGA-TS in the vehicle control period at Week 2, Week 4, and Week 8 for the combined TRuE-ADl (Study 303) and TRuE-AD2 (Study 304) studies. ) for vehicle, ruxolitinib cream 0.75% twice daily and ruxolitinib 1.5% cream twice daily (the first bar in each set is vehicle; the second bar in each set is ruxolitinib cream 0.75 % twice a day; and the third bar in each set is ruxolitinib cream 1.5%). Figure 28 shows the proportion of participants who achieved EASI-75 in the vehicle control period at Week 2, Week 4 and Week 8 for TRuE-ADl (Study 303) and TRuE-AD2 (Study 304) combined for vehicle, ruxolitinib cream 0.75% BID and ruxolitinib cream 1.5% BID (the first bar in each set is vehicle; the second bar in each set is ruxolitinib cream 0.75% BID; and the third bar of each set is ruxolitinib cream 1.5%). α^αζηη / ζζηζ / Β / γίΛΐ Figure 29 shows the proportion of participants who achieved an improvement of > 6 points in the PROMIS sleep disturbance score (8b) in the vehicle control period at week 2, week 4 and week 8 for patients who have a PROMIS (8b) sleep disturbance score > 6 at baseline for TRuE-ADl (Study 303) and TRuE-AD2 (Study 304) combined for vehicle, ruxolitinib cream 0.75% twice daily, and ruxolitinib cream 1.5% twice daily (the first bar in each set is vehicle; the second bar in each set is ruxolitinib cream 0.75% twice daily, and the third bar in each set is ruxolitinib cream 1.5%) . Figure 30 shows the proportion of participants who achieved a b 6-point improvement on PROMIS Sleep-Related Impairment (8a) in the vehicle control period at Week 2, Week 4, and Week 8 for gue patients. have a PROMIS Sleep Related Impairment (8a) > 6 at baseline for TRuE-ADl (Study 303) and TRuE-AD2 (Study 304) combined for vehicle, ruxolitinib cream 0.75% twice daily, and ruxolitinib cream 1.5% twice daily (the first bar of each set is vehicle; the second bar of each set is ruxolitinib cream 0.75% twice daily; and the third bar of each set is ruxolitinib cream 15% ). Qfraznn / zznz / E / YiAi Figure 31 shows a graph of the mean EASI scores in the vehicle control period at baseline, week 2, week 4 and week 8 for the TRuE-ADl (study 303) and the TRuE-AD2 (study 304) grouped (top line (vehicle), middle line (0.75% ruxolitinib cream twice daily) and bottom line (1.5% ruxolitinib cream twice daily). Figure 32 shows a plot of the mean score change from baseline in EASI scores in the vehicle control period at baseline, week 2, week 4, and week 8 for the combined TRuEADl (Study 303). and the TRuE-AD2 (Study 304) (top line (vehicle), midline (1.5% ruxolitinib cream twice daily) and bottom line (0.75% ruxolitinib cream twice daily). Figure 33 shows a plot of the mean percentage change from baseline in EASI scores in the vehicle control period at baseline, week 2, week 4, and week 8 for the combined TRuEADl (Study 303) and the TRuE-AD2 (Study 304) (top line (vehicle), midline (1.5% ruxolitinib cream twice daily), and bottom line (0.75% ruxolitinib cream twice daily). DETAILED DESCRIPTION OF THE INVENTION The present invention provides, among others Qfraznn / zznz / E / YiAi things, a method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the formulation in cream comprises 1.5% (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof, wherein the patient achieves a reduction in the itch Numerical Rating Scale score from baseline. The present invention also provides a method of reducing itching in a human patient with atopic dermatitis, which comprises administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / w) on a free base basis of ruxolitinib, or one of its pharmaceutically acceptable salts, wherein the patient achieves a reduction in the itch Numerical Rating Scale score from baseline. The present invention further provides a method for reducing itching in a human patient with atopic dermatitis, which comprises administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation comprises 1.5% Qfraznn / zznz / E / YiAi (w / w) on a ruxolitinib phosphate-free basis, where the patient achieved a reduction in the itch Numerical Rating Scale score from baseline. The present invention further provides a method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof a cream formulation twice daily, wherein the cream formulation comprises 0.75% ( p / p) on a ruxolitinib phosphate free base basis, where the patient achieved a reduction in the itch Numerical Rating Scale score from baseline. In some embodiments, the method provides a prompt reduction of itching in the patient. The present invention further provides a method for treating atopic dermatitis in a human patient, which comprises administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation comprises 0.75% (w / p) or 1.5% (w / w) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. The present invention further provides methods for treating atopic dermatitis in a human patient, which QbQZnn / 77nZ / E / YIAI comprise administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation comprises 1.5% (w / w) on a free base basis of ruxolitinib , or one of its pharmaceutically acceptable salts. The present invention further provides methods for treating atopic dermatitis in a human patient, comprising administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation comprises 1.5% (w / p) on a ruxolitinib phosphate free base basis. The present invention further provides a method for treating atopic dermatitis in a human patient, which comprises administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation comprises 0.75% (w / p) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. The present invention further provides a method for treating atopic dermatitis in a human patient, which comprises administering to the skin of the human patient in need thereof, a cream formulation twice daily, wherein the cream formulation comprises 0.75% (w / p) on a ruxolitinib phosphate free base basis. In some embodiments, ruxolitinib, or one of α^αζηη / ζζηζ / Β / γίΛΐ pharmaceutically acceptable salts thereof, is ruxolitinib phosphate. In some modalities, the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline. In some modalities, the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline. The present invention further provides a method of treating mild to moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice daily, wherein the topical formulation comprises 0.75% (p / p) or 1.5% (w / w) on a ruxolitinib free base basis, or a pharmaceutically acceptable salt thereof. The present invention further provides a method of treating mild to moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice daily, wherein the topical formulation comprises 0.75% (p / p) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. The present invention also provides a method for treating mild to moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice daily, wherein the topical formulation comprises 1.5% (p / p) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. The present invention further provides a method for treating mild to moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice daily, wherein the topical formulation comprises 0.75% (p / p) on a ruxolitinib phosphate free base basis. The present invention also provides a method for treating mild to moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice daily, wherein the topical formulation comprises 1.5% (p / p) on a ruxolitinib phosphate free base basis. The present invention further provides a method of treating mild to moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises Qfraznn / zznz / E / YiAi 0.75% (w / w) or 1.5% (w / w) on a ruxolitinib free base basis, or a pharmaceutically acceptable salt thereof. The present invention further provides a method for treating mild to moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / w) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. The present invention also provides a method of treating mild to moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. The present invention further provides a method for treating mild to moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / w) on a ruxolitinib phosphate free base basis. The present invention also provides a method Qfraznn / zznz / E / YiAi for treating mild to moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w) on a ruxolitinib phosphate free base basis. The present invention further provides a method for treating moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice a day, wherein the topical formulation comprises 0.75% (w / w) or 1.5% (w / w) on a free base basis of ruxolitinib, or one of its pharmaceutically acceptable salts. The present invention further provides a method for treating moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice a day, wherein the topical formulation comprises 0.75% (w / w) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. The present invention also provides a method for treating moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice a day, wherein the topical formulation comprises 1.5% (w / w) Qfraznn / zznz / E / YiAi on a free base basis of ruxolitinib, or one of its pharmaceutically acceptable salts. The present invention further provides a method for treating moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice a day, wherein the topical formulation comprises 0.75% (w / w) on a ruxolitinib phosphate free base basis. The present invention also provides a method for treating moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice a day, wherein the topical formulation comprises 1.5% (w / w) on a ruxolitinib phosphate free base basis. The present invention further provides a method of treating moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / p) or 1.5% (w / w) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. The present invention further provides a method of treating moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice daily. Qfraznn / zznz / E / YiAi day, wherein the cream formulation comprises 0.75% (w / w) on a free base basis of ruxolitinib, or one of its pharmaceutically acceptable salts. The present invention also provides a method of treating moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day wherein the cream formulation comprises 1.5% (w / w ) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. The present invention further provides a method of treating moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / p) on a ruxolitinib phosphate free base basis. The present invention also provides a method of treating moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / p) on a ruxolitinib phosphate free base basis. The present invention also provides a method of treating moderate to severe atopic dermatitis in a human patient comprising administering to the skin of the Qfraznn / zznz / E / YiAi human patient in need of a topical formulation twice daily, wherein the topical formulation comprises 0.75% (w / w) or 1.5% (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof. The present invention further provides a method for treating moderate to severe atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice daily, wherein the topical formulation comprises 0.75% (p / p) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. The present invention also provides a method for treating moderate to severe atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice daily, wherein the topical formulation comprises 1.5% (p / p) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. The present invention further provides a method for treating moderate to severe atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice daily, wherein the topical formulation comprises 0.75% (p / p) on a ruxolitinib phosphate free base basis. The present invention also provides a method for treating moderate to severe atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice daily, wherein the topical formulation comprises 1.5% (p / p) on a ruxolitinib phosphate free base basis. The present invention also provides a method of treating moderate to severe atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / w) or 1.5% (w / w) on a ruxolitinib free base basis, or a pharmaceutically acceptable salt thereof. The present invention further provides a method for treating moderate to severe atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / w) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. The present invention also provides a method of treating moderate to severe atopic dermatitis in a Qfraznn / zznz / E / YiAi human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice daily, wherein the cream formulation comprises 1.5% (w / w) on a free base basis of ruxolitinib, or one of its pharmaceutically acceptable salts. The present invention further provides a method for treating moderate to severe atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / w) on a ruxolitinib phosphate free base basis. The present invention also provides a method of treating moderate to severe atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w) on a ruxolitinib phosphate free base basis. In some of the modalities in the preceding twenty paragraphs, the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline. In some modalities of the modalities of the previous twenty paragraphs, the patient achieves a score of 0 QbQZnn / 77nZ / E / YIAI or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline. In some of the modalities in the preceding twenty paragraphs, the patient achieves a statistically significant improvement in the Eczema Area and Severity Index score from baseline. In some of the modalities in the preceding twenty paragraphs, the patient achieves a 75% improvement in the Eczema Area and Severity Index score from baseline. In some of the modalities in the preceding twenty paragraphs, the patient achieves a reduction of at least 4 points in the itch Numerical Rating Scale score from baseline; and the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline. In some of the modalities in the preceding twenty paragraphs, the patient achieves a reduction of at least 4 points in the itch Numerical Rating Scale score from baseline; and the patient achieves a 75% improvement in the Eczema Area and Severity Index score from baseline. In some of the modalities in the preceding twenty paragraphs, patient α^αζηη / ζζηζ / Β / γίΛΐ achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline; and the patient achieves a 75% improvement in the Eczema Area and Severity Index score from baseline. In some of the modalities in the preceding twenty paragraphs, the patient achieves a reduction of at least 4 points in the itch Numerical Rating Scale score from baseline; the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline; and the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline. In some embodiments of the modalities in the preceding twenty paragraphs, the patient achieves a reduction of at least 4 points in the itch Numerical Rating Scale score from baseline at Week 4 of administration. In some embodiments of the embodiments in the preceding twenty paragraphs, the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration. In some modalities of the modalities of the previous twenty paragraphs, the Qfraznn / zznz / E / YiAi patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at Week 4 of dosing. In some of the modalities in the preceding twenty paragraphs, the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at week 8 of administration. In some embodiments of the modalities in the preceding twenty paragraphs, the patient achieves a 75% improvement in the Eczema Area and Severity Index score from baseline at Week 4 of administration. In some embodiments of the modalities in the preceding twenty paragraphs, the patient achieves a 75% improvement in the Eczema Area and Severity Index score from baseline at week 8 of administration. In some embodiments of the modalities in the preceding twenty paragraphs, the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at Week 4 of administration; and the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at Week 4 of dosing. In some embodiments of the modalities in the preceding twenty paragraphs, the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration; and the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at week 8 of dosing. In some embodiments of the modalities in the preceding twenty paragraphs, the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at Week 4 of administration; and the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline at Week 4 of dosing. In some embodiments of the modalities in the preceding twenty paragraphs, the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration; and the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline at week 8 of dosing. In some of the modalities in the previous twenty paragraphs, the patient achieves a score of Qfraznn / zznz / E / YiAi Investigator's Global Assessment of 0 or 1 with an improvement of at least 2 points from baseline at Week 4 of administration; and the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at Week 4 of administration. In some modalities of the modalities of the twenty preceding paragraphs, the patient achieves an Investigator Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at week 8 of administration; and the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at week 8 of administration. In some modalities of the modalities of the twenty preceding paragraphs, the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at Week 4 of administration; the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at Week 4 of dosing; and the patient achieves a 75% improvement in the Eczema Area and Severity Index score from α^αζηη / ζζηζ / Β / γίΛΐ from baseline at Week 4 of administration. In some of the modalities of the above twenty paragraphs, the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration; the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at week 8 of dosing; and the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at week 8 of administration. In some modalities of the modalities of the twenty previous paragraphs, the administration is maintained for at least 4 weeks. In some modalities of the modalities of the twenty previous paragraphs, the administration is maintained for at least 8 weeks. In general, the EDA defines atopic dermatitis as mild to moderate, moderate, and moderate to severe, that is, in terms of the Investigator's Global Assessment score at baseline (see IGA definition above). For example, patients with mild atopic dermatitis have an Investigator's Global Assessment score of 2 at baseline; patients with moderate atopic dermatitis have an Investigator's Global Assessment score of 3 at baseline; and Qfraznn / zznz / E / YiAi patients with severe atopic dermatitis have an Investigator's Global Assessment score of 4 at baseline. Patients with mild to moderate atopic dermatitis have an Investigator Global Assessment score of 2 to 3 at baseline, while patients with moderate to severe atopic dermatitis have an Investigator Global Assessment score of 3 to 4 at baseline. In some modalities, the patient with mild to moderate atopic dermatitis has a Body Surface Area affected by atopic dermatitis of > 10% at baseline. In some modalities, the patient with moderate atopic dermatitis has a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline. In some modalities, the patient with moderate to severe atopic dermatitis has a Body Surface Area affected by atopic dermatitis of > 10% at baseline. In some modalities, the patient with mild to moderate atopic dermatitis has a Body Surface Area affected by atopic dermatitis of 10% to 20% at baseline. In some modalities, the patient with moderate atopic dermatitis has a Body Surface Area affected by atopic dermatitis of 10% to 20% at baseline. In some modalities, the patient with moderate to severe atopic dermatitis has a Body Surface Area Qfraznn / zznz / E / YiAi affected by atopic dermatitis from 10% to 20% at baseline. In some embodiments, the patient with moderate atopic dermatitis has an Eczema Area and Severity index of > 16 at baseline. In some embodiments, the patient with moderate to severe atopic dermatitis has an Eczema Area and Severity Index of 1 16 at baseline. In some modalities, the patient with moderate atopic dermatitis has an Investigator's Global Assessment score of 3 and a Body Surface Area of ​​involved atopic dermatitis involvement of 10% to 20% at baseline. In some embodiments, the patient with moderate to severe atopic dermatitis has an Eczema Area and Severity Index of > 16 at baseline, a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline, and a Global Assessment score. of the Investigator from 3 to 4. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice daily, wherein the topical formulation comprises 0.75% (w / w) or 1.5 % (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof, α^αζηη / ζζηζ / Β / γίΛΐ where the patient has: an Eczema Area and Severity Index score of > 16 at baseline; and a Body Surface Area affected by atopic dermatitis of > 10% at the beginning of the study. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice a day, wherein the topical formulation comprises 0.75% (w / w) on a ruxolitinib free base base, or a pharmaceutically acceptable salt thereof, wherein the patient has: an Eczema Area and Severity Index score of > 16 at baseline; and a Body Surface Area affected by atopic dermatitis of > 10% at the beginning of the study. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice a day, wherein the topical formulation comprises 1.5% (w / w) on a ruxolitinib free base base, or a pharmaceutically acceptable salt thereof, wherein the patient has: an Area and Severity Index score Qfraznn / zznz / E / YiAi Eczema > 16 at baseline; and a Body Surface Area affected by atopic dermatitis of > 10% at the beginning of the study. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice a day, wherein the topical formulation comprises 0.75% (w / w) on a ruxolitinib phosphate free base base, wherein the patient has: an Eczema Area and Severity Index score of > 16 at baseline; and a Body Surface Area affected by atopic dermatitis of > 10% at the beginning of the study. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice a day, wherein the topical formulation comprises 1.5% (w / w) on a ruxolitinib phosphate free base base, wherein the patient has: an Eczema Area and Severity Index score of > 16 at baseline; and a Body Surface Area affected by atopic dermatitis of > 10% at the beginning of the study. Qfraznn / zznz / E / YiAi The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice daily, wherein the cream formulation comprises 0.75% (w / w) or 1.5% (w / w) on a ruxolitinib free base basis, or a pharmaceutically acceptable salt thereof, where the patient has: an Eczema Area and Severity Index score of > 16 at baseline; and a Body Surface Area affected by atopic dermatitis of > 10% at the beginning of the study. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice daily, wherein the cream formulation comprises 0.75% (w / w) on a ruxolitinib free base basis, or a pharmaceutically acceptable salt thereof, wherein the patient has: an Eczema Area and Severity Index score of > 16 at baseline; and a Body Surface Area affected by atopic dermatitis of > 10% at the beginning of the study. The present invention further provides methods for treating atopic dermatitis in a human patient who Qfraznn / zznz / E / YiAi comprise administering to the skin of the human patient in need thereof a cream formulation twice daily, wherein the cream formulation comprises 1.5% (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof, wherein the patient has: an Eczema Area and Severity Index score of > 16 at baseline; and a Body Surface Area affected by atopic dermatitis of > 10% at the beginning of the study. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice daily, wherein the cream formulation comprises 0.75% (w / w) on a ruxolitinib phosphate free base basis, where the patient has: an Eczema Area and Severity Index score of ≥ 16 at baseline; and a Body Surface Area affected by atopic dermatitis of > 10% at the beginning of the study. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice daily, wherein the cream formulation comprises 1.5% (w / w) Over a base Qfraznn / zznz / E / YiAi of ruxolitinib phosphate free base, where the patient has: an Area and Severity index score of Eczema > 16 at baseline; and a Body Surface Area affected by atopic dermatitis of > 10% at the beginning of the study. In some of the modalities in the ten paragraphs above, the patient has an Investigator's Global Assessment score of 3 at baseline. In some of the modalities in the ten paragraphs above, the patient has an Investigator's Global Assessment score of 3 to 4 at baseline. In some of the modalities in the ten paragraphs above, the patient has an itch Numerical Rating Scale score of > 4 at baseline. In some of the modalities in the ten paragraphs above, the patient: has an Investigator's Global Assessment score of 3 at baseline; and has an itch Numerical Rating Scale score of b 4 at baseline. In some of the modalities in the ten paragraphs above, the patient: has an Investigator's Global Assessment score of 3 to 4 at baseline; and has an itch Numerical Rating Scale score of b 4 at baseline Qfraznn / zznz / E / YiAi studio. In some embodiments of the embodiments of the preceding ten paragraphs, the patient is b 12 years old. In some embodiments of the embodiments in the ten paragraphs above, the patient has a history of atopic dermatitis for at least 2 years. In some of the modalities in the ten paragraphs above, the patient: has an Investigator's Global Assessment score of 3 at baseline; have a history of atopic dermatitis for at least 2 years; and has an age of 12 years. In some of the modalities in the ten paragraphs above, the patient: has an Investigator's Global Assessment score of 3 to 4 at baseline; have a history of atopic dermatitis for at least 2 years; and has an age of 12 years. In some of the modalities in the ten paragraphs above, the patient: has an Investigator's Global Assessment score of 3 at baseline; has an itch Numerical Rating Scale score of b 4 at baseline; have a history of atopic dermatitis for at least 2 years; and has an age of 12 years. In some of the modalities in the ten paragraphs above, the patient: has an Investigator's Global Assessment score of 3 to 4 at baseline; has an itch Numerical Rating Scale score of b 4 at baseline; has Qfraznn / zznz / E / YiAi history of atopic dermatitis for at least 2 years; and is > 12 years old. In some of the modalities in the ten paragraphs above, the patient has one or more of the following characteristics: an Investigator's Global Assessment score of 3 at baseline; an itch Numerical Rating Scale with a score of > 4 at baseline; history of atopic dermatitis for at least 2 years; and age or 12 years. In some of the modalities in the ten paragraphs above, the patient achieves a reduction of at least 4 points in the Itch Numerical Rating Scale score from baseline. In some of the modalities in the ten paragraphs above, the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline. In some of the modalities in the ten paragraphs above, the patient achieves a statistically significant improvement in the Eczema Area and Severity Index score from baseline. In some of the modalities in the ten previous paragraphs, the patient achieves a 75% improvement in the Eczema Area and Severity Index score from baseline. In some of the modalities in the ten paragraphs above, the patient achieves a reduction of at least 4 points in the itch Numerical Rating Scale score from baseline; and the patient achieves an Evaluation score Investigator Overall of 0 or 1 with an improvement of at least 2 points from the initial value. In some of the modalities in the ten paragraphs above, the patient achieves a reduction of at least 4 points in the itch Numerical Rating Scale score from baseline; and the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline. In some of the modalities in the ten paragraphs above, the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline; and the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline. In some of the modalities in the ten paragraphs above, the patient achieves a reduction of at least 4 points in the itch Numerical Rating Scale score from baseline; the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at QbQZnn / 77nZ / E / YIAI minus 2 points from the initial value; and the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline. In some embodiments of the modalities in the ten paragraphs above, the patient achieves a reduction of at least 4 points in the itch Numerical Rating Scale score from baseline at Week 4 of administration. In some embodiments of the modalities in the ten paragraphs above, the patient achieves a reduction of at least 4 points in the itch Numerical Rating Scale score from baseline at week 8 of administration. In some of the modalities in the ten paragraphs above, the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at Week 4 of administration. In some embodiments of the modalities in the ten paragraphs above, the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at week 8 of administration. In some of the modalities in the ten paragraphs above, the patient achieves a 75% improvement in the Eczema Area and Severity Index score from baseline at Week 4 Qfraznn / zznz / E / YiAi from the administration. In some embodiments of the modalities in the ten paragraphs above, the patient achieves a 75% improvement in the Eczema Area and Severity Index score from baseline at week 8 of administration. In some embodiments of the modalities in the ten paragraphs above, the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at Week 4 of administration; and the patient achieves an Assessment score Investigator's Global of 0 or 1 with an improvement of at least 2 points from baseline at Week 4 of administration. In some embodiments of the modalities in the ten paragraphs above, the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration; and the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at week 8 of dosing. In some embodiments of the modalities in the ten paragraphs above, the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at Week 4 of administration; and Qfraznn / zznz / E / YiAi the patient achieves a 75% improvement in Eczema Area and Severity index score from baseline at Week 4 of dosing. In some modalities of the modalities in the ten paragraphs above, the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration; and the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at week 8 of administration. In some of the modalities in the ten paragraphs above, the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at Week 4 of administration; and the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at Week 4 of administration. In some modalities of the modalities of the ten preceding paragraphs, the patient achieves an Investigator Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at week 8 of administration; and the patient achieves a 75% improvement in Qfraznn / zznz / E / YiAi Eczema Area and Severity Index score from baseline at week 8 of administration. In some embodiments of the modalities in the ten paragraphs above, the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at Week 4 of administration; the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at Week 4 of dosing; and the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline at Week 4 of dosing. In some modalities of the modalities in the ten paragraphs above, the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration; the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at week 8 of dosing; and the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at week 8 of administration. In some modalities of the modalities of the ten paragraphs Qfraznn / zznz / E / YiAi above, dosing is maintained for at least 4 weeks. In some modalities of the modalities of the above ten paragraphs, the administration is maintained for at least 8 weeks. In some embodiments, the topical formulation is a cream formulation. In some embodiments, ruxolitinib or one of its salts is ruxolitinib phosphate. In some embodiments, the formulation comprises 0.75% (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof. In some embodiments, the formulation comprises 1.5% (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof. In some embodiments, the formulation comprises 0.75% (w / w) on a phosphate free base basis of ruxolitinib. In some embodiments, the formulation comprises 1.5% (w / w) on a phosphate free base basis of ruxolitinib. In some modalities, the patient achieves at least a 4-point improvement in Itch Numerical Rating Scale score improvement from baseline. In some embodiments, the patient achieves at least a 4-point improvement in improvement in the itch Numerical Rating Scale score from baseline, where the patient has a Numerical Rating Scale score from baseline. worth Baseline Qfraznn / zznz / E / YiAi equal to or greater than 4. In some modalities, the patient achieves at least a 4-point improvement in Itch Numerical Rating Scale score improvement from baseline after 2 weeks of administration, wherein the patient has a Numerical Rating Scale score from baseline equal to or greater than 4. In some modalities, the patient achieves at least a 4-point improvement in improvement of the Numerical Rating Scale score. Baseline itching Numerical Rating Scale after 4 weeks of administration, wherein the patient has a Baseline Numerical Rating Scale score equal to or greater than 4. In some embodiments, the patient achieves at least a 4-point improvement in itch Numerical Rating Scale score from baseline after 8 weeks of administration, where the patient has a baseline Numerical Rating Scale score equal to or greater to 4. In some modalities, the patient: is between 18 and 70 years old, has been diagnosed with atopic dermatitis for at least 2 years, has an Investigator's Global Assessment score of 2 to 3 at assessment and at baseline α^αζηη / ζζηζ / Β / γίΛΐ study, and has a BSA of atopic dermatitis involvement (excluding face and intertriginous areas) of 3% to 20% at baseline. In some modalities, the patient: is an adolescent from % 12 to 17 years inclusive, or a man or woman > 18 years; have a history of AD for at least 2 years; has an Investigator Global Assessment score of 2 to 3 at baseline; and has a BSA % of AD involvement, excluding the scalp, of 3% to 20% at baseline. In some modalities, the patient: is an adolescent between 12 and 17 years of age inclusive, or a man or woman > 18 years of age; has a history of AD for at least 2 years; has an Investigator Global Assessment score of 2 to 3 at baseline; has a BSA % of AD involvement, excluding the scalp, of 3% to 20% at baseline; and has at least one target lesion (that is representative of the participant's disease status and is not present on the hands, feet, or genitals) that measures around 10 cm2 or larger at baseline. In some modalities, the patient is Qfraznn / zznz / E / YiAi diagnoses atopic dermatitis as defined by the Hanifin and Rajika criteria. In some embodiments, the patient did not use topical atopic dermatitis treatments, other than emollients, within 2 weeks of onset. In some embodiments, the patient did not use systemic immunosuppressive or immunomodulatory drugs (e.g., oral or injectable corticosteroids, methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine) within 4 weeks or 5 half-lives from baseline (whichever is longer). ). In some embodiments, the patient did not use topical atopic dermatitis treatments, other than mild emollients, within 2 weeks of onset; and did not use systemic immunosuppressive drugs or systemic immunomodulatory drugs within 4 weeks of onset. In some embodiments, the patient is not administered other therapeutic agents used to treat atopic dermatitis. In some embodiments, the patient is not administered systemic immunosuppressive or systemic immunomodulatory drugs or topical treatments for atopic dermatitis, other than mild emollients. In some modalities, the patient: Qfraznn / zznz / E / YiAi (i) shows no evidence of active acute or chronic infections; (ii) did not use topical treatments for atopic dermatitis (other than mild emollients) within 2 weeks of onset; (iii) did not use systemic immunosuppressive or immunomodulatory drugs (e.g., oral or injectable corticosteroids, methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine) within 4 weeks or 5 half-lives from baseline (whichever is longer); (iv) was not diagnosed with another dermatological disease in addition to atopic dermatitis whose presence or treatments could complicate the evaluation of the disease; (v) history of other diseases in addition to dermatological disorders taking treatments that could complicate evaluations; (vi) did not show cytopenias at screening, defined as leukocytes < 3.0 x 109 / L, neutrophils < lower limit of normal, hemoglobin < 10 g / dL. Lymphocytes < 0.8 χ 109 / L, platelets < 100 x 109 / L; (vii) did not have severely impaired liver function (Child-Pugh Class C) or end-stage renal disease on dialysis or at least 1 of the following: serum creatinine > 1.5 mg / dL, alanine aminotransferase or aspartate aminotransferase > 1.5 χ the cutoff higher than normal; (viii) were not taking potent systemic cytochrome P4503A4 inhibitors or fluconazole within 2 weeks or 5 half-lives, whichever is longer, before the initial visit, other than topical agents with limited systemic availability; and / or (ix) were not administered systemic or topical Janus kinase inhibitors. In some modalities, the patient: (i) is an adolescent between 12 and 17 years of age, inclusive, or a man or woman > 18 years of age; (ii) has a diagnosis of AD as defined by the Hanifin and Rajka criteria; (iii) has a history of AD for at least 2 years; (iv) has a score of 2 to 3 on the Investigator's Global Assessment at the beginning of the study; (v) has a BSA % of AD involvement, excluding the scalp, of 3% to 20% at baseline; (vi) agreed to discontinue all agents used to treat AD during administration; and / or (vi) has at least one target lesion (that is representative of the participant's disease status and is not present on the hands, feet, or genitals) that measures about 10 cm2 or larger at baseline. In some modalities, the patient: (i) does not have an unstable course of AD (spontaneous improvement or rapid deterioration) as determined by a physician within 4 weeks prior to the start of the study; (ii) has no concurrent conditions or history of other diseases: (a) immunocompromised Qfraznn / zznz / E / YiAi (e.g. lymphoma, acquired immunodeficiency syndrome, Wiskott-Aldrich syndrome); (b) chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before onset; (c) active acute bacterial, fungal, or viral skin infection (e.g., herpes simplex, herpes zoster, chickenpox) in the week before onset; (d) any other concomitant skin disorder (e.g., generalized erythroderma such as Netherton syndrome), pigmentation, or extensive scarring that, in the opinion of the investigator, could interfere with the evaluation of AD lesions or compromise the safety of the participants; e) presence of AD lesions only in the hands or feet without a previous history of involvement of other classic areas of involvement such as the face or folds; (f) other types of eczema; (iii) does not have any serious illness or medical, physical, or psychiatric condition that, in the opinion of the investigator, would interfere with full participation in the study, including administration of study drug and attendance at required study visits; represent a significant risk to the participant; or interfere with the interpretation of study data. For example: (a) clinically significant or uncontrolled heart disease, including unstable angina, Qfraznn / zznz / E / YiAi acute myocardial infarction within 6 months of Day 1 of study drug administration, New York Heart Association class III or IV congestive heart failure, and arrhythmia requiring therapy or hypertension not controlled (blood pressure > 150 / 90 mmHg) unless approved by monitor / medical sponsor; (b) participants with a history of malignancies within 5 years prior to enrollment in this study, except for adequately treated non-metastatic malignancies; (c) low hemoglobin (<10 g / dL); (d) severe kidney disease on dialysis (serum creatinine > 2 mg / dL); (e) current and / or history of liver disease, including known hepatitis B or C with liver or biliary abnormalities; (iv) does not receive any of the following treatments within the indicated washout period before initiation: (a) 5 half-lives or 12 weeks, whichever is longer: biological agents (e.g., dupilumab); (b) 4 weeks: systemic corticosteroids or adrenocorticotropic hormone analogues, cyclosporine, methotrexate, azathioprine or other systemic immunosuppressive or immunomodulatory agents (for example, mycophenolate or tacrolimus); (c) 2 weeks: immunizations and sedative antihistamines, unless on long-term stable regimen (non-sedating antihistamines allowed); (d) 1 week: use of other topical AD treatments (other than emollients Mild Qfraznn / zznz / E / YiAi), such as corticosteroids, calcineurin inhibitors, coal tar (shampoo), antibiotics, antibacterial soap / body wash. Diluted sodium hypochlorite bleach baths are allowed as long as they do not exceed 2 baths per week and their frequency is the same throughout the study; (v) has not previously received JAK inhibitors, systemic or topical; (vi) have not had ultraviolet light therapy or prolonged exposure to natural or artificial sources of UV radiation (e.g., sunlight or tanning booth) within 2 weeks prior to the start of the study and / or intend to have exposure during the study, which is believed by the investigator to potentially impact the participant's AD; (vii) does not have positive serology test results for HIV antibodies; (viii) does not have liver function tests with the following: AST or ALT > 2 χ ULN; alkaline phosphatase and / or bilirubin > 1.5 χ ULN (isolated bilirubin > 1.5 χ ULN is acceptable if the bilirubin is fractionated and direct bilirubin < 35%); (ix) is not pregnant or lactating, or considering pregnancy; (x) has no history of alcoholism or drug addiction within 1 year prior to screening or current alcohol or drug use that, in the opinion of the investigator, will interfere with the participant's ability to comply with the administration program and the study evaluations; and / or (xi) is not currently receiving treatment or received treatment within 30 days or 5 half-lives (whichever is longer) prior to initiation of another investigational drug or current enrollment in another investigational drug protocol. In some embodiments, the two administrations per day are separated by at least 8 hours. In some embodiments, the cream formulation is an oil-in-water emulsion comprising ruxolitinib, or a pharmaceutically acceptable salt thereof. In some embodiments, the cream formulation is an oil-in-water emulsion comprising 1.5% (w / w) on a ruxolitinib phosphate free base basis. In some embodiments, the cream formulation is an oil-in-water emulsion comprising 0.75% (w / w) on a ruxolitinib phosphate free base basis. In some embodiments, the cream formulation has a pH of about 2.8 to about 3.9. In some embodiments, the cream formulation has a pH of about 2.8 to about 3.6. In some embodiments, the cream formulation is a solubilized cream. In some embodiments, the administration of the QbQZnn / 77nZ / E / YIAI cream formulation does not result in a statistically significant reduction in hemoglobin or platelets. In some embodiments, administration of the cream formulation does not produce burns at the administration site. In some embodiments, administration of the cream formulation does not result in itching at the administration site. In some modalities, the patient achieves a prompt reduction in itching. In some embodiments, the patient achieves a statistically significant reduction in itch on day 1 (i.e., within 12 hours) of administration. In some embodiments, the patient achieves a statistically significant reduction in itch on day 1 (i.e., within 12 hours) of administration of the cream formulation comprising 1.5% (w / w) ruxolitinib, or a of its pharmaceutically acceptable salts. In some embodiments, the patient achieves a statistically significant reduction in the itch Numerical Rating Scale score from baseline on day 2 of administration compared to a patient administered placebo during the same period. In some modalities, the patient achieves a statistically significant reduction in the Qfraznn / zznz / E / YiAi Numerical Rating Scale of itch from baseline on day 1 of administration compared to a patient administered placebo during the same period. In some embodiments, the patient achieves at least a 1-point reduction in the itch Numerical Rating Scale score from baseline on day 1 of administration. In some modalities, the patient achieves at least a 2-point improvement in the Pain Scale score. Qfraznn / zznz / E / YiAi Numerical rating of itching on day 1 of administration. In some modalities, a reduction of 1.5 points by 1; Numerical rating of itching on day 1 of administration. In some embodiments, a 1 point reduction in the Numerical Score of Itching on Day 2 of administration. In some modalities, a reduction of 1.5 points by 1; Numerical rating of itching on day 2 of administration. From the initial value the patient achieves at least . Scale score from baseline the patient achieves at least Scale score from baseline the patient achieves at least . Scale score from baseline In some embodiments, the patient achieves at least a 2-point reduction in the itch Numerical Rating Scale score from baseline on day 2 of administration. In some embodiments, the patient achieves at least a 2-point reduction in the itch Numerical Rating Scale score from baseline on day 4 of administration. In some embodiments, the patient achieves at least a 1-point reduction in the itch Numerical Rating Scale score on day 2 of administration. In some embodiments, the patient achieves at least a 1-point reduction in the itch Numerical Rating Scale score within 36 hours of administration. In some embodiments, the patient achieves at least a 2-point reduction in the itch Numerical Rating Scale score on day 6 of administration. In some embodiments, the patient achieves at least a 2-point reduction in the itch Numerical Rating Scale score at week 1 of administration. In some modalities, the patient achieves at least a 3-point reduction in the Pain Scale score. Qfraznn / zznz / E / YiAi Numerical rating of itching in week 3 of administration. In some embodiments, the patient achieves: at least a 1-point reduction in the itch Numerical Rating Scale score on day 2 of administration, at least a 2-point reduction in the itch Numerical Rating Scale score itching on day 6 of dosing and at least a 3-point reduction in the itching Numerical Rating Scale score on week 3 of dosing. In some embodiments, the patient achieves: at least a 1-point reduction in the Itch Numerical Rating Scale score within 36 hours of administration, at least a 2-point reduction in the Itch Numerical Rating Scale score. Numerical Rating of Itching on Day 6 of administration and at least a 3-point reduction in the Numerical Rating Scale of Itching score on Week 3 of administration. In some embodiments, the patient achieves: at least a 1-point reduction in the itch Numerical Rating Scale score on day 2 of administration, at least a 2-point reduction in the itch Numerical Rating Scale score itch Qfraznn / zznz / E / YiAi at week 1 of administration, and at least a 3-point reduction in the itch Numerical Rating Scale score at week 3 of administration. In some embodiments, the patient achieves: at least a 1-point reduction in the itch Numerical Rating Scale score within 36 hours of administration, at least a 2-point reduction in the Numerical Rating Scale score Numerical Itching at Week 1 of administration, and at least a 3-point reduction in Numerical Itching Rating Scale score at Week 3 of administration. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof, wherein the patient achieves at least a 1 point reduction in the itch Numerical Rating Scale score on day 2 of administration. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w) on a free base basis Qfraznn / zznz / E / YiAi ruxolitinib, or a pharmaceutically acceptable salt thereof, wherein the patient achieves at least a 1-point reduction in the itch Numerical Rating Scale score within 36 hours of administration. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w) on a free base basis of ruxolitinib, or one of its pharmaceutically acceptable salts, wherein the patient achieves a reduction of at least 2 points in the itch Numerical Rating Scale score on day 6 of administration. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w) on a free base basis of ruxolitinib, or one of its pharmaceutically acceptable salts, wherein the patient achieves a reduction of at least 2 points in the itch Numerical Rating Scale score in week 1 of administration. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to Qfraznn / zznz / E / YiAi the skin of the human patient who needs it a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w) on a free base basis of ruxolitinib, or one of its pharmaceutically acceptable salts, where the patient achieves a reduction of at least 3 points in the itch Numerical Rating Scale score in week 3 of administration. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof, wherein the patient achieves: at least a 1 point reduction in the itch Numerical Rating Scale score on day 2 of administration, at least a 2-point reduction in the itch Numerical Rating Scale score at day 6 of administration and at least a 3-point reduction in the itch Numerical Rating Scale score at week 3 of administration. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation Qfraznn / zznz / E / YiAi comprises 1.5% (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof, wherein the patient achieves: at least a 1 point reduction in the Itching Numerical Rating Scale within 36 hours of administration, at least a 2-point reduction in the itching Numerical Rating Scale score on day 6 of administration, and at least a 3-point reduction in the itch Numerical Rating Scale score at week 3 of administration. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof, wherein the patient achieves: at least a 1 point reduction in the itch Numerical Rating Scale score on day 2 of administration, at least a 2-point reduction in the itch Numerical Rating Scale score at week 1 of administration, and at least a 3-point reduction in the itch Numerical Rating Scale score at week 3 of administration . A method to reduce itching in a patient Qfraznn / zznz / E / YiAi human with atopic dermatitis, which comprises administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 15% (w / w) on a ruxolitinib free base base, or a pharmaceutically acceptable salt thereof, wherein the patient achieves: at least a 1-point reduction in the itch Numerical Rating Scale score within 36 hours of administration, at least a 2-point reduction in the itch Numerical Rating Scale score at week 1 of administration, and at least a 3-point reduction in the itch Numerical Rating Scale score at week 3 of administration. administration. In some embodiments, the patient achieves a minimal clinically important difference in the itch Numerical Rating Scale score on day 1 of administration. In some embodiments, the patient achieves a minimal clinically important difference in the itch Numerical Rating Scale score on day 2 of administration. In some embodiments, the patient achieves a minimal clinically important difference in the itch Numerical Rating Scale α^αζηη / ζζηζ / Β / γίΛΐ score on day 3 of administration. In some embodiments, the patient achieves a minimal clinically important difference in the itch Numerical Rating Scale score on day 4 of administration. In some embodiments, the patient achieves a clinically relevant improvement in the itch Numerical Rating Scale score on day 2 of administration. In some embodiments, the patient achieves a clinically relevant improvement in the itch Numerical Rating Scale score on day 3 of administration. In some embodiments, the patient achieves a clinically relevant improvement in the itch Numerical Rating Scale score on day 4 of administration. In some embodiments, the patient achieves a statistically significant reduction in the itch Numerical Rating Scale score from baseline in week 2 of administration compared to a patient administered placebo during the same period. In some modalities, the patient achieves at least a 3-point reduction in the α^αζηη / ζζηζ / Β / γίΛΐ Scale score. Numerical rating of itching from baseline in week 2 of administration. In some embodiments, the patient achieves a clinically relevant improvement in the itch Numerical Rating Scale score by week 2 of administration. In some embodiments, the patient achieves a statistically significant reduction in the itch Numerical Rating Scale score from baseline at Week 4 of administration compared to a patient administered placebo during the same period. In some embodiments, the patient achieves at least a 3-point reduction in the itch Numerical Rating Scale score from baseline at Week 4 of administration. In some modalities, the patient achieves a clinically relevant improvement in the itch Numerical Rating Scale score at Week 4 of administration. In some embodiments, the patient achieves a statistically significant reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration compared to a patient administered placebo. Qfraznn / zznz / E / YiAi during the same period. In some embodiments, the patient achieves at least a 3-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration. In some embodiments, the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration. In some embodiments, the patient achieves a clinically relevant improvement in the itch Numerical Rating Scale score by week 8 of administration. In some embodiments, the patient achieves at least a 4.5 point reduction in the itch Numerical Rating Scale score from baseline at week 12 of administration. In some embodiments, administration reverses the symptomatology of atopic dermatitis. In some embodiments, the patient achieves a statistically significant improvement in Eczema Area and Severity Index score from baseline at Week 4 of administration compared to a patient administered placebo during the same period. Qfraznn / zznz / E / YiAi In some embodiments, the patient achieves a statistically significant improvement in the Eczema Area and Severity Index score from baseline at week 8 of administration compared to a patient administered placebo during the same period. In some modalities, the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline at week 2 of administration. In some modalities, the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline at Week 4 of administration. In some modalities, the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline at week 8 of dosing. In some modalities, the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline at week 12 of administration. In some modalities, the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from the value Initial QbQZnn / 77nZ / E / YIAI 2 weeks after administration. In some modalities, the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at 4 weeks post-administration. In some modalities, the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at 8 weeks post-administration. In some modalities, the patient achieves a clinically significant improvement in the PROMIS Abbreviated Form Sleep Disturbance 24-hour recovery score (8b) at Week 8. In some modalities, the patient achieves at least a 50% improvement in the overall Skindex-16 score at week 2 of administration. In some modalities, the patient achieves at least a 60% improvement in the overall Skindex-16 score at week 2 of administration. In some modalities, the patient achieves at least a 50% improvement in the overall Skindex-16 score by Week 4 of administration. In some modalities, the patient achieves at least a 60% improvement in the overall Skindex-16 score in Qfraznn / zznz / E / YiAi Week 4 of administration. In some modalities, the patient achieves at least a 70% improvement in the overall Skindex-16 score by Week 4 of administration. In some embodiments, the patient achieves at least a 50% improvement in the overall Skindex-16 score by week 8 of administration. In some embodiments, the patient achieves at least a 60% improvement in the overall Skindex-16 score by week 8 of administration. In some embodiments, the patient achieves at least a 70% improvement in the overall Skindex-16 score by week 8 of administration. In some embodiments, the patient suffers from mild to moderate atopic dermatitis. In some embodiments, administration is maintained for at least 2 weeks. In some embodiments, administration is maintained for at least 4 weeks. In some embodiments, administration is maintained for at least 8 weeks. In some embodiments, administration is continued for at least 12 weeks. The present invention also provides a method for reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, Qfraznn / zznz / E / YiAi a twice-daily cream formulation, wherein the cream formulation is an oil-in-water emulsion, comprising 1.5% (w / w) on a free base basis of ruxolitinib phosphate, wherein administration is maintained for at least 8 weeks, wherein the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration. The present invention further provides a method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation is an emulsion of oil in water, comprising 0.75% (w / w) on a phosphate free base basis of ruxolitinib, wherein administration is maintained for at least 8 weeks, wherein the patient achieves at least a 4 point reduction in Numerical Rating Scale itch score from baseline at week 8 of administration. The present invention also provides a method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the patient Qfraznn / zznz / E / YiAi human in need, a twice-daily cream formulation, wherein the cream formulation is an oil-in-water emulsion, comprising 1.5% (w / w) on a free base basis of ruxolitinib phosphate, wherein administration is maintained for at least 8 weeks, wherein the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of the administration, and where the patient: are between 18 and 70 years old, have been diagnosed with atopic dermatitis for at least 2 years, have a Global Assessment score of Investigator 2 to 3 at assessment and at baseline, and has a Body Surface Area affected by atopic dermatitis (excluding face and intertriginous areas) of 3% to 20% at baseline. The present invention further provides a method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need a cream formulation twice a day, wherein the cream formulation is an emulsion of oil in water, comprising 0.75% (w / w) or 1.5% (w / w) on Qfraznn / zznz / E / YiAi a ruxolitinib phosphate freebase base, wherein administration is maintained for at least 8 weeks, wherein the patient achieves at least a 4-point reduction in Numerical Rating Scale score of itching from baseline at week 8 of administration, and where the patient: is an adolescent > 12 to 17 years of age inclusive, or a man or woman > 18 years of age; has a history of AD for at least 2 years; has an Investigator Global Assessment score of 2 to 3 at baseline; and has a BSA % of AD involvement, excluding the scalp, of 3% to 20% at baseline. The present invention also provides a method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation is an emulsion. of oil in water, comprising 1.5% (w / w) on a free base basis of ruxolitinib phosphate, wherein administration is maintained for at least 8 weeks, wherein the patient achieves at least a 4 point reduction in the Rating Scale score α^αζηη / ζζηζ / Β / γίΛΐ Numerical itch from baseline at week 8 of dosing, and where the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at 8 weeks of the administration. The present invention also provides a method for reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation is an emulsion. of oil in water, comprising 0.75% (w / w) or 1.5% (w / w) on a phosphate free base basis of ruxolitinib, wherein administration is maintained for at least 8 weeks, wherein the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration, and where the patient achieves an Investigator's Global Assessment score of 0 or 1 with a improvement of at least 2 points from baseline at 8 weeks after administration. The present invention further provides a method of reducing itching in a human patient with dermatitis. Qfraznn / zznz / E / YiAi atopic, comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation is an oil-in-water emulsion, comprising 1.5% (p / p) on a ruxolitinib phosphate-free base basis, wherein administration is maintained for at least 8 weeks, wherein the patient achieves at least a 4-point reduction in Numerical Rating Scale score for itching to from baseline at week 8 of dosing, where the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at 8 weeks of dosing, and where the patient: is between 18 and 70 years old, has been diagnosed with atopic dermatitis for at least 2 years, has an Investigator's Global Assessment score of 2 to 3 at assessment and at baseline, and has a BSA of atopic dermatitis involvement ( excluding the face and intertriginous areas) from 3% to 20% Qfraznn / zznz / E / YiAi at the beginning of the study. The present invention further provides a method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation is an emulsion of oil in water, comprising 0.75% (w / w) or 1.5% (w / w) on a phosphate free base basis of ruxolitinib, wherein administration is maintained for at least 8 weeks, wherein the patient achieves minus a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration, where the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from the initial value 8 weeks after administration, and where the patient: is an adolescent between 12 and 17 years of age inclusive, or a man or woman > 18 years of age; has a history of AD for at least 2 years; has an Investigator Global Assessment score of 2 to 3 at baseline; and has a BSA % of AD involvement, excluding the scalp, of 3% to 20% at baseline. In another modality, the Qfraznn / zznz / E / YiAi The present invention provides a method for reducing itching in a human patient with atopic dermatitis, which comprises administering twice a day to the skin of the human patient in need thereof, a composition comprising: (1) 1.5% (w / w) on a free base basis of ruxolitinib phosphate, and (2) means for effecting dose-dependent skin penetration of ruxolitinib phosphate, wherein the patient achieves a reduction in the itch Numerical Rating Scale score from baseline. In another embodiment, the present invention provides a method for reducing itching in a human patient with atopic dermatitis, comprising administering twice daily to the skin of the human patient in need thereof, a composition comprising: (1) 0.75% (w / w) on a ruxolitinib phosphate free base basis, and (2) means for effecting dose-dependent skin penetration of ruxolitinib phosphate, wherein the patient achieves a reduction in the itch Numerical Rating Scale score from baseline. The present invention also provides a method Qfraznn / zznz / E / YiAi for reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w) on a free base basis of ruxolitinib, or one of its pharmaceutically acceptable salts, wherein the patient achieves a reduction in the itch Numerical Rating Scale score from baseline. The present invention also provides a method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / w) on a free base basis of ruxolitinib, or one of its pharmaceutically acceptable salts, wherein the patient achieves a reduction in the itch Numerical Rating Scale score from baseline. The present invention further provides a method of treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / w ) or 1.5% (w / w) on a free base basis of ruxolitinib, or one of its Qfraznn / zznz / E / YiAi pharmaceutically acceptable salts; wherein the patient has one or more characteristics selected from the group consisting of: an Eczema Area and Severity Index score of > 16 at baseline; a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline; an itch Numerical Rating Scale score of %4 at baseline; and an Investigator's Global Assessment score of at least 3 at baseline. The present invention also provides a method of treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / w ) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts; wherein the patient has one or more characteristics selected from the group consisting of: an Eczema Area and Severity Index score of > 16 at baseline; a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline; a score on the Rating Scale Qfraznn / zznz / E / YiAi Itching numeric of 1 4 at baseline; and an Investigator's Global Assessment score of at least 3 at baseline. The present invention further provides a method of treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w ) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts; wherein the patient has one or more characteristics selected from the group consisting of: an Eczema Area and Severity Index score of > 16 at baseline; a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline; a score on the Rating Scale Itching numeric of 1 4 at baseline; and a Global Assessment score Researcher of at least 3 at the beginning of the study. The present invention also provides a method of treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / w ) in a base of α^αζηη / ζζηζ / Β / γίΛΐ ruxolitinib phosphate-free base; wherein the patient has one or more characteristics selected from the group consisting of: an Eczema Area and Severity Index score of > 16 at baseline; a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline; a score on the Rating Scale Itching number of or 4 at the beginning of the study; and a Global Assessment score Researcher of at least 3 at the beginning of the study. The present invention further provides a method of treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w ) on a ruxolitinib phosphate free base basis; wherein the patient has one or more characteristics selected from the group consisting of: an Eczema Area and Severity Index score of > 16 at baseline; > a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline; an itch Numerical Rating Scale score of 1 4 at baseline; and QbQZnn / 77nZ / E / YIAI Investigator's Global Assessment score of at least 3 at baseline. In some embodiments, the patient has one or more characteristics selected from the group consisting of: an Eczema Area and Severity Index score of > 16 at baseline; a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline; an itch Numerical Rating Scale score of 1 4 at baseline; a Global Assessment score Researcher of > 3 at the beginning of the study; an age between 12 to 85 years; and history of atopic dermatitis for at least 2 years. In some embodiments, the patient has one or more characteristics selected from the group consisting of: an Eczema Area and Severity Index score of > 16 at baseline; a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline; and a score of 3 on the Investigator's Global Assessment at baseline. In some modalities, the patient has an Eczema Area and Severity Index score of > 16 Qfraznn / zznz / E / YiAi at the beginning of the study. In some embodiments, the patient has a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline. In some embodiments, the patient has a Body Surface Area affected by atopic dermatitis of 10% to 20% at baseline. In some modalities, the patient has an itch Numerical Rating Scale score of > 4 at baseline. In some modalities, the patient has an Investigator's Global Assessment score of 3 at baseline. In some embodiments, the patient suffers from moderate atopic dermatitis. In some embodiments, the patient suffers from moderate to severe atopic dermatitis. In some modalities, the patient has an Eczema Area and Severity Index of > 16 at baseline and a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline. In some embodiments of the embodiments of this paragraph, the Body Surface Area of ​​involvement by atopic dermatitis is alternatively 10% to 20% at baseline. In some modalities, the patient has an Eczema Area and Severity Index score of > 16 Qfraznn / zznz / E / YiAi at baseline, a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline, and an itch Numerical Rating Scale score of 1 4 at baseline. In some embodiments of the embodiments of this paragraph, the Body Surface Area of ​​involvement by atopic dermatitis is alternatively 10% to 20% at baseline. In some modalities, the patient, who has an Eczema Area and Severity Index score of 1 16 at baseline and a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline, achieves a 75% improvement in Baseline Eczema Area and Severity index score at week 2 of administration. In some embodiments of the embodiments of this paragraph, the Body Surface Area of ​​involvement by atopic dermatitis is alternatively 10% to 20% at baseline. In some modalities, the patient, who has an Eczema Area and Severity Index score of > 16 at baseline and a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline, achieves a 75% improvement in Baseline Eczema Area and Severity Index score at Week 4 of administration. In some embodiments of the embodiments of this paragraph, the Body Surface Area of ​​involvement by atopic dermatitis is alternatively 10% to 20% at baseline. In some embodiments, the patient, who has a QbQZnn / 77nZ / E / YIAI Eczema Area and Severity Index score of / 16 at baseline and a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline, achieves a 75% improvement in index score Baseline Eczema Area and Severity at week 8 of administration. In some embodiments of the embodiments of this paragraph, the Body Surface Area of ​​involvement by atopic dermatitis is alternatively 10% to 20% at baseline. In some modalities, the patient who has an Eczema Area and Severity Index score of 1 16 at baseline and a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at 2 weeks after administration. In some embodiments of the embodiments of this paragraph, the Body Surface Area of ​​involvement by atopic dermatitis is alternatively 10% to 20% at baseline. In some modalities, the patient, who has an Eczema Area and Severity Index score of 1 16 at baseline and a Body Surface Area with atopic dermatitis involvement of > 10% at baseline, achieves an Investigator's Global Assessment score. of 0 or 1 with an improvement of at least 2 points from baseline at 4 weeks after administration. In some Qfraznn / zznz / E / YiAi 100 modalities of the modalities of this paragraph, the Body Surface Area of ​​involvement by atopic dermatitis is alternatively 10% to 20% at the beginning. In some modalities, the patient, who has an Eczema Area and Severity Index score of 1 16 at baseline and a Body Surface Area with atopic dermatitis involvement of > 10% at baseline, achieves an Investigator's Global Assessment score. of 0 or 1 with an improvement of at least 2 points from baseline at 8 weeks after administration. In some embodiments of the embodiments of this paragraph, the Body Surface Area of ​​involvement by atopic dermatitis is alternatively 10% to 20% at baseline. In some modalities, the patient has an eczema area and severity index score of > 16 at baseline and a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline, achieves at least a 4-point reduction in Baseline itch Numerical Rating Scale score at week 2 of administration. In some embodiments of the embodiments of this paragraph, the Body Surface Area of ​​involvement by atopic dermatitis is alternatively 10% to 20% at baseline. In some modalities, the patient has an Eczema Area and Severity Index score of > 16 Qfraznn / zznz / E / YiAi 101 at the beginning of the study; a Body Surface Area with atopic dermatitis involvement of b 10% at baseline achieves a reduction of at least 4 points in the itch Numerical Rating Scale score from baseline at Week 4 of administration. In some embodiments of the embodiments of this paragraph, the Body Surface Area of ​​involvement by atopic dermatitis is alternatively 10% to 20% at baseline. In some modalities, the patient, who has an Eczema Area and Severity Index score of b 16 at baseline and a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline, achieves at least a 4-point reduction on the Numerical Rating Scale score from baseline at week 8 of administration. In some embodiments of the embodiments of this paragraph, the Body Surface Area affected by atopic dermatitis is alternatively 10% to 20% at the beginning. In some embodiments, the patient, who has an Eczema Area and Severity Index score of b 16 at baseline, a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline, and a Numerical Rating Scale score b 4 itch at baseline, achieves at least a 4-point reduction in the itch Numerical Rating Scale score from 102 baseline value at week 2 of administration. In some embodiments of the embodiments of this paragraph, the Body Surface Area of ​​involvement by atopic dermatitis is alternatively 10% to 20% at baseline. In some embodiments, the patient, who has an Eczema Area and Severity Index score of 1 16 at baseline, a Body Surface Area of ​​atopic dermatitis involvement of b 10% at baseline, and a Numerical Rating Scale score of L 4 itch at baseline, achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at Week 4 of administration. In some embodiments of the embodiments of this paragraph, the Body Surface Area of ​​involvement by atopic dermatitis is alternatively 10% to 20% at baseline. In some embodiments, the patient, who has an Eczema Area and Severity Index score of b 16 at baseline, a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline, and a Numerical Rating Scale score of b 4 itch at baseline, achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of dosing. In some embodiments of the embodiments of this paragraph, the Body Surface Area affected by dermatitis α^αζηη / ζζηζ / Β / γίΛΐ 103 atopic is alternatively 10% to 20% at the beginning. In some modalities, the patient has an Eczema Area and Severity Index score of 16 at baseline, a Body Surface Area with atopic dermatitis involvement of b 10% at baseline, and an Investigator's Global Assessment score of b 3. in the assessment and study initiation visits. In some embodiments of the embodiments of this paragraph, the Body Surface Area of ​​involvement by atopic dermatitis is alternatively 10% to 20% at baseline. In some modalities, the patient has an Eczema Area and Severity Index score of > 16 at baseline, a Body Surface Area with atopic dermatitis involvement of b 10% at baseline, and an Investigator's Global Assessment score of 3 at baseline. assessment and study initiation visits. In some embodiments of the embodiments of this paragraph, the Body Surface Area of ​​involvement by atopic dermatitis is alternatively 10% to 20% at baseline. In some modalities, the patient has characteristics comprising: an Eczema Area and Severity Index score of b 16 at baseline; a Body Surface Area affected by atopic dermatitis of b 10% at the beginning of the study; an age between 12 to 85 years; and history of atopic dermatitis during 104 minus 2 years. In some modalities, the characteristics also include an Investigator Global Assessment score of > 3 at the assessment and baseline visits. In some modalities, the characteristics also include an Investigator Global Assessment score of 3 at the assessment and study initiation visits. In some embodiments, the features further include an itch Numerical Rating Scale score of > 4 at baseline. In some embodiments of the embodiments of this paragraph, the Body Surface Area of ​​involvement by atopic dermatitis is alternatively 10% to 20% at baseline. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice daily, wherein the cream formulation comprises 0.75% (w / w) on a ruxolitinib phosphate-free base basis, wherein administration is maintained for at least 8 weeks, wherein the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from the initial in week 8 of administration, where the patient achieves a score of Qfraznn / zznz / E / YiAi 105 Investigator's Global Rating of 0 or 1 with an improvement of at least 2 points from baseline at 8 weeks after administration, and where the patient has one or more characteristics selected from the group consisting of: an Eczema Area and Severity Index score of > 16 at baseline; a Body Surface Area affected by atopic dermatitis of > 10% at baseline; a score on the Rating Scale Itch number 1 4 at baseline; a Global Assessment score Investigator of at least 3 at the beginning of the study; age > 12 years; and a history of atopic dermatitis for at least 2 years. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice daily, wherein the cream formulation comprises 0.75% (w / w) on a ruxolitinib phosphate-free base basis, wherein administration is maintained for at least 8 weeks, wherein the patient achieves at least a reduction Qfraznn / zznz / E / YiAi 106 out of 4 points on the itch Numerical Rating Scale score from baseline at week 8 of administration, where the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at 8 weeks post dosing, and where the patient has features including: an Eczema Area and Severity Index score of > 16 at baseline; a Body Surface Area affected by atopic dermatitis of > 10% at baseline; age > 12 years; and a history of atopic dermatitis for at least 2 years. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice daily, wherein the cream formulation comprises 0.75% (w / w) on a ruxolitinib phosphate-free base basis, wherein administration is maintained for at least 8 weeks, wherein the patient achieves at least a reduction Qfraznn / zznz / E / YiAi 107 out of 4 points on the itch Numerical Rating Scale score from baseline at week 8 of administration, where the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from the initial value 8 weeks after administration, and where the patient has characteristics that include: an Eczema Area and Severity Index score of > 16 at baseline; a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline; an itch Numerical Rating Scale score of 1 4 at baseline; age > 12 years; and history of atopic dermatitis for at least 2 years. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice daily, wherein the cream formulation comprises 0.75% (w / w) on a ruxolitinib phosphate free base basis, Qfraznn / zznz / E / YiAi where the administration is maintained for at least 108 minus 8 weeks, where the patient achieves at least a 4-point reduction in Itch Numerical Rating Scale score from baseline at week 8 of dosing, where the patient achieves an Evaluation score Investigator's Overall of 0 or 1 with an improvement of at least 2 points from baseline at 8 weeks after administration, and where the patient has: an Eczema Area and Severity Index score of > 16 at baseline; a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline; a score on the Rating Scale Itching numeric of % 4 at baseline; a score from the Global Assessment of Investigator of at least 3 at the beginning of the study; age > 12 years; and history of atopic dermatitis for at least 2 years. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein Qfraznn / zznz / E / YiAi 109 the cream formulation comprises 0.75% (w / w) on a phosphate free base basis of ruxolitinib, where administration is maintained for at least 8 weeks, where the patient achieves at least a 4 point reduction in Itching Numerical Rating Scale score from baseline at week 8 of administration, where the patient achieves an Investigator's Global Assessment score of 0 or 1 with at least a 2-point improvement from baseline. initial 8 weeks after administration, and where the patient has: an Eczema Area and Severity Index score of 2 16 at baseline; a Body Surface Area of ​​atopic dermatitis involvement of 2 10% at the beginning of the study; an itch Numerical Rating Scale score of 2 4 at baseline; a score of 3 on the Investigator's Global Assessment at the assessment and baseline visits; age 2 12 years; and history of atopic dermatitis for at least 2 years. In another embodiment, the present invention QbQZnn / 77nZ / E / YIAI 110 provides a method for treating atopic dermatitis in a human patient with atopic dermatitis, comprising administering twice daily to the skin of the human patient in need thereof, a composition comprising: (1) 0.75% (w / w) on a free base basis of ruxolitinib phosphate, and (2) means for effecting dose-dependent skin penetration of ruxolitinib phosphate, wherein the patient achieves successful IGA treatment. In another embodiment, the present invention provides a method for treating atopic dermatitis in a human patient with atopic dermatitis, which comprises administering twice daily to the skin of the human patient in need thereof, a composition comprising: (1) 0.75% (w / w) on a free base basis of ruxolitinib phosphate and (2) means to effect dose-dependent skin penetration of ruxolitinib phosphate, wherein the patient achieves EASI-75. In another embodiment, the present invention provides a method for treating atopic dermatitis in a human patient with atopic dermatitis, which comprises administering twice daily to the skin of the human patient in need thereof, a composition comprising: (1) 0.75% (w / w) on a free basis basis Qfraznn / zznz / E / YiAi 111 ruxolitinib phosphate, and (2) means for effecting dose-dependent skin penetration of ruxolitinib phosphate, wherein the patient achieves a reduction in the itch Numerical Rating Scale score from baseline. In another embodiment, the present invention provides a method for treating atopic dermatitis in a human patient with atopic dermatitis, which comprises administering twice daily to the skin of the human patient in need thereof, a composition comprising: (1) 0.75% (w / w) on a ruxolitinib phosphate free base basis, and (2) means for effecting dose-dependent skin penetration of ruxolitinib phosphate, wherein the patient achieves at least one 4-point improvement in Itch Numerical Rating Scale score improvement from baseline. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice daily, wherein the cream formulation comprises 1.5% (w / w) on a ruxolitinib phosphate free base basis, Qfraznn / zznz / E / YiAi where the administration is maintained for at least 112 minus 8 weeks, where the patient achieves at least a 4-point reduction in Itch Numerical Rating Scale score from baseline at week 8 of dosing, where the patient achieves an Assessment score Investigator's Overall of 0 or 1 with an improvement of at least 2 points from baseline at 8 weeks after administration, and where the patient has one or more characteristics selected from the group consisting of: an Eczema Area and Severity Index score of b 16 at baseline; a Body Surface Area affected by atopic dermatitis of b 10% at the beginning of the study; an itch Numerical Rating Scale score of b 4 at baseline; an Investigator Global Assessment score of b 3 at the assessment and baseline visits; age b 12 years; and a history of atopic dermatitis for at least 2 years. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient that α^αζηη / ζζηζ / Β / γίΛΐ 113 needs a twice daily cream formulation, wherein the cream formulation comprises 1.5% (w / w) on a phosphate free base basis of ruxolitinib, wherein administration is maintained for at least 8 weeks, wherein the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of dosing, where the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at 8 weeks after administration, and where the patient has characteristics that include: an Eczema Area and Severity Index score of b 16 at baseline; a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline; age > 12 years; and history of atopic dermatitis for at least 2 years. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient that Qfraznn / zznz / E / YiAi 114 need, a cream formulation twice a day, wherein the cream formulation comprises o 1.5% (w / w) on a phosphate free base basis of ruxolitinib, where administration is maintained for at least 8 weeks, wherein the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of dosing, wherein the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at 8 weeks after administration, and where the patient has characteristics that include: an Eczema Area and Severity Index score of b 16 at baseline; a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline; an itch Numerical Rating Scale score of b 4 at baseline; age b 12 years; and history of atopic dermatitis for at least 2 years. Qfraznn / zznz / E / YiAi The present invention further provides methods 115 for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w) on a base basis ruxolitinib phosphate-free, wherein administration is continued for at least 8 weeks, wherein the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 administration, where the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at 8 weeks post-administration, and where the patient has: an Eczema Area and Severity Index score of ¿16 at baseline; a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline; a score on the Rating Scale Itching numeric of % 4 at baseline; a Global Assessment score Investigator of at least 3 in the assessment and study initiation visits; Qfraznn / zznz / E / YiAi 116 age > 12 years; and history of atopic dermatitis for at least 2 years. The present invention further provides methods for treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a cream formulation twice daily, wherein the cream formulation comprises 1.5% (w / w) on a ruxolitinib phosphate-free base basis, wherein administration is maintained for at least 8 weeks, wherein the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from the baseline at week 8 of dosing, where the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at 8 weeks of dosing, and where patient has: an Eczema Area and Severity Index score of > 16 at baseline; a Body Surface Area of ​​atopic dermatitis involvement of > 10% at baseline; a score on the Rating Scale QbQZnn / 77nZ / E / YIAI 117 Itching number of 4 at the beginning of the study; a score of 3 on the Investigator's Global Assessment at the assessment and baseline visits; age h 12 years; and history of atopic dermatitis for at least 2 years. In another embodiment, the present invention provides a method for treating atopic dermatitis in a human patient with atopic dermatitis, which comprises administering twice daily to the skin of the human patient in need thereof, a composition comprising: (1) 1.5% (w / w) on a free base basis of ruxolitinib phosphate, and (2) means for effecting dose-dependent skin penetration of ruxolitinib phosphate, wherein the patient achieves successful IGA treatment. In another embodiment, the present invention provides a method for treating atopic dermatitis in a human patient with atopic dermatitis, which comprises administering twice daily to the skin of the human patient in need thereof, a composition comprising: (1) 1.5% (w / w) on a free base basis of ruxolitinib phosphate, and (2) means for effecting dose-dependent skin penetration of ruxolitinib phosphate, wherein Qfraznn / zznz / E / YiAi 118 the patient reaches EASI-75. In another embodiment, the present invention provides a method for treating atopic dermatitis in a human patient with atopic dermatitis, which comprises administering twice daily to the skin of the human patient in need thereof, a composition comprising: (1) 1.5% (w / w) on a free base basis of ruxolitinib phosphate, and (2) means for effecting dose-dependent skin penetration of ruxolitinib phosphate, wherein the patient achieves a reduction in the itch Numerical Rating Scale score from baseline. In another embodiment, the present invention provides a method for treating atopic dermatitis in a human patient with atopic dermatitis, which comprises administering twice daily to the skin of the human patient in need thereof, a composition comprising: (1) 1.5% (w / w) on a free base basis of ruxolitinib phosphate, and (2) means for effecting dose-dependent skin penetration of ruxolitinib phosphate, wherein the patient achieves at least one 4-point improvement in Itch Numerical Rating Scale score improvement from baseline. α^αζηη / ζζηζ / Β / γίΛΐ 119 Definitions As used herein, ruxolitinib phosphate means the phosphoric acid salt of ruxolitinib, wherein ruxolitinib and phosphoric acid are in a 1:1 ratio. In some embodiments, cream means a semisolid emulsion dosage form for application to the skin. When methods refer to on Day 2, Week 4, Week 8, Week 12, within 36 hours or within 12 hours of administration, this refers to the period of time after administration. first dose of the cream formulation where there is no interruption in administration. For example, if the method refers to a reduction in the NRS itch score from baseline at Week 8 for a patient administered the BID cream formulation, this means that the NRS itch score was assessed after 8 weeks of BID administration of the cream formulation after the first dose of the cream formulation without skipping days. In terms of NRS for itch, because ruxolitinib cream or vehicle is applied in the morning and NRS for itch is measured at night (see Phase 2 and Phase 3 studies in the Examples), in day 1 means after Qfraznn / zznz / E / YiAi 120 approximately 12 hours of administration, on day 2 means after approximately 36 hours of administration, on day 3 means after approximately 2.5 days of administration, etc. As used here, immediate itch reduction means that there is a statistically significant reduction in the NRS itch score within 12 hours (or as used here on day 1) of the first administration of ruxolitinib cream in comparison with the vehicle. The Hanifin and Rajika criteria are described in Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis, Acta Derm Venereol Suppl (Stockh) 1980; 92:4447, which is incorporated herein by reference in its entirety. As used herein, %BSA refers to the percentage of total Body Surface Area affected by AD. It can be determined with an accuracy of 0.1% (handprint) using, as guides, the palm of the hand with the fingers at 1% and the thumb at 0.1% for areas identified to be treated with ruxolitinib cream at baseline ( excluding the face and intertriginous areas; or alternatively, excluding the scalp). As used herein, punctuation Itching NRS refers to the Rating Scale 121 Itching numeric. The Itch NRS is a daily, patient-reported (24-hour recall) measure of itch intensity. Subjects will be asked to rate the severity of itching due to their AD by selecting a number from 0 (no itching) to 10 (worst itching imaginable) that best describes their worst level of itching in the last 24 hours. In one non-limiting example, patients may be provided with a portable device (eDiary) in which to record the severity of itching. The patient may be instructed to complete the eDiary each night. As used herein, EASI refers to the Eczema Area and Severity Index. The EASI scoring system is a validated disease measure for clinical studies (Hanifin JM, et al., Exp Dermatol 2001;10:11-18). The severity strata for EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very serious. As used herein, EASI-75 refers to a > 75% improvement in the patient's Eczema Area and Severity Index. As used in this document, BID refers to twice a day. As used in this document, QD refers to 122 once a day. As used herein, statistically significant means a p-value of <0.05 (preferably <0.001 and most preferably <0.0001). As used in this document, IGA refers to Investigator Global Assessment. The qualifications for IGA are shown in the following table: Grade Severity State 0 Free No inflammatory signs of AS 1 Almost free Faint erythema and faint papulation / infiltration 2 Mild disease Mild erythema and mild papulation / infiltration 3 Moderate disease Moderate erythema and moderate papulation / infiltration 4 Severe disease Severe erythema and papulation / severe infiltration 5 Very severe disease Severe erythema and severe papulation / infiltration with suppuration / crusting As used herein, IGA-TS stands for Investigator's Global Assessment Treatment Success, which is an IGA score of 0 or 1 with a 1-2 degree improvement from baseline. As used herein, the phrase "pharmaceutically acceptable" means those compounds, materials, compositions, and / or dosage forms that, 123 within the scope of good medical judgment, are suitable for use in contact with human and animal tissues. In some embodiments, pharmaceutically acceptable means approved by a regulatory agency of the federal or state government or listed in the US Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, pharmaceutically acceptable salts refers to derivatives of the described compounds in which the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkaline or organic salts of acid residues such as carboxylic acids; and the like. Pharmaceutically acceptable salts of the present invention include conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound containing a basic or acidic moiety by chemical methods α^αζηη / ζζηζ / Β / γι 124 conventional. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate acid or base in water or in an organic solvent, or in a mixture of the two; In general, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile (MeCN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety. In some embodiments, the pharmaceutically acceptable salt is a phosphoric acid salt, a sulfuric acid salt, or a maleic acid salt. As used herein, PROMIS refers to the Patient-Reported Outcomes Measurement Information System (PROMIS®), which is a set of widely used and accepted patient-reported outcome measures that have been developed using robust methods. of clinical outcome assessment development and are psychometrically supported. The selected PROMIS Short Form - Sleep-Related Impairment (8a) and Short Form - Sleep Disturbance (8b) questionnaires have been modified to be completed by diary on a daily basis with 24-hour recall: 125 Short Form - Sleep Related Impairment (8a) is collected in the evening, and Short Form - Sleep Disturbance (8b) is collected in the morning during the vehicle monitoring period. As used herein, minimal clinically important difference or MCID refers to a 2-3 point reduction in the itch NRS compared to baseline. As used herein, clinically relevant improvement or CRI refers to a 4-point reduction in the itch NRS compared to baseline. As used herein, the term emulsifying component refers, in one aspect, to a substance or mixtures of substances that maintain an element or particle in suspension within a fluid medium. In some embodiments, the emulsifying component allows an oil phase to form an emulsion when combined with water. In some embodiments, the emulsifying component refers to one or more nonionic surfactants. As used herein, the term occlusive agent component refers to a hydrophobic agent or mixtures of hydrophobic agents that form an occlusive film on the skin that reduces transepidermal water loss (TEWL) by preventing evaporation of water 126 of the stratum corneum. As used herein, the term hardening agent component refers to a substance or mixture of substances that increases the viscosity and / or consistency of the cream or improves the rheoloqy of the cream. As used herein, the term emollient component refers to an agent that softens or soothes the skin or soothes an irritated internal surface. As used herein, the term stabilizing agent component refers to a substance or mixture of substances that improves the stability of the cream and / or the compatibility of the components in the cream. In some embodiments, the stabilizing agent component prevents agglomeration of the emulsion and stabilizes the droplets in the oil-in-water emulsion. As used herein, the term "solvent component" is a liquid substance or mixture of liquid substances capable of dissolving ruxolitinib (or its salt) or other substances in the cream. In some embodiments, the solvent component is a liquid substance or a mixture of liquid substances in which ruxolitinib, or its pharmaceutically acceptable salt, has a reasonable solubility. For example, the solubilities of ruxolitinib (free base) or its phosphate salt (1:1 salt) are reported in the αίταζηη / ζζηζ / Ε / γΐι 127 Table 1. In some embodiments, a solvent is a substance or a mixture thereof, wherein ruxolitinib, or its pharmaceutically acceptable salt (whichever is used), has a solubility of at least about 10 mg / mL or greater, at less about 15 mg / mL or greater, or at least about 20 mg / mL or greater, when measured as described in Example 2. As used herein, the phrase antimicrobial preservative component is a substance or mixtures of substances that inhibit microbial growth in the cream. As used herein, the phrase "chelating agent component" refers to a compound or mixtures of compounds that have the ability to bind strongly with metal ions. As used herein, emulsion wt % means that the percentage concentration of the component in the emulsion is based on w / w. For example, 1% w / w of component A = [(mass of component A) / (total mass of emulsion)] x 100. As used herein, % by weight of the emulsion on a basis free of ruxolitinib, or one of its pharmaceutically acceptable salts, means that the % w / w is calculated based on the weight of ruxolitinib in the total emulsion. For example, 1.5% w / w on a basis of 128 ruxolitinib phosphate free base means that, for 100 grams of total formulation, there are 1.98 grams of ruxolitinib phosphate in the emulsion (which is equivalent to 1.5 grams of the free base, ruxolitinib). As used herein, the term component can mean a substance or a mixture of substances. As used herein, the term fatty acid refers to an aliphatic acid that is saturated or unsaturated. In some embodiments, the fatty acid is in a mixture of different fatty acids. In some embodiments, the fatty acid has between about eight and about thirty carbons on average. In some embodiments, the fatty acid has an average of about 12 to 20, 14-20 or 16-18 carbons. Suitable fatty acids include, but are not limited to, cetyl acid, stearic acid, lauric acid, myristic acid, erucic acid, palmitic acid, palmitoleic acid, capric acid, caprylic acid, oleic acid, linoleic acid, linolenic acid, hydroxystearic acid, 12-hydroxystearic acid , cetostearic acid, isostearic acid, sesquioleic acid, sesqui-9-octadecanoic acid, sesquiisooctadecanoic acid, behenic acid, isobehenic acid and arachidonic acid, or mixtures thereof. As used herein, the term fatty alcohol refers to an aliphatic alcohol that is saturated or 129 unsaturated. In some embodiments, the fatty alcohol is found in a mixture of different fatty alcohols. In some embodiments, the fatty alcohol has between about 12 to about 20, about 14 to about 20, or about 16 to about 18 carbons on average. Suitable fatty alcohols include, but are not limited to, stearyl alcohol, lauryl alcohol, palmityl alcohol, cetyl alcohol, capryl alcohol, capryl alcohol, oleyl alcohol, linolenyl alcohol, arachidonic alcohol, behenyl alcohol, isobehenyl alcohol, selakyl alcohol, chemical alcohol, and alcohol. linoleic, or mixtures thereof. As used herein, the term polyalkylene glycol, used alone or in combination with other terms, refers to a polymer containing oxyalkylene monomer units, or copolymer of different oxyalkylene monomer units, wherein the alkylene group has 2 to 6, 2a4, or 2a3 carbon atoms. As used herein, the term oxyalkylene, used alone or in combination with other terms, refers to a group of formula -O-alkylene-. In some embodiments, the polyalkylene glycol is polyethylene glycol. As used herein, the term sorbitan fatty ester includes products derived from sorbitan or sorbitol and fatty acids and, optionally, 130 poly(ethylene glycol) units, including sorbitan esters and polyethoxylated sorbitan esters. In some embodiments, the sorbitan fatty ester is a polyethoxylated sorbitan ester. As used herein, the term "sorbitan ester" refers to a compound, or mixture of compounds, derived from the esterification of sorbitol and at least one fatty acid. Fatty acids useful for deriving sorbitan esters include, but are not limited to, those described herein. Suitable sorbitan esters include, but are not limited to, the Span™ series (available from Uniqema), which includes Span 20 (sorbitan monolaurate), 40 (sorbitan monopalmitate), 60 (sorbitan monostearate), 65 (sorbitan tristearate) , 80 (sorbitan monooleate) and 85 (sorbitan trioleate). Other suitable sorbitan esters include those listed in R. C. Rowe and P. J. Shesky, Handbook of Pharmaceutical excipients, (2006), 5aed., which is incorporated herein by reference in its entirety. As used herein, the term "polyethoxylated sorbitan ester" refers to a compound, or mixture thereof, derived from the ethoxylation of a sorbitan ester. The polyoxethylene portion of the compound may be between the fatty ester and the sorbitan moiety. As used herein, the term sorbitan ester refers to a compound or mixture of compounds, α^αζηη / ζζηζ / Β / γίΛΐ 131 derived from the esterification of sorbitol and at least one fatty acid. Fatty acids useful for deriving polyethylated sorbitan esters include, but are not limited to, those described herein. In some embodiments, the polyoxyethylene portion of the compound or mixture has from about 2 to about 200 oxyethylene units. In some embodiments, the polyoxyethylene portion of the compound or mixture has from about 2 to about 100 oxyethylene units. In some embodiments, the polyoxyethylene portion of the compound or blend has from about 4 to about 80 oxyethylene units. In some embodiments, the polyoxyethylene portion of the compound or blend has about 4 to about 40 oxyethylene units. In some embodiments, the polyoxyethylene portion of the compound or blend has from 4 to 20 oxyethylene units. Suitable polyethoxylated sorbitan esters include, but are not limited to, the Tween™ series (available from Uniqema), which includes Tween 20 (POE(20) sorbitan monolaurate), 21 (POE(4) sorbitan monolaurate), 40 (POE(4) sorbitan monolaurate), 20) sorbitan monopalmitate), 60 (POE(20) sorbitan monostearate), 60K (POE(20) sorbitan monostearate), 61 (POE(4) sorbitan monostearate), 65 (POE(20) sorbitan tristearate) , 80 (POE(20) sorbitan monooleate), 80K (sorbitan monooleate 132 sorbitan POE(20)), 81 (sorbitan monooleate POE(5)) and 85 (sorbitan trioleate POE(20)). As used herein, the abbreviation POE refers to polyoxyethylene. The number following the abbreviation POE refers to the number of repeating oxyethylene units in the compound. Other suitable polyethoxylated sorbitan esters include the polyoxyethylene sorbitan fatty acid esters listed in R. C. Rowe and P. J. Shesky, Handbook of Pharmaceutical Excipients, (2006), 5aed., which is incorporated herein by reference in its entirety. In some embodiments, the polyethoxylated sorbitan ester is a polysorbate. In some embodiments, the polyethoxylated sorbitan ester is polysorbate 20. As used herein, the term glyceryl fatty esters refers to mono-, di- or triglycerides of fatty acids. The glyceryl fatty esters may be optionally substituted with sulfonic acid groups or their pharmaceutically acceptable salts. Fatty acids suitable for deriving fatty acid glycerides include, but are not limited to, those described herein. In some embodiments, the glyceryl fatty ester is a monoglyceride of a fatty acid having 12 to 18 carbon atoms. In some embodiments, the glyceryl fatty ester is glyceryl stearate. As used herein, the term Qfraznn / zznz / E / YiAi 133 triglycerides refers to a triglyceride of a fatty acid. In some embodiments, the triglyceride is medium chain triglycerides. As used herein, the term alkylene glycol refers to a group of formula -0alkylene-, wherein the alkylene group has 2 to 6, 2 to 4 or 2 to 3 carbon atoms. In some embodiments, the alkylene glycol is propylene glycol (1,2-propanediol). As used herein, the term polyethylene glycol refers to a polymer containing ethylene glycol monomeric units of formula -O-CH2-CH2-. Suitable polyethylene glycols may have a free hydroxyl group at each end of the polymer molecule, or may have one or more hydroxyl groups etherified with a lower alkyl, for example a methyl group. Polyethylene glycol derivatives having esterifiable carboxyl groups are also suitable. Polyethylene glycols useful in the present invention can be polymers of any chain length or molecular weight and can include branches. In some embodiments, the average molecular weight of the polyethylene glycol is about 200 to about 9000. In some embodiments, the average molecular weight of the polyethylene glycol is about 200 to about 5000. In some embodiments, the average molecular weight of the polyethylene glycol is QbQZnn / 77nZ / E / YIAI 134 about 200 to about 900. In some embodiments, the average molecular weight of the polyethylene glycol is about 400. Suitable polyethylene glycols include, but are not limited to, polyethylene glycol-200, polyethylene glycol-300, polyethylene glycol-4 0 0, polyethylene glycol-600 and polyethylene glycol- 900. The number following the hyphen in the name refers to the average molecular weight of the polymer. In some embodiments, approximately means roughly 10% of the value. Cream formulations In some embodiments, the cream formulation is an oil-in-water emulsion. In some embodiments, the cream is a solubilized cream. In some embodiments, the cream has a pH of about 2.8 to about 3.6. In the context of pH, approximately refers to +0.3 (preferably +0.2or more preferably +0.1). In some embodiments, the cream comprises an oil-in-water emulsion, comprising 1.5% (w / w) on a ruxolitinib phosphate free base basis. In some embodiments, the cream is an oil-in-water emulsion as described in US 2015 / 0250790, which is incorporated herein by reference in its entirety. In particular, Examples 3-6 of US 2015 / 0250790 (and particularly Tables 3-5 and the text Qfraznn / zznz / E / YiAi 135 attached) are incorporated herein by reference. In some embodiments, the oil component is present in an amount of about 10% to about 40% by weight of the emulsion. In some embodiments, the oil component is present in an amount of about 10% to about 24% by weight of the emulsion. In some embodiments, the oil component is present in an amount of about 15% to about 24% by weight of the emulsion. In some embodiments, the oil component is present in an amount of about 18% to about 24% by weight of the emulsion. In some embodiments, the oil component comprises one or more substances independently selected from petrolatum, fatty alcohols, mineral oils, triglycerides and silicone oils. In some embodiments, the oil component comprises one or more substances independently selected from white petrolatum, cetyl alcohol, stearyl alcohol, light mineral oil, medium chain triglycerides and dimethicone. In some embodiments, the oil component comprises an occlusive agent component. In some embodiments, the agent component QbQZnn / 77nZ / E / YIAI 136 occlusive is present in an amount of about 2% to about 15% by weight of the emulsion. In some embodiments, the occlusive agent component is present in an amount of about 5% to about 10% by weight of the emulsion. In some embodiments, the occlusive agent component comprises one or more substances selected from fatty acids (e.g., lanolin acid), fatty alcohols (e.g., lanolin alcohol), hydrocarbon oils and waxes (e.g., petroleum jelly), polyhydric alcohols (e.g. propylene glycol), silicones (e.g. dimethicone), sterols (e.g. cholesterol), vegetable or animal fat (e.g. cocoa butter), vegetable wax (e.g. carnauba wax ) and wax ester (e.g. beeswax). In some embodiments, the occlusive agent component comprises one or more substances selected from fatty alcohols of lanolin acid, lanolin alcohol, petrolatum, propylene glycol, dimethicone, cholesterol, cocoa butter, carnauba wax and beeswax. In some embodiments, the occlusive agent component comprises petroleum jelly. In some embodiments, the occlusive agent component comprises white petroleum jelly. In some embodiments, the oil component Qfraznn / zznz / E / YiAi 137 comprises a hardening agent component. In some embodiments, the curing agent component is present in an amount of about 2% to about 8% by weight of the emulsion. In some embodiments, the curing agent component is present in an amount of about 3% to about 6% by weight of the emulsion. In some embodiments, the curing agent component is present in an amount of about 4% to about 7% by weight of the emulsion. In some embodiments, the curing agent component comprises one or more substances independently selected from fatty alcohols. In some embodiments, the curing agent component comprises one or more substances independently selected from C12-20 fatty alcohols. In some embodiments, the curing agent component comprises one or more substances independently selected from Cig-is fatty alcohols. In some embodiments, the hardening agent component comprises one or more substances independently selected from cetyl alcohol and stearyl alcohol. 138 In some embodiments, the oil component comprises an emollient component. In some embodiments, the emollient component is present in an amount of about 5% to about 15% by weight of the emulsion. In some embodiments, the emollient component is present in an amount of about 7% to about 13% by weight of the emulsion. In some embodiments, the emollient component comprises one or more substances independently selected from mineral oils and triglycerides. In some embodiments, the emollient component comprises one or more substances independently selected from light mineral oil and medium chain triglycerides. In some embodiments, the emollient component comprises one or more substances independently selected from light mineral oil, medium chain triglycerides and dimethicone. In some embodiments, water is present in an amount of about 35% to about 65% by weight of the emulsion. In some embodiments, water is present in an amount of about 40% to about 60% by weight of the emulsion. α^αζηη / ζζηζ / Β / γίΛΐ 139 In some embodiments, water is present in an amount of about 45% to about 55% by weight of the emulsion. In some embodiments, the emulsifying component is present in an amount of about 1% to about 9% by weight of the emulsion. In some embodiments, the emulsifying component is present in an amount of about 2% to about 6% by weight of the emulsion. In some embodiments, the emulsifying component is present in an amount of about 3% to about 5% by weight of the emulsion. In some embodiments, the emulsifying component is present in an amount of about 4% to about 7% by weight of the emulsion. In some embodiments, the emulsion comprises an emulsifier component and a hardening agent component, wherein the combined amount of emulsifying component and hardening agent component is at least about 8% by weight of the emulsion. In some embodiments, the emulsifying component comprises one or more substances independently selected from glyceryl fatty esters and sorbitan fatty esters. In some embodiments, the emulsifying component Qfraznn / zznz / E / YiAi 140 comprises one or more substances independently selected from glyceryl stearate and polysorbate 20. In some embodiments, the emulsion further comprises a stabilizing agent component. In some embodiments, the stabilizing agent component is present in an amount of about 0.05% to about 5% by weight of the emulsion. In some embodiments, the stabilizing agent component is present in an amount of about 0.1% to about 2% by weight of the emulsion. In some embodiments, the stabilizing agent component is present in an amount of about 0.3% to about 0.5% by weight of the emulsion. In some embodiments, the stabilizing agent component comprises one or more substances independently selected from polysaccharides. In some embodiments, the stabilizing agent component comprises xanthan gum. In some embodiments, the emulsion further comprises a solvent component. In some embodiments, the solvent component is present in an amount of about 10% to 141 about 35% by weight of the emulsion. In some embodiments, the solvent component is present in an amount of about 15% to about 30% by weight of the emulsion. In some embodiments, the solvent component is present in an amount of about 20% to about 25% by weight of the emulsion. In some embodiments, the solvent component comprises one or more substances independently selected from alkylene glycols and polyalkylene glycols. In some embodiments, the solvent component comprises one or more substances independently selected from propylene glycol and polyethylene glycol. In some embodiments, the emulsion comprises: from about 35% to about 65% water by weight of the emulsion; from about 10% to about 40% of an oil component by weight of the emulsion; from about 1% to about 9% of an emulsifier component by weight of the emulsion; from about 10% to about 35% of a solvent component by weight of the emulsion; from about 0.05% to about 5% of a stabilizing agent component by weight of the emulsion; and 142 from 0.5% to 1.5% ruxolitinib, or one of its pharmaceutically acceptable salts, by weight of the free base emulsion. In some embodiments, the emulsion comprises: from about 35% to about 65% water by weight of the emulsion; from about 10% to about 24% of an oil component by weight of the emulsion; from about 1% to about 9% of an emulsifier component by weight of the emulsion; from about 10% to about 35% of a solvent component by weight of the emulsion; from about 0.05% to about 5% of a stabilizing agent component by weight of the emulsion; and from 0.5% to 1.5% of ruxolitinib, or one of its pharmaceutically acceptable salts, by weight of the free base emulsion. In some embodiments, the emulsion comprises: from about 40% to about 60% water by weight of the emulsion; from about 15% to about 30% of an oil component by weight of the emulsion; from about 2% to about 6% of an emulsifying component by weight of the emulsion; from about 15% to about 30% of a α^αζηη / ζζηζ / Β / γΐί 143 solvent component by weight of the emulsion; from about 0.1% to about 2% of a stabilizing agent component by weight of the emulsion; and 0.5% to 1.5% of ruxolitinib, or a pharmaceutically acceptable salt thereof, by weight of the free base emulsion. In some embodiments, the emulsion comprises: from about 40% to about 60% water by weight of the emulsion; from about 15% to about 30% of an oil component by weight of the emulsion; from about 2% to about 6% of an emulsifying component by weight of the emulsion; from about 15% to about 24% of a solvent component by weight of the emulsion; from about 0.1% to about 2% of a stabilizing agent component by weight of the emulsion; and 0.5% to 1.5% of ruxolitinib, or a pharmaceutically acceptable salt thereof, by weight of the free base emulsion. In some embodiments, the emulsion comprises: from about 45% to about 55% water by weight of the emulsion; from about 15% to about 24% of an oil component by weight of the emulsion; 144 from about 3% to about 5% of an emulsifying component by weight of the emulsion; from about 20% to about 25% of a solvent component by weight of the emulsion; from about 0.3% to about 0.5% of a stabilizing agent component by weight of the emulsion; and 0.5% to 1.5% of ruxolitinib, or a pharmaceutically acceptable salt thereof, by weight of the free base emulsion. In some embodiments, the emulsion comprises: from about 45% to about 55% water by weight of the emulsion; from about 15% to about 24% of an oil component by weight of the emulsion; from about 4% to about 7% of an emulsifying component by weight of the emulsion; from about 20% to about 25% of a solvent component by weight of the emulsion; from about 0.3% to about 0.5% of a stabilizing agent component by weight of the emulsion; and 0.5% to 1.5% of ruxolitinib, or a pharmaceutically acceptable salt thereof, by weight of the free base emulsion. In some modalities: the oil component comprises one or more substances 145 independently selected from petrolatum, fatty alcohols, mineral oils, triglycerides and dimethicones; the emulsifying component comprises one or more substances independently selected from glyceryl fatty esters and sorbitan fatty esters; the solvent component comprises one or more substances independently selected from alkylene glycols and polyalkylene glycols; and the stabilizing agent component comprises one or more substances independently selected from polysaccharides. In some modalities: the oil component comprises one or more substances independently selected from white petroleum jelly, cetyl alcohol, stearyl alcohol, light mineral oil, medium chain triglycerides and dimethicone; the emulsifying component comprises one or more substances independently selected from glyceryl stearate and polysorbate 20; the solvent component comprises one or more substances independently selected from propylene glycol and polyethylene glycol; and the stabilizing agent component comprises xanthan gum. In some embodiments, the emulsion comprises: 146 from about 35% to about 65% water by weight of the emulsion; from about 2% to about 15% of an occlusive component by weight of the emulsion; from about 2% to about 8% of a curing agent component by weight of the emulsion; from about 5% to about 15% of an emollient component by weight of the emulsion; from about 1% to about 9% of an emulsifier component by weight of the emulsion; from about 0.05% to about 5% of a stabilizing agent component by weight of the emulsion; from about 10% to about 35% of a solvent component by weight of the emulsion; and from 0.5% to 1.5% ruxolitinib, or a pharmaceutically acceptable salt thereof, by weight of the free base emulsion. In some embodiments, the emulsion comprises: from about 40% to about 60% water by weight of the emulsion; from about 5% to about 10% of an occlusive agent component by weight of the emulsion; from about 2% to about 8% of a hardening agent component by weight of the 147 emulsion; from about 7% to about 12% of an emollient component by weight of the emulsion; from about 2% to about 6% of an emulsifying component by weight of the emulsion; from about 0.1% to about 2% of a stabilizing agent by weight of the emulsion; from about 15% to about 30% of a solvent component by weight of the emulsion; and 0.5% to 1.5% of ruxolitinib, or a pharmaceutically acceptable salt thereof, by weight of the free base emulsion. In some embodiments, the emulsion comprises: from about 45% to about 55% water by weight of the emulsion; from about 5% to about 10% of an occlusive agent component by weight of the emulsion; from about 3% to about 6% of a stiffening agent component by weight of the emulsion; from about 7% to about 13% of an emollient component by weight of the emulsion; from about 3% to about 5% of an emulsifying component by weight of the emulsion; from about 0.3% to about 0.5% of a stabilizing agent component by weight of the emulsion; 148 from about 20% to about 25% of a solvent component by weight of the emulsion; and 0.5% to 1.5% of ruxolitinib, or a pharmaceutically acceptable salt thereof, by weight of the free base emulsion. In some embodiments, the emulsion comprises: from about 45% to about 55% water by weight of the emulsion; from about 5% to about 10% of an occlusive component by weight of the emulsion; from about 4% to about 7% of a stiffener component by weight of the emulsion; from about 7% to about 13% of an emollient component by weight of the emulsion; from about 4% to about 7% of an emulsifier component by weight of the emulsion; from about 0.3% to about 0.5% of a stabilizing agent component by weight of the emulsion; from about 20% to about 25% of a solvent component by weight of the emulsion; and from 0.5% to 1.5% ruxolitinib, or a pharmaceutically acceptable salt thereof, by weight of the free base emulsion. In some embodiments, the emulsion comprises: from about 45% to about 55% water 149 by weight of the emulsion; about 7% of an occlusive agent component by weight of the emulsion; from about 4.5% to about 5% of a stiffening agent component by weight of the emulsion; about 10% of an emollient component by weight of the emulsion; from about 4% to about 4.5% of an emulsifier component by weight of the emulsion; about 0.4% of a stabilizing agent component by weight of the emulsion; about 22% of a solvent component by weight of the emulsion; and from 0.5% to 1.5% ruxolitinib, or a pharmaceutically acceptable salt thereof, by weight of the free base emulsion. In some embodiments, ruxolitinib, or a pharmaceutically acceptable salt thereof, is present as ruxolitinib phosphate. In some embodiments, the emulsion comprises 1.5% ruxolitinib, or a pharmaceutically acceptable salt thereof, by weight of the emulsion. In some embodiments, the emulsion comprises 1.5% ruxolitinib phosphate by weight of the emulsion. In some embodiments, the emulsion comprises 0.75% 150 of ruxolitinib, or one of its pharmaceutically acceptable salts, by weight of the emulsion. In some embodiments, the emulsion comprises 0.75% ruxolitinib phosphate by weight of the emulsion. In some embodiments, the combined amount of the curing agent component and the emulsifier component is at least about 8% by weight of the emulsion. In some modalities: the occlusive agent component comprises petroleum jelly; the curing agent component comprises one or more substances independently selected from one or more fatty alcohols; the emollient component comprises one or more substances independently selected from mineral oils and triglycerides; the emulsifying component comprises one or more substances independently selected from glyceryl fatty esters and sorbitan fatty esters; the stabilizing agent component comprises one or more substances independently selected from polysaccharides; and the solvent component comprises one or more substances selected independently of Qfraznn / zznz / E / YiAi 151 alkylene glycols and polyalkylene glycols. In some modalities: the occlusive agent component comprises white petroleum jelly; the curing agent component comprises one or more substances independently selected from cetyl alcohol and stearyl alcohol; the emollient component comprises one or more substances independently selected from light mineral oil, medium chain triglycerides and dimethicone; the emulsifying component comprises one or more substances independently selected from glyceryl stearate and polysorbate 20; the stabilizing agent component comprises xanthan gum; and the solvent component comprises one or more substances independently selected from propylene glycol and polyethylene glycol. In some embodiments, the emulsion further comprises an antimicrobial preservative component. In some embodiments, the antimicrobial preservative component is present in an amount of about 0.05% to about 3% by weight of the emulsion. Qfraznn / zznz / E / YiAi In some embodiments, the conservative component 152 antimicrobial is present in an amount of about 0.1% to about 1% by weight of the emulsion. In some embodiments, the antimicrobial preservative component comprises one or more substances independently selected from alkylparabens and phenoxyethanol. In some embodiments, the antimicrobial preservative component comprises one or more substances independently selected from methylparaben, propylparaben and phenoxyethanol. In some embodiments, the emulsion further comprises a chelating agent component. In some embodiments, the chelating agent component comprises edetate disodium. Ruxolitinib can be prepared as described in US Patent 7,598,257 and US Patent Publication No. 2 0 0 9 / 0181959, each of which is incorporated herein by reference in its entirety. The 1:1 ruxolitinib phosphate salt can be prepared as described in US Patent Publication No. 2008 / 0312259, which is incorporated herein by reference in its entirety. As will be appreciated, some components of the cream (emulsion) described herein may have various functions. For example, a given substance can QbQZnn / 77nZ / E / YIAI 153 act as an emulsifying agent component and as a stabilizing agent. In some of these cases, the function of a given component may be considered singular, although its properties may allow for multiple functionality. In some embodiments, each component of the formulation comprises a different substance or mixture of substances. It is further appreciated that certain features of the invention, which are described, for clarity, in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention that, for the sake of brevity, are described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. The following modalities are provided: . A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w) on a ruxolitinib phosphate-free base basis, where the patient achieves a reduction in Itch Numerical Rating Scale score from baseline. Qfraznn / zznz / E / YiAi 154 2. The modality 1 method, where the patient: is between 18 and 70 years old, has been diagnosed with atopic dermatitis for at least 2 years, has an IGA score of 2 to 3 at assessment and at baseline, and has a BSA of atopic dermatitis involvement (excluding face and intertriginous areas) from 3% to 20% at the beginning of the study. 3. The modality 1 or 2 method, where the patient is diagnosed with atopic dermatitis as defined by the Hanifin and Rajika criteria. 4. The method of any of the modalities 1-3, where the two administrations per day have a difference of at least 8 hours. 5. The method of any of embodiments 1-4, wherein the cream formulation is an oil-in-water emulsion comprising 1.5% (w / w) on a ruxolitinib phosphate free base basis. 6. The method of any of embodiments 1-5, wherein the cream formulation has a pH of about 2.8 to about 3.6. 7. The method of any of the modalities 1-6, Qfraznn / zznz / E / YiAi wherein the cream formulation is a solubilized cream. 155 8. The method of any of the modalities 1-7, wherein the patient achieves a statistically significant reduction in the itch Numerical Rating Scale score from baseline on day 2 of administration compared to a patient who was administered placebo during the same period. 9. The method of any of modalities 1-8, wherein the patient achieves at least a 1.5 point reduction in the itch Numerical Rating Scale score from baseline on day 2 of administration. 10. The either modality ΙΟ method, wherein the patient achieves a statistically significant reduction in the itch Numerical Rating Scale score from baseline at week 2 of administration compared to a patient receiving placebo was administered during the same period. 11. The any of the ΙΙΟ modalities method, wherein the patient achieves a reduction of at least 3 points in the itch Numerical Rating Scale score from baseline in week 2 of administration. 12. The method of any of the modalities 1- 11, where the patient achieves a statistically significant reduction in the Scale score Qfraznn / zznz / E / YiAi 156 Numerical Rating of itch from baseline at Week 4 of administration compared to a patient administered placebo during the same period. 13. The method of any of the 112 modalities, wherein the patient achieves a reduction of at least 3 points in the itch Numerical Rating Scale score from baseline at Week 4 of administration. 14. The method of any of the modalities 1- 13, where the patient achieved a statistically significant reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration as compared to a patient administered placebo for the same period. 15. The method of either modality 114, wherein the patient achieves a reduction of at least 3 points in the itch Numerical Rating Scale score from baseline at week 8 of administration. 16. Either modality method 115, where the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week α^αζηη / ζζηζ / Β / γίΛΐ 157 of the administration. 17. The method of either modality 116, wherein the patient achieves at least a 4.5 point reduction in the itch Numerical Rating Scale score from baseline at week 12 of administration. 18. The method of any of the 117 modalities, wherein the administration reverses the symptoms of atopic dermatitis. 19. The either-modality method 118 , where the patient achieves a statistically significant improvement in Eczema Area and Severity Index score from baseline at Week 4 of dosing compared to a placebo to which one patient was administered during the same period. 20. The either-modality method 119, wherein the patient achieves a statistically significant improvement in the Eczema Area and Severity Index score from baseline at week 8 of dosing compared to a patient receiving placebo was administered during the same period. 21. The method of any of the 120 modalities, where the patient achieves a 75% improvement in the Eczema Area and Severity index score from Qfraznn / zznz / E / YiAi from baseline at week 2 of administration. 158 22. The either-modality method 121, wherein the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at Week 4 of administration. 23. The either-modality method 122, wherein the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at week 8 of administration. 24. The either-modality method 123, wherein the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at week 12 of administration. 25. The method of either modality 124, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at 2 weeks post-administration. 26. The method of either modality 125, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at 4 weeks post-administration. 27. The method of any of the modalities 126, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at QbQZnn / 77nZ / E / YIAI 159 minus 2 points from baseline at 8 weeks after administration. 28. The either-modality method 127, wherein the patient achieves a clinically significant improvement in the PROMIS Abbreviated Form 24-Hour Recovery Score - Sleep Disorders (8b) at week 8. 29. The method of any of the 128 modalities, wherein the administration is maintained for at least 2 weeks. 30. The method of any of the modalities 129, where the administration is maintained for at least 4 weeks. 31. The method of any of the modalities 130, wherein the administration is maintained for at least 8 weeks. 32. The method of any of the 131 modalities, where the administration is maintained for at least 12 weeks. 33. The either modality method 132, where the patient did not use topical treatments for atopic dermatitis, other than mild emollients, within 2 weeks of baseline; and did not use systemic immunosuppressive or systemic immunomodulatory drugs Qfraznn / zznz / E / YiAi within 4 weeks of onset. 160 34. The method of any of the 133 modalities, wherein the patient is not administered other therapeutic agents used to treat atopic dermatitis. 35. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation is an oil-in-water emulsion , comprising 1.5% (w / w) on a ruxolitinib phosphate free base basis, wherein administration is maintained for at least 8 weeks, wherein the patient achieves at least a 4-point reduction in the NRS score of itching from baseline at week 8 of dosing, and where the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at 8 weeks of dosing administration. 36. The modality 35 method, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at 8 weeks after administration. 37. The method of modality 35 or 36, where the 161 patient: is between 18 and 70 years old, has been diagnosed with atopic dermatitis for at least 2 years, has an IGA score of 2 to 3 at assessment and at baseline, and has a BSA of atopic dermatitis involvement (excluding face and intertriginous areas) from 3% to 20% at the beginning of the study. 38. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / p) on a free base basis of ruxolitinib, or one of its pharmaceutically acceptable salts, wherein the patient achieves a reduction in the itch Numerical Rating Scale score from baseline. 39. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / p) on a free base basis of ruxolitinib, or one of its salts 162 pharmaceutically acceptable, where the patient achieves a reduction in the itch Numerical Rating Scale score from baseline. 40. The method of embodiment 38 or 39, wherein ruxolitinib, or a pharmaceutically acceptable salt thereof, is ruxolitinib phosphate. 41. The method of any of the modalities 38 where the patient: is between 18 and 70 years old, has been diagnosed with atopic dermatitis for at least 2 years, has an Investigator's Global Assessment score of 2 to 3 at assessment and at baseline, and has a BSA of atopic dermatitis involvement ( excluding face and intertriginous areas) from 3% to 20% at baseline. 42. The method of any of the modalities 38- 41, where the patient is diagnosed with atopic dermatitis as defined by the Hanifin and Ra j ika criteria. 43. The method of any of the modalities 38- 42, where the patient achieves at least a 4-point improvement in the improvement of the α^αζηη / ζζηζ / Β / γΐί Scale score 163 Numerical rating of itch from the initial value. 44. The method of any of the modalities 38- 43, where the patient achieves at least a 4-point improvement in itch Numerical Rating Scale score improvement from baseline, where the patient has a Numerical Rating Scale score from baseline initial value equal to or greater than 4. 45. Method of either modality 3844, wherein the patient achieves at least a 4-point improvement in the itch Numerical Rating Scale score from baseline after 2 weeks of administration, wherein the method patient has a score on the Numerical Rating Scale from the initial value of equal to or greater than 4. 46. ​​Method of any of the 3845 modalities, where the patient achieves at least a 4-point improvement in Escalade score improvement Numeric Rating of itch from baseline after 4 weeks of administration, where the patient has a Numeric Rating Scale score from baseline of equal to or greater than 4. 47. The method of any of the modalities38- 46, where the patient achieves at least a 4-point improvement in the improvement of the Escalade score 164 Numeric Rating of itch from baseline after 8 weeks of administration, where the patient has a Numeric Rating Scale score from baseline of equal to or greater than 4. 48. The method of either modality 3847, wherein the patient achieves at least a 2-point improvement in the itch Numerical Rating Scale score from baseline on day 2 of administration. 49. The method of any of the 3849 modalities, where the patient achieves a prompt reduction in itching. 50. The method of any of the modalities 38- 49, where the patient achieves a statistically significant reduction in itching on day 1 of administration. 51. The method of any of the modalities 38- 50, where the patient achieved a statistically significant reduction in the itch Numerical Rating Scale score from baseline on day 1 of administration as compared to a patient administered placebo for the same period. 52. The method of any of the 3851 modalities, wherein the patient achieves at least a reduction of 1 165 point itch Numerical Rating Scale score from baseline on day 1 of administration. 53. The either-modality method 3852, wherein the patient achieves a statistically significant reduction in the itch Numerical Rating Scale score from baseline on day 2 of dosing compared to a patient receiving placebo was administered during the same period. 54. The method of either modality 3853, wherein the patient achieves at least a 2-point reduction in the itch Numerical Rating Scale score from baseline on day 2 of administration. 55. The method of either modality 3854, wherein the patient achieves at least a 3-point reduction in the itch Numerical Rating Scale score from baseline in week 2 of administration. 56. The method of any of the 3855 modalities, wherein the patient achieves at least a 3-point reduction in the itch Numerical Rating Scale score from baseline at the Week of administration. 166 57. The method of either modality 3856, wherein the patient achieves at least a 3-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration. 58. The either modality method 3857, wherein the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline in week 2 of administration. 59. The either-modality method 3858, wherein the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at Week 4 of administration. 60. The method of either modality 3859, wherein the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration. 61. The method of any of the modalities 3860, wherein the administration reverses the symptomatology of atopic dermatitis. 62. The method of any of the 3861 modalities, where the patient achieves a statistical improvement 167 significant improvement in the Eczema Area and Severity Index score from baseline at Week 4 of dosing compared to a patient given placebo during the same period. 63. The either-modality method 3862, where the patient achieves a statistically significant improvement in Eczema Area and Severity Index score from baseline at week 8 of dosing compared to a placebo to which one patient was administered during the same period. 64. The method of either modality 3863, wherein the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at week 2 of administration. 65. The method of either modality 3864, wherein the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at Week 4 of administration. 66. The method of either modality 3865, wherein the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at week 8 of administration. 67. The method of either modality 3866, where the patient achieves a 75% improvement in the Eczema Area and Severity index score from α^αζηη / ζζηζ / Β / γι 168 from baseline at week 12 of administration. 68. The method of either modality 3867, where the patient achieves an Investigator Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at 2 weeks post-administration. 69. The method of either modality 3868, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at 4 weeks post-administration. 70. The either modality method 3869, wherein the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at 8 weeks after administration. 71. The method of either modality 3870, where the patient achieves a clinically significant improvement in the PROMIS Short Form 24-Hour Recovery Score - Sleep Disorders (8b) at week 8. 72. The method of any of the modalities 3871, where the administration is maintained for at least 2 weeks. 73. The method of any of the modalities 38 169 72, where the administration is maintained for at least 4 weeks. 74. The method of any of the modalities 3873, where the administration is maintained for at least 8 weeks. 75. The method of any of the modalities 3874, where the administration is maintained for at least 12 weeks. 76. Any modality method 3875, where the patient did not use topical treatments for atopic dermatitis, other than mild emollients, within 2 weeks of baseline; and did not use systemic immunosuppressive drugs or systemic immunomodulatory drugs within 4 weeks of onset. 77. The method of any of the modalities 3876, wherein the patient is not administered other therapeutic agents used to treat atopic dermatitis. 78. The method of any of the embodiments 3877, wherein the administration of the cream formulation does not result in a statistically significant reduction in hemoglobin or platelets. 79. The method of any of the embodiments 3878, wherein the administration of the cream formulation does not produce burns at the site of administration. 80. The method of any of the modalities 38 170 9, wherein the cream formulation is an oil-in-water emulsion comprising ruxolitinib, or a pharmaceutically acceptable salt thereof. 81. The method of any of the embodiments 3880, wherein the cream formulation has a pH of about 2.8 to about 3.6. 82. The method of any of the 3881 modalities, wherein the cream formulation is a solubilized cream. 83. The method of either modality 3882, where the two administrations per day are at least 8 hours apart. 84. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation is an oil emulsion in water, comprising 1.5% (w / w) on a ruxolitinib phosphate free base basis, wherein administration is maintained for at least 8 weeks, wherein the patient achieves at least a 4-point reduction in NRS score itching from baseline at week 8 of dosing, and where the patient achieves a score of QbQZnn / 77nZ / E / YIAI 171 Investigator Global Rating of 0 or 1 with an improvement of at least 2 points from baseline at 8 weeks post-administration. 85. The modality 84 method, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at 8 weeks after administration. 86. The method of modality 84 or 85, where the patient: is between 18 and 70 years old, has been diagnosed with atopic dermatitis for at least 2 years, has an Investigator's Global Assessment score of 2 to 3 at assessment and at baseline, and has a BSA of atopic dermatitis involvement ( excluding face and intertriginous areas) from 3% to 20% at baseline. 87. A method of treating atopic dermatitis in a human patient, comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / w) on a free base base base of ruxolitinib, or one of its salts pharmaceutically Qfraznn / zznz / E / YiAi 172 acceptable. 88. The method of modality 87, wherein ruxolitinib, or a pharmaceutically acceptable salt thereof, is ruxolitinib phosphate 89. The method of any of the 8788 modalities, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline. 90. The either modality method 8789, wherein the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at 2 weeks after administration. 91. The either modality method 8790, wherein the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at 4 weeks after administration. 92. The either modality method 8791, wherein the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at 8 weeks after administration. 93. The method of any of the modalities 8792, where the patient achieves a 75% improvement in the α^αζηη / ζζηζ / Β / γίΛΐ 173 Eczema Area and Severity Index score from baseline. 94. The either modality method 8793, wherein the patient achieves a statistically significant improvement in the Eczema Area and Severity Index score from baseline at Week 4 of administration compared to a placebo to which the patient was administered during the same period. 95. The either modality 8Ί94 method, wherein the patient achieves a statistically significant improvement in Eczema Area and Severity Index score from baseline at week 8 of administration compared to a patient who placebo was administered during the same period. 96. The either modality method 8795, wherein the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline in week 2 of administration. 97. The either modality method 8796, wherein the patient achieves a 75% improvement in the Eczema Area and Severity Index score from baseline at Week 4 of administration. 98. The method of any of the 8797 modalities, where the patient achieves a 75% improvement in the Eczema Area and Severity index score from Qfraznn / zznz / E / YiAi 174 from baseline at week 8 of administration. 99. The either modality method 8798, wherein the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline at week 12 of administration. 100. The method of any of the modalities 87-99, where the patient achieves a clinically significant improvement in the 24-hour recovery score of the PROMIS Short Form - Sleep Disorders (8b). 101. The method of any of the modalities 87-100, where the patient achieves a clinically significant improvement in the 24-hour recovery score of the PROMIS Short Form - Sleep Disorders (8b) at week 8. 102. The method of any of the modalities 87-101, wherein the administration is maintained for at least 2 weeks. 103. The method of any of the modalities 87-102, wherein the administration is maintained for at least 4 weeks. 104. The method of any of the modalities 87-103, wherein the administration is maintained for at least 8 weeks. 105. The method of any of the modalities 87-104, where the administration is maintained for at least Qfraznn / zznz / E / YiAi 175 minus 12 weeks. 106. The method of any of the modalities 87-105, where the patient did not use topical treatments for atopic dermatitis, other than mild emollients, within 2 weeks of baseline; and did not use systemic immunosuppressive drugs or systemic immunomodulatory drugs within 4 weeks of onset. 107. The method of any of modalities 87-106, wherein the patient is not administered other therapeutic agents used to treat atopic dermatitis. 108. The method of any of the modalities 87-107, where the two administrations per day have a difference of at least 8 hours. 109. The method of any of embodiments 87-108, wherein the cream formulation is an oil-in-water emulsion comprising 0.75% (w / w) on a free base basis of ruxolitinib phosphate. 110. The method of any of embodiments 87-109, wherein the cream formulation has a pH of about 2.8 to about 3.6. 111. The method of any of embodiments 87-110, wherein the cream formulation is a solubilized cream. 112. The method of any of the modalities α^αζηη / ζζηζ / Β / γίΛΐ 176 87-111, where the patient: is between 18 and 70 years old, has been diagnosed with atopic dermatitis for at least 2 years, has an Investigator's Global Assessment score of 2 to 3 at assessment and at baseline, and has a BSA of atopic dermatitis involvement ( excluding face and intertriginous areas) from 3% to 20% at baseline. 113. The method of any of the modalities 87-112, wherein the patient is diagnosed with atopic dermatitis as defined by the Hanifin and Raj ika criteria. 114. The method of any of the 87-113 modalities, wherein the patient achieves at least a 4-point improvement in improvement in the itch Numerical Rating Scale score from baseline. 115. The method of any of the modalities 87-114, wherein the patient achieves at least a 4-point improvement in the improvement of the itch Numerical Rating Scale score from baseline, wherein the patient has a score on the Numerical Rating Scale from the initial value equal to or greater than 4. Qfraznn / zznz / E / YiAi 177 116. The method of any of the modalities 87-115, wherein the patient achieves at least a 4-point improvement in the itch Numerical Rating Scale score from baseline after 2 weeks of administration, in where the patient has a score on the Numerical Rating Scale from the initial value of equal to or greater than 4. 117. The method of any of the modalities 87-116, wherein the patient achieves at least a 4-point improvement in the improvement of the Itch Numerical Rating Scale score from baseline after 4 weeks of the administration, where the patient has a Numerical Rating Scale score from baseline of equal to or greater than 4. 118. The method of any of the modalities 87-117, wherein the patient achieves at least a 4-point improvement in the itch Numerical Rating Scale score from baseline after 8 weeks of administration, in where the patient has a score on the Numerical Rating Scale from the initial value of equal to or greater than 4. 119. The method of any of the modalities 87-118, wherein the patient achieves at least a 2-point improvement in the itch Numerical Rating Scale score from baseline on day 2 QbQZnn / 77nZ / E / YIAI 178 of the administration. 120. The method of any of embodiments 87-119, wherein administration of the cream formulation does not result in a statistically significant reduction in hemoglobin or platelets. 121. The method of any of embodiments 87-120, wherein the administration of the cream formulation does not produce burns at the site of administration. 122. A method of treating moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice a day, wherein the topical formulation comprises 0.75% (w / w) or 1.5% (w / w) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts. 123. A method of treating moderate to severe atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice a day, wherein the topical formulation comprises 0.75% (w / w) or 1.5% (w / w) on a free base basis of ruxolitinib, or one of its pharmaceutically acceptable salts. 124. A method of treating atopic dermatitis in a human patient comprising administering to the skin Qfraznn / zznz / E / YiAi 179 of the human patient in need of a twice-daily topical formulation, wherein the topical formulation comprises 0.75% (w / w) or 1.5% (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt of the same, where the patient has: an Eczema Area and Severity Index score of > 16 at baseline; and a Body Surface Area affected by atopic dermatitis of > 10% at the beginning of the study. 125. The method of any of embodiments 122-124, wherein the topical formulation is a cream formulation. 126. The method of any of embodiments 122-125, wherein the formulation comprises 0.75% (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof. 127. The method of any of embodiments 122-125, wherein the formulation comprises 1.5% (w / w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof. 128. The method of any of embodiments 122-125, wherein the formulation comprises 0.75% (w / w) on a free base basis of ruxolitinib phosphate. 129. The method of any of the modalities 122-125, where the formulation comprises 1.5% (w / w) on Qfraznn / zznz / E / YiAi 180 a base of ruxolitinib phosphate free base. 130. The method of any of the modalities 122-129, where the patient has an itch Numerical Rating Scale score of > 4 at baseline. 131. The method of any of the modalities 122-130, where the patient has an Investigator's Global Assessment score of 3 at the beginning of the study. 132. The method of any of the modalities 122-130, where the patient has an Investigator's Global Assessment score of 3 to 4 at the beginning of the study. 133. The method of any of the modalities 122-129, where the patient: has a score of 3 on the Investigator's Global Assessment at baseline; and has an itch Numerical Rating Scale score of b 4 at baseline. 134. The method of any of the modalities 122-129, where the patient: has an Investigator Global Assessment score of 3 to 4 at baseline; and has an itch Numerical Rating Scale score of b 4 at baseline. 135. The method of any of the modalities Qfraznn / zznz / E / YiAi 181 122-134, where the patient is > 12 years old. 136. The method of any of the modalities 122-135, where the patient has a history of atopic dermatitis for at least 2 years. 137. The method of any of the modalities 122-129, where the patient: has a score of 3 on the Investigator's Global Assessment at baseline; have a history of atopic dermatitis for at least 2 years; and is > 12 years old. 138. The method of any of the modalities 122-129, where the patient: has an Investigator Global Assessment score of 3 to 4 at baseline; have a history of atopic dermatitis for at least 2 years; and is > 12 years old. 139. The method of any of the modalities 122-129, where the patient: has an Investigator Global Assessment score of 3 at baseline; has an itch Numerical Rating Scale score of 1 4 at baseline; have a history of atopic dermatitis for at least QbQZnn / 77nZ / E / YIAI 182 less than 2 years; and is > 12 years old. 140. The method of any of the modalities 122-129, where the patient: has an Investigator Global Assessment score of 3 to 4 at baseline; has an itch Numerical Rating Scale score of 1 4 at baseline; have a history of atopic dermatitis for at least 2 years; and is > 12 years old. 141. The method of any of the modalities 122-129, where the patient has one or more of the following characteristics: an Investigator Global Assessment score of 3 at baseline; a Numerical Rating Scale for itch with a score of 1 4 at baseline; history of atopic dermatitis for at least years; and age > 12 years. 142. The method of any of the modalities 122-129, where the patient has one or more of the following characteristics: a score of Assessment Global of Qfraznn / zznz / E / YiAi 183 Researcher from 3 to 4 at the beginning of the study; an itch Numerical Rating Scale with a score of > 4 at baseline; history of atopic dermatitis for at least 2 years; and age > 12 years. 143. The method of any of the modalities 122-142, where the patient is diagnosed with atopic dermatitis as defined by the Hanifin and Ra j ika criteria. 144. The method of any of the modalities 122-143, where the administration is maintained for at least 2 weeks. 145. The method of any of the modalities 122-143, where the administration is maintained for at least 4 weeks. 146. The method of any of the modalities 122-143, where the administration is maintained for at least 8 weeks. 147. The method of any of the modalities 122-146, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline. 148. The method of any of the modalities 122-146, where the patient achieves a score of 0 or Qfraznn / zznz / E / YiAi 184 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at 2 weeks post-administration. 149. The method of any of the modalities 122-146, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at 4 weeks after administration . 150. The method of any of the modalities 122-146, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at 8 weeks after administration . 151. The method of any of the modalities 122-150, where the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline. 152. The method of any of the modalities 122-151, wherein the patient achieves a statistically significant improvement in the Eczema Area and Severity index score from baseline at Week 4 of administration compared to a patient who was administered placebo during the same period. Qfraznn / zznz / E / YiAi 153. The method of any of the modalities 185 122-152, wherein the patient achieves a statistically significant improvement in Eczema Area and Severity Index score from baseline at week 8 of administration compared to a patient administered placebo during week 8 of administration period. 154. The method of any of the modalities 122-153, wherein the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline in week 2 of administration. 155. The method of any of the modalities 122-153, wherein the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at Week 4 of administration. 156. The method of any of the modalities 122-153, wherein the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at week 8 of administration. 157. The method of any of the modalities 122-156, wherein the patient achieves at least a 4-point improvement in the improvement of the itch Numerical Rating Scale score from baseline, wherein the patient has a score on the Numerical Rating Scale from the initial value equal to or greater than 4. Qfraznn / zznz / E / YiAi 186 158. The method of any of the modalities 122-156, wherein the patient achieves at least a 4-point improvement in the improvement of the Itch Numerical Rating Scale score from baseline after 2 weeks of the administration, where the patient has a Numerical Rating Scale score from baseline of equal to or greater than 4. 159. The method of any of the modalities 122-156, wherein the patient achieves at least a 4-point improvement in the itch Numerical Rating Scale score from baseline after 4 weeks of administration, in where the patient has a score on the Numerical Rating Scale from the initial value of equal to or greater than 4. 160. The method of any of the modalities 122-156, wherein the patient achieves at least a 4-point improvement in the improvement of the Itch Numerical Rating Scale score from baseline after 8 weeks of the administration, where the patient has a Numerical Rating Scale score from baseline of equal to or greater than 4. 161. The method of any of the modalities 122-160, wherein the patient achieves at least a 2-point improvement in the itch Numerical Rating Scale score from baseline on day 2 Qfraznn / zznz / E / YiAi 187 of the administration. 162. The method of any of the modalities 122-161, wherein the patient achieves a clinically significant improvement in the 24-hour recovery score of the PROMIS Short Form - Sleep Disorders (8b). 163. The method of any of the modalities 122-162, wherein the patient achieves a clinically significant improvement in the 24-hour recovery score of the PROMIS Short Form - Sleep Disorders (8b) at week 8. 164. The method of any of the modalities 122-143, where: the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at Week 4 of dosing; and the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at Week 4 of dosing. 165. The method of any of the modalities 122 143 where: patient achieves at least a 4-point reduction in Itch Numerical Rating Scale score from baseline at 1 week Qfraznn / zznz / E / YiAi 188 from the administration; and the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at week 8 of dosing. 166. The method of any of the modalities 122-143, where: the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at Week 4 of dosing; and the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline at Week 4 of dosing. 167. The method of any of the modalities 122-143, where: the patient achieves at least a 4-point reduction in Itch Numerical Rating Scale score from baseline at week 8 of dosing; and the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at week 8 of administration. 168. The method of any of the modalities α^αζηη / ζζηζ / Β / γίΛΐ 122-143, where: 189 the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at Week 4 of administration; and the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline at Week 4 of dosing. 169. The method of any of the modalities 122-143, where: the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at week 8 of dosing; and the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at week 8 of administration. 170. The method of any of the modalities 122-143, where: the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at Week 4 of dosing; the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at Week 4 of Qfraznn / zznz / E / YiAi 190 administration; and patient achieves 75% improvement in Eczema Area and Severity Index score from baseline at Week 4 of dosing 171. The method of any of the modalities 122-143, where: the patient achieves at least a 4-point reduction in Itch Numerical Rating Scale score from baseline at week 8 of dosing; the patient achieves an Investigator's Global Assessment score of 0 or 1 with an improvement of at least 2 points from baseline at week 8 of dosing; and the patient achieves a 75% improvement in the Eczema Area and Severity index score from baseline at week 8 of administration. 172. The method of any of the modalities 122-171, where the patient did not use topical treatments for atopic dermatitis, other than mild emollients, within 2 weeks of onset; and did not use systemic immunosuppressive drugs or systemic immunomodulatory drugs within 4 weeks of onset. 173. The method of any of the modalities 122-172, where the patient is not administered other α^αζηη / ζζηζ / Β / γίΛΐ 191 therapeutic agents used to treat atopic dermatitis. 174. The method of any of the modalities 122-173, wherein the two administrations per day are at least 8 hours apart. 175. The method of any of the modalities 122-174, where the formulation has a pH of about 2.8 to about 3.9. 176. The method of any of the embodiments 122-174, wherein the formulation has a pH of from about 2.8 to about 3.6. 177. The method of any of the modalities 122-176, wherein the formulation is a solubilized cream. 178. The method of any of embodiments 122-177, wherein administration of the formulation does not result in a statistically significant reduction in hemoglobin or platelets. 179. The method of any of the modalities 122-178, wherein the administration of the formulation does not produce burns at the site of administration. 180. A method of treating moderate atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice a day, wherein the topical formulation comprises 1.5% (w / w) on a basis free base base Qfraznn / zznz / E / YiAi 192 ruxolitinib, or a pharmaceutically acceptable salt thereof. 181. The method of modality 180, wherein ruxolitinib, or a pharmaceutically acceptable salt thereof, is ruxolitinib phosphate. 182. The 180 modality method, where the patient is 12 years old or older. 183. The modality 180 method, wherein the patient has a Body Surface Area affected by atopic dermatitis of 10% to 20% at baseline. 184. The 180 modality method, where the patient has an Eczema Area and Severity Index score of > 16 at baseline. 185. The 180 modality method, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline. 186. The 180 modality method, where the patient achieves a 75% improvement in the Eczema Area and Severity Index score from baseline. 187. The 180 modality method, wherein the patient achieves at least a 4-point improvement in the itch Numerical Rating Scale score from baseline, and wherein the patient has a 193 score on the reference Numerical Rating Scale equal to or greater than 4. 188. The 180 modality method, where the patient achieves: a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline; a 4-point improvement in itch Numerical Rating Scale score improvement from baseline, where the patient has a baseline Numerical Rating Scale score equal to or greater than 4; and a 75% improvement in Eczema Area and Severity Index score from baseline. 189. The 180 modality method, where the patient achieves: a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at Week 4; a 4-point improvement in itch Numerical Rating Scale score improvement from baseline at Week 4, where the patient has an equal or greater Numerical Rating Scale score from baseline to 4; and a 75% improvement in the index score Qfraznn / zznz / E / YiAi 194 Area and Severity of Eczema from baseline in Week 4. 190. The 180 modality method, where the patient achieves: a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at Week 8; a 4-point improvement in itch Numerical Rating Scale score improvement from baseline at Week 8, where the patient has an equal or greater Numerical Rating Scale score from baseline to 4; and a 75% improvement in Eczema Area and Severity Index score from baseline at Week 8. 191. The 180 modality method, wherein the patient achieves at least a 2-point improvement in the itch Numerical Rating Scale score from baseline on day 2 of administration. 192. The 180 modality method, where the patient achieves a clinically significant improvement in the PROMIS Short Form - Sleep Disorders 24-hour recovery score (8b) at week 8. 193. The method of modality 180, where the Qfraznn / zznz / E / YiAi formulation is a cream formulation. 195 194. The method of embodiment 193, wherein the cream formulation is an oil-in-water emulsion. 195. The method of embodiment 194, wherein the cream formulation has a pH of about 2.8 to about 3.9. 196. The method of embodiment 195, wherein administration of the formulation does not result in a statistically significant reduction in hemoglobin or platelets. 197. The method of embodiment 196, wherein administration of the formulation does not result in burns at the administration site. 198. A method of treating atopic dermatitis in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation twice a day, wherein the topical formulation comprises 1.5% (w / w) on a basis of ruxolitinib phosphate free base, where the patient: is 12 years old or older; has a Body Surface Area of ​​atopic dermatitis involvement of 10% to 20% at baseline; and has a score of 3 on the Investigator's Global Assessment at the beginning of the study 199. The modality 198 method, where the patient achieves a score of 0 or 1 on the Assessment Qfraznn / zznz / E / YiAi 196 Investigator's Global with an improvement of at least 2 points from the initial value. 200. The method of modality 198, where the patient achieves a 75% improvement in the Eczema Area and Severity index score from the initial value. 201. The method of modality 198, wherein the patient achieves at least a 4-point improvement in the Itch Numerical Rating Scale score from baseline, and wherein the patient has an Itch Numerical Rating Scale score Numerical reference rating equal to or greater than 4. 202. The method of modality 198, where the patient achieves: a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline; a 4-point improvement in itch Numerical Rating Scale score improvement from baseline, where the patient has a baseline Numerical Rating Scale score equal to or greater than 4; and a 75% improvement in Eczema Area and Severity Index score from baseline. 203. The method of modality 198, where the QbQZnn / 77nZ / E / YIAI 197 patient achieves: a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at Week 4; a 4-point improvement in itch Numerical Rating Scale score improvement from baseline at Week 4, where the patient has an equal or greater Numerical Rating Scale score from baseline to 4; and a 75% improvement in Eczema Area and Severity Index score from baseline at Week 4. 204. The method of modality 198, where the patient achieves: a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at Week 8; a 4-point improvement in itch Numerical Rating Scale score improvement from baseline at Week 8, where the patient has an equal or greater Numerical Rating Scale score from baseline to 4; and a 75% improvement in the index score Area and Severity of Eczema from the initial value in the QbQZnn / 77nZ / E / YIAI Week 8. 198 205. The method of embodiment 198, wherein the formulation is a cream formulation. 206. The method of embodiment 205, wherein the cream formulation is an oil-in-water emulsion. 207. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / p) on a ruxolitinib free base basis, or one of its pharmaceutically acceptable salts; wherein the patient achieves a statistically significant reduction in Itch Numerical Rating Scale score from baseline within 36 hours of administration. 208. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / p) on a free base basis of ruxolitinib, or one of its pharmaceutically acceptable salts, where the patient achieves at least a 1 point reduction in the Numerical Rating Scale score for itching on day 2 of the Qfraznn / zznz / E / YiAi admin. 199 209. The method of embodiment 208, wherein ruxolitinib, or a pharmaceutically acceptable salt thereof, is ruxolitinib phosphate. 210. The modality 208 method, wherein the patient achieves a statistically significant reduction in the itch Numerical Rating Scale score from baseline within 12 hours of administration. 211. The modality 208 method, where the patient achieves a 2-point improvement in the itch Numerical Rating Scale score within 12 hours of administration. 212. The modality 208 method, where the patient achieves a 2-point improvement in the itch Numerical Rating Scale score within 36 hours of administration. 213. The modality 208 method, where the patient achieves a 4-point improvement in the itch Numerical Rating Scale score within 36 hours of administration. 214. The modality 208 method, wherein the patient achieves a reduction of at least 2 points in the itch Numerical Rating Scale score in week 1 of administration. 215. Qfraznn / zznz / E / YiAi The method of modality 208, where the 200 patient achieves at least a 3-point reduction in Itch Numerical Rating Scale score by week 3 of administration. 216. The method of modality 208, wherein the patient achieves a minimum clinically important difference in score on the Numerical Rating Scale for itching within 36 hours of administration, wherein the minimum clinically important difference in score Itch Numerical Rating Scale score is a 2 to 3 point reduction in the itch Numerical Rating Scale score compared to baseline, where the patient has an equal baseline Numerical Rating Scale score or greater than 2. 217. The method of modality 208, wherein the patient achieves a clinically relevant improvement in the Itch Numerical Rating Scale score within 36 hours of administration, wherein the clinically relevant improvement in the Scale score Itch Numerical Rating Scale score is a 4-point reduction in the itch Numerical Rating Scale score from baseline, where the patient has a baseline Numerical Rating Scale score equal to or greater than 4. 218. The method of modality 208, where the 201 patient is 12 years old or older. 219. The method of modality 218, wherein the patient has a Body Surface Area (BSA) of atopic dermatitis involvement (excluding the scalp) of 3% to 20% at baseline. 220. The modality 219 method, where the patient has an Investigator's Global Assessment score of 2 to 3 at the start of the study. 221. The modality 220 method, where the patient has been diagnosed with atopic dermatitis for at least 2 years. 222. The modality 221 method, where the patient is diagnosed with atopic dermatitis as defined by the Hanifin and Rajika criteria. 223. The method of modality 222, where the patient did not use topical treatments for atopic dermatitis, other than emollients, within 2 weeks of baseline. 224. The method of modality 208, wherein the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline in week 2 of administration. 225. The method of modality 208, where the patient achieves at least a 4-point reduction in the 202 itch Numerical Rating Scale score from baseline at Week 4 of administration. 226. The method of modality 208, wherein the patient achieves at least a 4-point reduction in the itch Numerical Rating Scale score from baseline at week 8 of administration. 227. The modality 208 method, wherein the patient achieves a 75% improvement in the Eczema Area and Severity Index score from baseline in week 2 of administration. 228. The modality 208 method, wherein the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline at Week 4 of administration. 229. The modality 208 method, wherein the patient achieves a 75% improvement in Eczema Area and Severity Index score from baseline at week 8 of administration. 230. The modality 208 method, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline in week 2 of administration. 203 231. The modality 208 method, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at Week 4 of administration. 232. The modality 208 method, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at week 8 of administration. 233. The method of mode 209, wherein the cream formulation is an oil-in-water emulsion. 234. The method of embodiment 233, wherein the cream formulation has a pH of about 2.8 to about 3.6. 235. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / p) in a ruxolitinib phosphate free base base; where the patient: is 12 years old or older; has an Investigator Global Assessment score of 2 to 3 at baseline; has an area 204 Body surface area affected by atopic dermatitis (excluding the scalp) from 3% to 20% at the beginning of the study; and achieves a minimal clinically important difference in the Rating Scale score Numeric of itching within 36 hours of administration, where the minimal clinically important difference in Rating Scale score Numeric Itch is a 2 to 3 point reduction in the Itch Numerical Rating Scale score from baseline, where the patient has a baseline Itch Numerical Rating Scale score of 1 2. 236. A method of reducing itching in a human patient with atopic dermatitis, comprising administering to the skin of the human patient in need thereof a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w ) on a phosphate free base basis of ruxolitinib; where the patient: is 12 years old or older; has an Investigator Global Assessment score of 2 to 3 at baseline; has a Body Surface Area affected by atopic dermatitis (excluding the scalp) of 3% to 20% at the beginning of the 205 study; and achieves a clinically relevant improvement in the itch Numerical Rating Scale score within 36 hours of administration, where the clinically relevant improvement in the itch Numerical Rating Scale score is a reduction of > 4 points on the itch Numerical Rating Scale score compared to baseline, where the patient has a baseline Numerical Rating Scale score of > 4. 237. A method of treating atopic dermatitis in a human patient, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / w) on a free base basis ruxolitinib base, or a pharmaceutically acceptable salt thereof. 238. The method of modality 237, wherein ruxolitinib, or a pharmaceutically acceptable salt thereof, is ruxolitinib phosphate. 239. The modality 237 method, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline. 240. The method of modality 237, where the 206 patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at week 2 of dosing. 241. The modality 237 method, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at Week 4 of administration. 242. The modality 237 method, where the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from baseline at week 8 of administration. 243. The modality 237 method, where the patient achieves a 75% improvement in the Eczema Area and Severity Index score from baseline. 244. The modality 237 method, wherein the patient achieves a 75% improvement in the Eczema Area and Severity Index score from baseline in week 2 of administration. 245. The method of modality 237, where the patient achieves a 75% improvement in the Eczema Area and Severity index score from the value 207 initial in Week 4 of the administration. 246. The modality 237 method, wherein the patient achieves a 75% improvement in the Eczema Area and Severity Index score from baseline at week 8 of administration. 247. The modality 237 method, wherein the patient achieves at least a 4-point improvement in improvement in the itch Numerical Rating Scale score from baseline. 248. The method of modality 237, wherein the patient achieves at least a 4-point improvement in Itch Numerical Rating Scale score improvement from baseline, and wherein the patient has a score of the Numerical Rating Scale from the initial value equal to or greater than 4. 249. The method of modality 237, wherein the patient achieves at least a 4-point improvement in the itch Numerical Rating Scale score from baseline in week 2 of administration, and wherein the patient has a score on the Numerical Rating Scale from the initial value of equal to or greater than 4. 250. The modality 237 method, where the patient achieves at least a 4-point improvement in the itch Numerical Rating Scale score 208 from baseline at Week 4 of administration, and where the patient has a Numerical Rating Scale score from baseline of equal to or greater than 4. 251. The method of modality 237, wherein the patient achieves at least a 4-point improvement in the itch Numerical Rating Scale score from baseline at week 8 of administration, and wherein the patient has a score on the Numerical Rating Scale from the initial value of equal to or greater than 4. 252. The method of modality 237, wherein the patient achieves a minimum clinically important difference in the Itch Numerical Rating Scale score within 36 hours of administration, wherein the minimum clinically important difference in score Itch Numerical Rating Scale score is a 2 to 3 point reduction in the itch Numerical Rating Scale score from baseline, where the patient has a Numerical Rating Scale score from baseline equal to or greater than 2. 253. The modality 237 method, where the patient achieves a clinically relevant improvement in the Itch Numerical Rating Scale score αίταζηη / ζζηζ / Ε / γΐι 209 within 36 hours of administration, where the clinically relevant improvement in the itch Numerical Rating Scale score is a 2 4-point reduction in the itch Numerical Rating Scale score versus baseline study, where the patient has a baseline Numerical Rating Scale score equal to or greater than 4. 254. The method of modality 237, where the administration is maintained for at least 2, 4 or 8 weeks. 255. The modality 237 method, where the patient is 12 years old or older. 256. The modality 255 method, where the patient has a Body Surface Area (BSA) of atopic dermatitis involvement (excluding the scalp) of 3% to 20% at baseline. 257. The modality 256 method where the patient has an Investigator's Global Assessment score of 2 to 3 at the start of the study. 258. The method of modality 257, where the patient has been diagnosed with atopic dermatitis for at least 2 years. 259. The method of modality 258, where the patient is diagnosed with atopic dermatitis according to 210 is defined by the criteria of Hanifin and Rajika. 260. The modality 259 method, where the patient did not use topical treatments for atopic dermatitis, other than emollients, within 2 weeks of baseline. 261. The method of embodiment 238, wherein the cream formulation is an oil-in-water emulsion. 262. The method of embodiment 261, wherein the cream formulation is a solubilized cream. 63. The method of embodiment 2 62, wherein the cream formulation has a pH of about 2.8 to about 3.6. 264. A method of treating atopic dermatitis in a human patient, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / w) on a free base basis based on ruxolitinib, or one of its pharmaceutically acceptable salts, where the patient: is 12 years of age or older; has an Investigator Global Assessment score of 2 to 3 at baseline; has a Body Surface Area of ​​atopic dermatitis involvement (excluding scalp) of 3% to 20% at baseline; and achieves a score of 0 or 1 on the Evaluation Qfraznn / zznz / E / YiAi 211 Investigator's Global with an improvement of at least 2 points from baseline at week 8 of administration. 265. A method of treating atopic dermatitis in a human patient, comprising administering to the skin of the human patient in need thereof, a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / w) on a free base basis based on ruxolitinib, or one of its pharmaceutically acceptable salts, wherein the patient: is 12 years old or older; has an Investigator Global Assessment score of 2 to 3 at the start of the study; has a Body Surface Area of ​​atopic dermatitis involvement (excluding scalp) of 3% to 20% at baseline; and achieves a 75% improvement in Eczema Area and Severity Index score from baseline at week 8 of administration. The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes and are not intended to limit the invention in any way. Those skilled in the art will readily recognize a variety of non-critical parameters, which can be changed or modified to essentially produce the QbQZnn / 77nZ / E / YIAI 212 same results. In some embodiments, the present invention provides pharmaceutical formulations comprising the components specified in the example formulations (e.g., Example 3), wherein the components are present in approximately the amounts of Tables 2-5. EXAMPLES Example 1: Preparation of Ruxolitinib Phosphate Oil-in-Water Cream Formulations (INCB018424) First, to determine the solubility of ruxolitinib (free base) or its 1:1 phosphate salt, approximately 5 ml of a potential solvent was added to approximately 50 mg of API or its salt at room temperature. The mixtures were suspended and rotated on a wheel. If the mixtures became clear solutions, more solid material was added. The suspensions were then suspended for 24 hours. The samples were filtered through 0.2 micron filters. The liquid portions were collected and diluted with 50 / 50 methanol / water. The concentrations of the diluted samples were analyzed by HPLC. When the free base or salt was quite insoluble, the results are only approximate. 213 Table 1 Potential Solvent Solubility of Phosphate Salt (mg / mL) Solubility of Free Base (mg / mL) Water 2.7 2.0 pH 4, Citric Buffer, 0.1 M 1.5 1.1 pH 6, Citric Buffer, 0.1 M 0.2 0.15 Ethanol 7.3 5.5 Isopropanol 0.6 0.45 Benzyl Alcohol 3 2.3 Propylene Glycol 24 18.2 PEG 200 23 17.4 PEG 300 14 10.6 Glycerin 11 8.3 Transcutol 10 7.6 Trolamine 51 38.6 Water / PEG 200 (50 / 50) 23 17.4 Water / Glycerin (50 / 50) 21 1 5.9 Water / glycerin / trolamine (40 / 40 / 20) 18 13.6 Potential solvent Solubility of phosphate salt (mg / mL) Solubility of free base (mg / mL) Isopropyl myristate <0.1 0.08 Isosorbide dimethyl ether 0.4 0.3 214 Mineral oil <0.1 0.08 Oleyl alcohol 0.1 0.08 Dimethicone <0.2 0.15 C12-15 alcohol benzoate <0.2 0.15 Caprylic triglyceride <0.2 0.15 An oil cream formulation in α^αζηη / ζζηζ / Β / γι water was prepared for the phosphoric acid salt of ruxolitinib 1:1 at 0.5, 1.0 and 1.5% by weight of the formulation (free base equivalent). The compositions for a 15 gram tube are provided in Table 2 below. The formulation for all three concentrations was identical except for adjustments to the amount of purified water based on the amount of active ingredient. All excipients used in the formulation were compendial grade (ie USP / NF or BP) or are approved for use in topical products. Quantitative formulas for representative 400 kg batches of the 0.5, 1.0 and 1.5% cream formulation are also provided in Tables 3, 4 and 5, respectively. The oil-in-water cream formulations were synthesized according to the following procedure on a 3.5 kg or 400 kg scale (when made in a 3.5 kg batch size, the amounts in Tables 3-5 are 215 scaled appropriately). Some batches were subject to minor changes associated with scaling up, such as the size of mixing vessels and mixers. Generally, overhead mixer with high and low shear mixing blades is suitable for the process. Procedure 1. A paraben phase was prepared by mixing methyl and propyl paraben with a portion of the propylene glycol (see % in Tables 2-5). 2. Next, a xanthan gum phase was prepared by mixing xanthan gum with propylene glycol (see % in Tables 2-5). 3. Next, an oil phase was prepared by mixing light mineral oil, glyceryl stearate, polysorbate 20, white petrolatum, cetyl alcohol, stearyl alcohol, dimethicone and medium chain triglycerides. The phase is heated to 70-80°C to melt and form a uniform mixture. 4. Next, the aqueous phase was prepared by mixing purified water, polyethylene glycol and disodium EDTA. The phase is heated to 70-80°C. 5. The aqueous phase from step 4, the paraben phase from step 1 and Example 2 (phosphate salt of API) were combined to form a mixture. 6. The xanthan gum phase from step 2 was then added to the mixture from step 5. α^αζηη / ζζηζ / Β / γίΛΐ 216 7. The oil phase from step 3 was then combined with high shear mixing with the mixture from step 6 to form an emulsion. 8. Phenoxyethanol was then added to the emulsion from step 7. Mixing was continued and then the product was cooled α^αζηη / ζζηζ / Β / γΐί with low shear mixing. Table 2 FORMULA Function Percentage of Total (% w / w) Grams / Tube PHASE COMPONENT Paraben Propylene Glycol USP Solvent 10.00 1.5 Methyl paraben NF Antimicrobial preservative 0.10 0.015 Propyl Paraben NF Antimicrobial preservative 0.05 0.0075 Xanthan gum Propylene glycol USP Solvent 5.00 0.75 Xanthan Gum NF Suspending Agent, stabilization, viscosity improver 0.40 0.06 Oil Light mineral oil NF Emollient, solvent 4.00 0.6 Glyceryl stearate SE Emulsifier 3.00 0.45 Polysorbate 20 NF Emulsifying / stabilizing agent 1.25 0.1875 White petrolatum USP Occlusive agent 7.00 1.05 Cetyl alcohol NF Agent hardener, improver 3.00 0.45 Stearyl alcohol NF Hardening agent 1.75 0.2625 Dimethicone 360 ​​NF Skin protectant 1.00 0.15 217 FORMULA Function Percentage of Total (% W / W) Grams / Tube PHASE COMPONENT Medium chain triglyceride NF Emollient, solvent 5.00 0.75 Aqueous / Active Purified water USP Solvent 50.24 - 48.92 7.536 - 7.338 Edetate disodium USP Chelating agent 0.05 0.0075 Polyethylene glycol USP Solvent 7.00 1.05 Example 2 * Active 0.66-1.98 0.099 - 0.297 Final Phenoxyethanol BP Antimicrobial preservative 0.50 0.075 Total 100.00% 15 Qfraznn / zznz / E / YiAi Table 3 Ingredient Kilograms Percent (w / w) Ruxolitinib Phosphate 2.64 (phosphate salt) / 2.0 (free base) 0.66 (phosphate salt) / 0.5 (free base) Propylene Glycol USP 40.0 10.00 Methyl Paraben NF 0.4 0.10 Propyl Paraben NF 0.2 0.05 Propylene Glycol USP 20 .0 5.00 218 Cetyl alcohol NF 12.0 3.00 Stearyl alcohol NF 7.0 1.75 Dimethicone 360 ​​NF 4.0 1.00 Medium chain triglycerides NF 20.0 5.00 Purified water USP (approximate) 201 50.25 Edetate disodium USP 0.2 0.05 Polyethylene glycol USP 28.0 7.0 0 Phenoxyethanol BP 2.0 0.5 Total (approximate) 400.0 100 αίταζηη / ζζηζ / Ε / γίΛΐ Table 4 Ingredient Kilograms Percent (w / w) Ruxolitinib Phosphate 5.28 (phosphate salt) / 4.0 (free base) 1.32 (phosphate salt) / 1.00 (free base) Propylene Glycol USP 40.0 10.00 Methyl Paraben NF 0.4 0.10 Propyl Paraben NF 0.2 0.05 Propylene Glycol USP 2 0.0 5.00 219 Cetyl alcohol NF 12.0 3.00 Stearyl alcohol NF 7.0 1.75 Dimethicone 360 ​​NF 4.0 1.00 Medium chain triglycerides NF 20.0 5.00 Purified water USP (approximate) 198.5 49.6 Edetate disodium USP 0.2 0.05 Polyethylene glycol USP 28.0 7. 00 Phenoxyethanol BP 2.0 0.5 Total (approximate) 400.0 100 Qfraznn / zznz / E / YiAi Table 5 Ingredient Kilograms Percent (w / w) Ruxolitinib Phosphate 7.92 (phosphate salt) / 6.0 (free base) 1.98 (phosphate salt) / 1.5 (free base) Propylene Glycol USP 40.0 10.00 Methyl Paraben NF 0.4 0.10 Propyl Paraben NF 0.2 0.05 Propylene Glycol USP 20 .0 5.00 220 Cetyl alcohol NF 12.0 3.00 Stearyl alcohol NF 7.0 1.75 Dimethicone 360 ​​NF 4.0 1.00 Medium chain triglycerides NF 20.0 5.00 Purified water USP (approximate) 195.5 48.9 Edetate disodium USP 0.2 0.05 Polyethylene glycol USP 28.0 7. 00 Phenoxyethanol BP 2.0 0.5 Total (approximate) 400.0 100 More consistent batches could be obtained at larger scales (e.g. 140 kg) by gradually adding ruxolitinib phosphate to the aqueous phase and then combining it with the other phases. Similarly, more consistent batches could be obtained by slower cooling (for example, by using room temperature water in the outer jacket of the reactor, instead of lower temperature water). Table 5A shows the 0.75% and 1.5% ruxolitinib cream formulation used in Example 3. Table 5A Component 0.75% cream 1.5% cream %w gper 60 g tube %w g per 60 g tube Ruxolitinib phosphate 0.99 (0.0751)) 0.594 1.98 (1.50b) 1.188 221 Propylene glycol 15.0 9.00 15.0 9.00 Methylparaben 0.10 0.06 0.10 0.06 Propylparaben 0.05 0.03 0.05 0.03 Xanthan gum 0.40 0.24 0.40 0.24 Light mineral oil 4.00 2.40 4.00 2.4 0 Glyceryl stearate SE 3.00 1.80 3.00 1.80 Polysorbate 20 1.25 0.75 1.25 0.75 White Vaseline 7.00 4.20 7.00 4.20 Cetyl alcohol 3.00 1.80 3.00 1.80 Sterilized alcohol 1.75 1.05 1.75 1.05 Dimethicone 360 ​​1.00 0.60 1.00 0.60 Triglycerides, Medium Chain 5.00 3.00 5.00 3.00 Purified water 49.91 29.95 48.92 2 9.36 Edetate disodium 0.05 0.03 0.05 0.03 Polyethylene glycol 200 7.00 4.20 7.00 4.20 Phenoxyethanol 0.50 0.30 0.50 0.30 Total 100% 60g 100% 60g Batches were tested for stability at 25°C and found to be stable for up to 24 months with a pH consistent with the pH range described above (see Tables 7, 9, 11, 12, 13, 15, 17 and 19 of US Patent Publication No. 2 015 / 0250790, which is incorporated 222 here for reference in its entirety). The viscosity of the cream formulations (eg, containing 0.75% or 1.5% ruxolitinib phosphate on the free base) had a viscosity of > 17,000 cPs at time of release and a lifetime viscosity of > 10,000 cPs. Example 2: Phase 2, randomized, dose-ranging, vehicle-controlled and triamcinolone cream 0.1%-controlled study to evaluate the safety and efficacy of ruxolitinib phosphate cream (INCB018424) applied topically to adults with dermatitis atopic This was a randomized, vehicle-controlled, active (0.1% triamcinolone cream) study in subjects with mild to moderate atopic dermatitis (AD). The study was double-blind to vehicle, ruxolitinib cream doses, and active control. 307 subjects were randomized 1:1:1:1:1:1 to ruxolitinib 1.5% cream twice daily, ruxolitinib 1.5% cream once daily, ruxolitinib 0.5% cream once daily, of ruxolitinib 0.15% once daily, vehicle twice daily, and active control (triamcinolone cream 0.1% BID) and stratified by EASI score (<7 and >7). Ruxolitinib in ruxolitinib cream was present as ruxolitinib phosphate with the percentages as % w / w in free base. Ruxolitinib cream formulations were 223 Oil-in-water cream formulations prepared as described in Example 1 (see also US Patent Publication No. 2015 / 0250790), which is incorporated herein by reference in its entirety. Subjects receiving QD regimens applied vehicle in the afternoon application. Subjects received study drug blindly for 8 weeks. Subjects were randomized to receive 0.1% triamcinolone cream twice daily for 4 weeks and vehicle cream for 4 weeks so as not to exceed the allowable duration of triamcinolone application. Ruxolitinib 1.5% cream, ruxolitinib 0.5% cream, and ruxolitinib 0.15% cream were given and applied topically as a thin film to affected areas in the morning and evening at least 1 hour before bedtime. For every 1% of BSA (palm to fingers) treated with study drug, approximately 5 cm (2 inches) of study drug was used. Subjects should be advised to limit use to no more than 1 tube per application. If sunscreen, makeup, or other cream were applied to the areas to be treated, subjects would be instructed to wash the treatment areas with mild soap and water and dry before applying study drug. If used, topical anti-infectives or other topical treatments should be avoided during 224 at least 1 hour before and after application of the study drug to an area. Subjects were warned to avoid excessive exposure to natural or artificial sunlight (including tanning booths, sunlamps, etc.) and, when outdoors, were advised to wear loose fitting clothing that would protect the area treaty of the sun The vehicle cream looked similar to ruxolitinib creams, except that it did not contain the active drug. The vehicle cream and 0.1% triamcinolone cream were applied in the same manner as the ruxolitinib cream. Treatment with 0.1% triamcinolone cream for 4 weeks was followed by vehicle treatment for 4 weeks. Subjects receiving ruxolitinib cream QD regimens received vehicle cream in the evening application. At week 8, subjects who met criteria received open-label treatment with ruxolitinib cream 1.5% twice daily for 4 weeks. Subjects who developed additional areas of AD after the start of treatment were allowed to treat these additional areas (except the face and intertriginous areas) as long as the total treated BSA did not exceed 20% and there were no safety concerns regarding the additional application of the study drug. 225 The study population was men or women, aged 18 to 70 years, who had been diagnosed with atopic dermatitis (AD) for at least 2 years, with an Investigator Global Assessment (IGA) score of 2 to 3, and Body Surface Area (BSA) involvement (excluding face and intertriginous areas) from 3% to 20%. Subjects who met all of the following key inclusion criteria could be included in the study: (i) men and women aged 18 to 70 years, inclusive; (ii) diagnosed with AD as defined by the Hanifin and Rajka criteria; (iii) history of AD for at least 2 years; (iv) an IGA score of 2 to 3 at assessment and baseline; (v) BSA of AD involvement, excluding the face and intertriginous areas, 3% to 20% at assessment and baseline; and (vi) agreement to discontinue all agents used to treat AD from assessment to the last follow-up visit. Subjects who met any of the following key exclusion criteria were excluded from the study: (i) evidence of active acute or chronic infections; (ii) use of topical AD treatments (other than mild emollients) within 2 weeks of onset; (iii) use of systemic immunosuppressive or immunomodulatory drugs (for example, oral or injectable corticosteroids, methotrexate, cyclosporine, 226 mycophenolate mofetil, azathioprine) within 4 weeks or 5 half-lives from baseline (whichever is longer); (iv) subjects with another dermatological disease in addition to AD whose presence or treatments could complicate the evaluation of the disease (for example, psoriasis); (v) history of other diseases in addition to dermatological disorders (e.g., other autoimmune diseases) taking treatments that could complicate evaluations; (vi) subjects with cytopenias at assessment, defined as leukocytes < 3.0 χ 109 / L, neutrophils < lower limit of normal, hemoqlobin < 10 g / dL. Lymphocytes < 0.8 χ 109 / L, platelets < 100 χ 109 / L; (vii) subjects with severe hepatic impairment (Child-Pugh Class C) or end-stage renal disease on dialysis or at least 1 of the following: serum creatinine > 1.5 mg / dL, alanine aminotransferase or aspartate aminotransferase > 15 χ upper limit of normal; (viii) subjects taking strong systemic cytochrome P4503A4 inhibitors or fluconazole within 2 weeks or 5 half-lives, whichever is longer, before the baseline visit (topical agents with limited systemic availability are permitted); and (ix) subjects who have previously received systemic or topical Janus kinase inhibitors (e.g., ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, or pacritinib). αίταζηη / ζζηζ / Ε / γΐι 227 The primary endpoint of the study was the percentage change from baseline in EASI score at Week 4 in subjects treated with ruxolitinib 1.5% cream twice daily compared to subjects treated with vehicle cream twice daily. . Secondary endpoints included the mean percentage change from baseline in EASI score at Week 4 in subjects treated with ruxolitinib cream compared to subjects treated with vehicle cream twice daily; the mean percent change from baseline in EASI score at Week 4 in subjects treated with ruxolitinib cream compared to subjects treated with triamcinolone 0.1% cream twice daily; the mean percentage change from baseline in the EASI score at week 2 and week 8; the proportion of subjects achieving >50% improvement from baseline in EASI (EASI-50) at Weeks 2, 4, and 8; dose response assessment based on percentage change from baseline in EASI score at Week 4; time to achieve EASI50; proportion of subjects achieving an IGA score of 0 to 1 who have an improvement of h 2 points from baseline at Weeks 2, 4, and 8; the mean change from baseline in the itch Numerical Rating Scale (NRS) score at weeks 2, 4, and 228 8; and safety and tolerability evaluated by monitoring the frequency, duration and severity of adverse events (AEs); conduct physical examinations; collect vital signs; and collect laboratory data for hematology, serum chemistry, and urinalysis. Additional secondary endpoints included change from baseline in quality of life according to the Skindex-16 (overall, each question, and specific groups) at weeks 2, 4, 8, 10, and 12. Skindex-16 (Atherton PJ, et al., Support Care Cancer. 2012 Aug; 20(8): 1729-1735) is a 16-question quality of life assessment that asks how much the subject has been bothered by various aspects of their cancer condition. skin during the last week. Patients answered questions about the effect of various AD symptoms during the past week on a scale from 0 (never bothered) to 6 (always bothered). Patients were evaluated at the beginning of the study and at weeks 2, 4, 8, 10 and 12. RESULTS Patient demographics are shown in Table 6. Baseline clinical characteristics are shown in Table 7. Overall Skindex-16 score was 3.7 ± 1.3 at baseline. 229 α^αζηη / ζζηζ / Β / γι Table 6 Demographic Total (N=307) Age, median (range), years 35.0 (18.0-70.0) Female, n (%) 168 (54.7) Race, n (%) white 172 (56.0) Black 85 (27.7) Asian 41 ( 13.4) Other 9 (2.9) Table 7 Total Clinical Characteristic (N=307) BSA, mean ± SD, % 9.6±5.4 Baseline EASI, mean ± SD 8.4±4.7 <7, n (%) 147 (47.9) <7, n (%) 159 (51.8) Absent , n (%) 1 (0.3) IGA at baseline, n (%) 2 95 (31) 3 210(69) NRS itch score, * mean ± SD 6.0±2.1 Duration of illness, median (range), years 20.8(0.1-66.1) Number of outbreaks in the last 12 months, mean ± SD 7.3±23.3 230 In the figures showing a triamcinolone outcome, the triamcinolone (TAC) arm received 0.1% triamcinolone cream until Week 4 and vehicle thereafter. As shown in Figure 1, ruxolitinib cream showed significant improvement in EASI scores in a dose- and time-dependent manner at all concentrations compared to vehicle control. As shown in Figure 2, ruxolitinib 1.5% cream showed the highest efficacy among all treatment arms (across all efficacy endpoints), while ruxolitinib 1.5% cream twice daily demonstrated non-inferiority to triamcinolone (TAC) in EASI scores (weeks 2 and 4) with numerically greater improvement rates. Additionally, an increasing number of patients achieved EASI-75 (at least a 75% improvement in EASI from baseline) in a dose- and time-dependent manner (see Figure 3), and more patients achieved EASI-75 with ruxolitinib cream 1.5% BID at Week 4 than with 0.1% TAC. As shown in Figure 4, ruxolitinib cream demonstrated a significant improvement in IGA response (an IGA responder was a patient achieving an IGA score of 0-1 with an improvement of b 2 α^αζηη / ζζηζ / Β / γι 231 points from baseline) in a dose- and time-dependent manner. Additionally, ruxolitinib cream 1.5% BID showed significantly more IGA responders versus vehicle at Weeks 4 and 8 (Figure 4) and a greater response than TAC 0.1% at Week 4. As shown in Figure 5, transition to ruxolitinib 1.5% cream twice daily at week 8 was associated with a substantial improvement in EASI scores. Similarly, switching to ruxolitinib 1.5% cream twice daily at week 8 was associated with substantial improvement across all treatment arms in IGA response (see Figure 6). Additionally, as shown in Figure 7, ruxolitinib cream was associated with a rapid and sustained reduction in NRS itch scores (NRS score has a range of 0 to 10, where 0 is no itch and 10 is the worst possible itch). In particular, as shown in Figure 8 and Table 8, significant reductions in NRS itch scores were observed with ruxolitinib 1.5% cream twice daily within 36 hours after the first application (i.e. , after 2 days) versus the vehicle (-1.8 vs. 0.2; p < 0.0001). Furthermore, as shown in Figure 9 and Table 8, the transition to ruxolitinib cream 1.5% two α^αζηη / ζζηζ / Β / γΐί times a day at week 8 was 232 associated with additional and sustained improvement in itch. Clinically significant reductions in NRS itch scores were observed within 36 hours of first application of ruxolitinib 1.5% cream twice daily versus vehicle (-1.8 vs -0.2; P<0.0001). The decreases in NRS itch scores observed within the first 2 weeks of treatment for all ruxolitinib cream regimens were maintained throughout the double-blind period. At week 4, both ruxolitinib 1.5% cream regimens produced more pronounced relief of itch (mean percent change from baseline, -64.6 for 1.5% BID and -54.0 for 1.5% QD) compared to triamcinolone (-50.3); The difference was statistically significant for ruxolitinib 1.5% twice daily versus triamcinolone according to the mean change from baseline (-4.0 vs. -2.5, respectively; P = 0.003). Improvements from baseline in NRS itch scores depended on treatment regimen, with a mean improvement of 68.5% in patients treated with ruxolitinib 1.5% cream twice daily at week 8, which was significantly better than the vehicle (17.6%; P<0.0001). In patients eligible for CRI analysis (baseline itch NRS of >4; n = 232), a proportion 233 significantly more patients on ruxolitinib cream achieved a CRI response after a single day of therapy than those on vehicle (day 2 response rates for 1.5% ruxolitinib cream twice daily vs. vehicle, 10.5% vs. 2.9%); Response rates at day 4 for ruxolitinib 1.5% cream twice daily and vehicle were 26.3% and 2.9, respectively (P<0.05). At Week 2, significantly more patients achieved CKD with ruxolitinib 1.5% BID (47.5%; P<0.001), ruxolitinib 1.5% QD (32.4%; P<0.01), and ruxolitinib 0.5% QD (25.0% ; P<0.05) versus vehicle (5.4%; figure 1). Response rates observed with ruxolitinib 1.5% cream twice daily at week 2 were also significantly higher compared to triamcinolone (19.4%, P<0.05). Cumulative incidence rates for time to first CKD response were substantially higher in all ruxolitinib cream (log-rank P<0.001) versus vehicle groups. A shorter median time to first response was observed in the ruxolitinib 1.5% cream twice daily and once daily treatment groups (8 and 12.5 days, respectively) versus vehicle (response not achieved). Similarly, among eligible patients 234 for the MCID analysis (initial itch NRS of >2; n = 272), higher rates of MCID were observed as early as day 2 (within 36 hours of starting treatment) with ruxolitinib cream at 1.5 % BID (42.5%; P<0.01) and QD (37.2%; P<0.05) vs. vehicle (13.6%); Significantly higher MCID rates were also observed for ruxolitinib 1.5% cream twice daily compared to triamcinolone on day 2 (20.5%; P<0.05). Surprisingly, the reductions in itch with ruxolitinib cream in the study appeared greater through indirect comparison than the improvements reported in patients treated with dupilumab in phase 3 trials for patients with moderate to severe AD, although the NRS scores Initial itch rates were slightly higher in the dupilumab studies (Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis, N Engl J Med 2016;375:2335-48). Itch NRS scores and Skindex-16 scores were correlated at baseline. Reduction in itch was positively associated with decreased quality of life burden (Pearson correlation, 0.67; P < 0.001). 235 Table 8 Time Point Mean Itch NRS Score (Ruxolitinib Cream 1.5% BID) Change in Mean Itch NRS Score from Baseline (Ruxolitinib Cream 1.5% BID) Mean Itch NRS Score (Vehicle) Mean Itch NRS Score Itching NRS (vehicle arm transitioning to ruxolitinib 1.5% cream at week 8) Onset 5.9 5.7 - 2 Weeks 2.3 -3.6 4.9 - 4 Weeks 2.1 -3.8 4.7 - 8 Weeks 1.8 -4.1 4.5 - 10 Weeks 1.9 - 4 - 2.3 12 Weeks 1.3 -4.6 - 2.4 Significant improvements in quality of life were observed for all ruxolitinib cream regimens. The improvements were dependent on the treatment regimen (FIG. 10). The mean percent improvement from baseline in overall Skindex-16 scores in patients treated with ruxolitinib 1.5% cream twice daily was 63.5% at Week 2 (vehicle, 10.5%; P<0.001) and 73.2% at Week 8 (vehicle, 19.7%; P<0.001). At Week 4, the mean percentage improvement in overall score was significantly greater with ruxolitinib 1.5% cream twice daily (73.7%; P=0.02) compared to triamcinolone (59.7%). The scores 236 Itch NRS and Skindex-16 scores were correlated at baseline. Reduction in itch was positively associated with decreased quality of life burden (Pearson correlation, 0.67; P < 0.001). As shown in Table 9 (double-blind period), ruxolitinib cream was well tolerated and was not associated with a clinically significant site reaction in the double-blind and open-label periods. There were no serious treatment-emergent adverse events (TEAEs) or discontinuations due to TEAEs during the open-label period. All treatment-related adverse events were mild or moderate in severity. α^αζηη / ζζηζ / Β / γΐί Table 9 Safety in the open-label period by initial treatment group Vehicle BID (n=41) 0.1% TAC BID (n=40) 0.15% RUX QD (n=45) 0.5% RUX QD (n=41) 1.5% RUX QD (n=42) 1.5% RUX BID (n= 43) Days in study, 28.0 28.0 28.0 28.0 28.0 28.0 (50.0- median (range) (0—66.0) (12-38.0) (10.0-51.0) (13.0-10.0) (20.0-36.0) 106.0) Patients with TEAE, n (%) 5 (12.2) 11 (27.5) 11 (24.2) 8 (19.5) 11 (26.2) 17 (39.5) Most common TEAEs* Nasopharyngitis 1 (2.4) 1 (2.5) 4 (8.9) 1 (2.4) 2 (4.8) 4 (9.3) Upper respiratory tract infection 1 (2.4) 2(5.0) 0 1 (2.4) 2 (4.8) 1 (2.3) AD 1 (2.4) 1 (2.5) 0 0 1 (2-4) 1 (2.3) Migraine 0 0 1 (2.2) 1 (2.4) 0 2 (4.7) TEAE related to treatment, n (%) 0 0 0 1 (2.4) 1 (2.4) 2 (4.7) TEAE, treatment-emergent adverse event*: Occurs in >1% of the total patient population. 237 In summary, ruxolitinib cream demonstrated improvement in EASI score, IGA response, and NRS itch score in a dose- and time-dependent manner. Responses to ruxolitinib cream 1.5% twice daily in the double-blind period were maintained in the open-label period (at week 12: a mean improvement of 84.9% from baseline in EASI score; 58.5% responders IGA). Patients who switched to ruxolitinib cream 1.5% twice daily in the open-label period experienced substantial improvements. The twice-daily regimen with 1.5% ruxolitinib cream produced rapid and sustained itch relief that was significantly greater than that of triamcinolone at Week 4. Finally, ruxolitinib cream was well tolerated with no severe ASDs related to itch. study drug and no patients discontinued treatment due to TEAEs. Example 3. Two phase 3, double-blind, randomized, 8-week, vehicle-controlled efficacy and safety studies of ruxolitinib cream followed by a long-term safety extension period in adolescents and adults with atopic dermatitis Two randomized vehicle-control (VC) studies were conducted in adolescent and adult participants (>12 years) with AD eligible for topical therapy. Qfraznn / zznz / E / Yii 238 Approximately 600 participants were randomized in each study 2:2:1 to ruxolitinib 0.75% cream twice daily, ruxolitinib 1.5% cream twice daily, or vehicle cream. Additionally, approximately 20% of the overall study population were adolescents. Participants with a baseline IGA score of 2 made up approximately 25% of the overall study population. Participants with AD involvement of 3% to 20% BSA and an IGA score of 2 to 3 received blinded study treatment for 8 weeks. Ruxolitinib in creams is present as ruxolitinib phosphate and the percentages are % (w / w) on the free base. The ruxolitinib cream formulations were oil-in-water cream formulations prepared as described in Example 1 (see Table 5 of US Patent Publication No. 2015 / 0250790; 0.75% ruxolitinib cream was prepared by the method of Example 1 by adjusting the mass of the API in the formulation with water), which is incorporated herein by reference in its entirety. For participants who met all study inclusion criteria and none of the exclusion criteria, study drug assignment was obtained. The key entry criteria for participants to be eligible for the enrollment period 239 8-week VC treatment were diagnosed with AD (as defined by the Hanifin and Rajka criteria) with a disease duration of at least 2 years, IGA score of 2 to 3, and a participation of % of BSA of 3% to 20% (excluding scalp) at assessment and at baseline. Participants who developed additional areas of AD were allowed to treat these additional areas with investigator approval as long as the total BSA treated did not exceed 20% and there were no safety concerns regarding additional application of study drug. Approval to treat additional areas was to occur by telephone during the VC period, although the researcher, at her discretion, could ask the participant to return for an unscheduled visit. Through Week 8, participants continued to treat the areas identified for treatment at baseline, even if the areas began to improve. At Week 8, the primary endpoint of the study, participants' efficacy was assessed with the percentage of participants achieving a treatment response on the IGA score. Participants were also evaluated for safety and tolerability by monitoring the frequency, duration, and severity of 240 DAs; conduct physical examinations; and collect vital signs and clinical / laboratory evaluations at various times during the study. Participants who completed Week 8 assessments without additional safety concerns will be offered to continue into the long-term safety (LTS) period with the same treatment regimen, except for those who were initially on the vehicle, who will also be assigned in Week 8 to 1 of the 2 active treatment groups. At that time, the IGA score required for participants to enter the LTS period is 0 to 4. With respect to %BSA, no lower limit is required; participants may have BSA in the range of 0% to 20%. In the LTS period, participants will have study visits every 4 weeks until the end of the study (52 weeks total). At those visits, the investigator will assess AD lesions to confirm whether the participant still requires continuation of therapy (IGA > 1) or can otherwise (re)enter the observation / no treatment cycle (IGA = 0). During the LTS period (i.e. after the Week 8 visit), participants will self-assess AD recurrence and treat skin areas with 241 active DA changes (not exceeding 20% ​​of BSA). If lesions disappear between study visits, participants will stop treatment applications 3 days after they disappear. Participants will restart treatment for their AD at the first sign of recurrence. In the event that new lesions are outside the usual location and / or are more widespread than at baseline, the participant must contact the site for approval. Participants will be in the study for a duration of up to 60 weeks (28 days of screening, 8 weeks of treatment in the VC period, 44 weeks of treatment in the LTS period, and a 30 (+ 7) day safety follow-up. The primary endpoint of the study was the proportion of patients achieving IGA-TS at Week 8. Key secondary endpoints of the study were: (i) the proportion of participants achieving EASI-75 at Week 8; (ii) the proportion of participants with an h 4-point improvement in NRS itch score from baseline at Week 8; and (iii) the proportion of participants with a clinically significant improvement in the PROMIS Short Form - Sleep Disorders 24-hour memory score (8b) at Week 8. 242 Other secondary endpoints included: (i) the frequency, duration and severity of adverse events; conduct physical examinations; collect vital signs; and collection of laboratory data for hematology, serum chemistry, and urinalysis; (ii) proportion of participants achieving an IGA-TS in Weeks 2 and 4; (iii) proportion of participants achieving an IGA of 0 or 1 at each visit; (iv) proportion of participants with a 2 4 point improvement in NRS pruritus score from baseline to weeks 2 and 4; (v) proportion of participants achieving EASI50 at each visit during the CV period; (vi) proportion of participants achieving EASI75 in Weeks 2 and 4; (vii) proportion of participants achieving EASI90 at each visit during the CV period; (viii) mean percentage change from baseline in EASI score at each visit during the CV period; (ix) mean percentage change from baseline in SCORAD score at each visit during the CV period; (x) change from baseline in NRS itch score at each visit during the CV period; (xi) time to achieve an improvement in NRS itch score of at least 2, 3, or 4 points; (xii) change from baseline in skin pain NRS score at each visit during the CV period; (xiii) proportion of 243 participants with clinically significant improvement in PROMIS Short Form - Sleep-Related Impairment (8a) 24-hour recovery score at weeks 2, 4, and 8; (xiv) change from baseline in 24-hour recovery PROMIS Short Form - Sleep-Related Impairment (8a) and Short Form - Sleep Disturbance (8b) 24-hour recovery score in weeks 2, 4 and 8; (xv) PROMIS Short Form - Sleep Related Impairment 7-day recovery score (8a) and Sleep Disorder Short Form 7-day recovery score (8b) at weeks 8, 12, 24, and 52; (xvi) change from baseline in %ASO affected by AD at each visit; (xvii) change from baseline in POEM score at each visit; (xviii) change from baseline in DLQI score at Weeks 2, 4, 8, 12, 24, and 52 and at unscheduled visits; (xix) mean PGIC score at weeks 2, 4, and 8; (xx) proportion of participants with each PGIC score in weeks 2, 4 and 8; (xxi) proportion of participants with a score of 1 or 2 on the PGIC at Weeks 2, 4, and 8; (xxii) change from baseline in EQ-5D-5L score during the VC period; (xxiii) change from baseline in WPAI-SHP v2.0 at Weeks 2, 4, 8, 12, 24, 36, and 52; (xxiv) 244 ruxolitinib trough plasma concentrations at all study visits. Subjects who met all of the following key inclusion criteria are eligible to be included in the study: (i) adolescents aged 12 to 17 years, inclusive, and men and women > 18 years; (ii) diagnosed with AD as defined by the Hanifin and Rajka criteria; (iii) history of AD for at least 2 years; (iv) for the vehicle control period, an IGA score of 2 to 3 at assessment and baseline; for the long-term safety period, an IGA score of 0 to 4; (v) for vehicle control period, % BSA of DA involvement, excluding scalp, from 3% to 20% at assessment and baseline; for the long-term safety period, % BSA of AD involvement, excluding scalp, 0% to 20%; (vi) agreement to discontinue all agents used to treat AD from assessment until the final follow-up visit; (vi) have at least 1 target lesion (that is representative of the participant's disease state and is not present on the hands, feet, or genitals) that measures around 10 cm2 or larger at assessment and at baseline; (vii) the desire to avoid pregnancy or parenthood of children based on specific criteria; and (viii) the ability to understand and 245 willingness to sign an informed consent form or written informed consent from parents or legal guardians and written assent from participants when possible. Subjects who met any of the following key exclusion criteria were excluded from the study: (i) Participants who have an unstable course of AD (spontaneous improvement or rapid deterioration) as determined by the investigator in the 4 weeks prior to baseline ; (ii) Participants with concurrent conditions and history of other diseases: (a) Immunocompromised (e.g., lymphoma, acquired immunodeficiency syndrome, Wiskott-Aldrich syndrome); (b) chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before onset; (c) active acute bacterial, fungal, or viral skin infection (e.g., herpes simplex, herpes zoster, chickenpox) in the week before onset; (d) any other concomitant skin disorder (e.g., generalized erythroderma such as Netherton syndrome), pigmentation, or extensive scarring that, in the opinion of the investigator, may interfere with the evaluation of AD lesions or compromise the safety of participants; e) presence of AD lesions only on the hands or feet without 246 previous history of involvement of other classic areas of involvement such as the face or folds; (f) other types of eczema; (iii) participants with any serious illness or medical, physical, or psychiatric condition that, in the opinion of the investigator, would interfere with full participation in the study, including administration of study drug and attendance at required study visits; represent a significant risk to the participant; or interfere with the interpretation of study data. For example: (a) clinically significant or uncontrolled cardiac disease, including unstable angina, acute myocardial infarction within 6 months of day 1 of study drug administration, class III or IV congestive heart failure New York Heart Association and arrhythmia requiring therapy or uncontrolled hypertension (blood pressure > 150 / 90 mmHg) unless approved by the medical monitor / sponsor; (b) participants with a history of malignancies within 5 years prior to enrollment in this study, except for adequately treated non-metastatic malignancies; (c) low hemoglobin (< 10 g / dL); (d) severe kidney disease on dialysis (serum creatinine > 2 mg / dL); (e) current liver disease and / or history, including known hepatitis B or C, with liver abnormalities or αίταζηη / ζζηζ / Ε / γΐι 247 biliary; (iv) participants using any of the following treatments within the indicated washout period before initiation: (a) 5 half-lives or 12 weeks, whichever is longer: biologic agents (e.g., dupilumab); (b) 4 weeks: systemic corticosteroids or adrenocorticotropic hormone analogues, cyclosporine, methotrexate, azathioprine or other systemic immunosuppressive or immunomodulatory agents (for example, mycophenolate or tacrolimus); (c) 2 weeks: immunizations and sedative antihistamines, unless on long-term stable regimen (non-sedating antihistamines allowed); (d) 1 week: use of other topical AD treatments (other than mild emollients), such as corticosteroids, calcineurin inhibitors, coal tar (shampoo), antibiotics, antibacterial body wash / soap. Diluted sodium hypochlorite bleach baths are allowed as long as they do not exceed 2 baths per week and their frequency is the same throughout the study; (v) participants who have previously received JAK inhibitors, systemic or topical; (vi) ultraviolet light therapy or prolonged exposure to natural or artificial sources of UV radiation (e.g., sunlight or tanning booth) within 2 weeks prior to the start of the study and / or intention to have exposure during the study , which the researcher believes to impact α^αζηη / ζζηζ / Β / γι 248 potentially the participant's DA; (vii) positive results of the serology test in the detection of antibodies against HIV; (viii) liver function tests: AST or ALT > 2 χ ULN; alkaline phosphatase and / or bilirubin > 1.5 χ ULN (isolated bilirubin > 1.5 χ ULN is acceptable if the bilirubin is fractionated and direct bilirubin < 35%); (ix) pregnant or lactating participants, or those considering pregnancy; (x) history of alcoholism or drug addiction within 1 year prior to screening or current alcohol or drug use that, in the opinion of the investigator, will interfere with the participant's ability to comply with the administration program and evaluations of the study; (xi) current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before initiation with another investigational drug or current enrollment in another investigational drug protocol; (xii) participants who, in the opinion of the investigator, are unable or unlikely to comply with the study administration schedule and assessments; (xiii) participants who are committed to a mental health institution pursuant to an order issued by judicial or administrative authorities; (xiv) employees of the sponsor or investigator or are dependents of them. SCORAD is a tool to assess the scope and 249 the severity (i.e., intensity) of the eczema and will be completed before, during, and after treatment has begun to determine whether the treatment has been effective (Oakley, 2009. https: / / www.dermnetnz.org / topics / scorad / . Accessed November 1, 2018). This was carried out during all VC study visits, beginning at baseline. To determine the extent, the rule of 9 or the handprint method was used to calculate the area affected by eczema (A) as a percentage of the entire body. The scores were summed to give a possible maximum of 100%. To determine intensity, a representative area of ​​eczema was selected (see target lesion below). The intensity of each of the following signs of redness, swelling, oozing / crusting, scratching, thickening of the skin (lichenification), dryness (this is assessed in an area where there is no inflammation) was evaluated as follows: None (0) ; Mild (1) ; Moderate (2) ; Severe (3) . Intensity scores are added to give B (maximum score of 18). Subjective symptoms, i.e., itch and insomnia, are rated by the participant using a visual analog scale where 0 is no itch (or no insomnia) and 10 is the worst itch imaginable (or insomnia). These scores were summed for α^αζηη / ζζηζ / Β / γι 250 give C (maximum score of 20) . The total score gave approximate weights of 60% to intensity and 20% to extent and subjective signs (i.e. insomnia, etc.) for the participant and were calculated as follows: A / 5 + 7B / 2 +C. Evaluation of the target lesion was carried out as follows. At baseline, a lesion that is representative of the participant's overall illness and that is to be treated with the study drug was selected as the target lesion. This injury was identified, measured, and documented in the participant's medical record at each subsequent visit during the CV period. A note should be made in your medical record and reference photographs may be marked with the location of the target injury. The target injury should not have been on the hands, feet, or genitals. The target lesion should have had an area of ​​approximately 10 cm2 or more in size. The largest diameter and the measurement perpendicular to the largest diameter were measured in millimeters. Skin stripping (with tape discs), S. aureus swabs of lesional skin, and TEWL assessments were taken from the target lesion after taking photographs and before applying study treatment. The % of total BSA affected by DA was estimated at each visit in the VC period. The evaluation of the Area of 251 Body Surface Area approximated to the nearest 0.1% using the Palmar Method as a guide, palm plus 5 digits, with fingers together and thumb sideways (handprint), such as 1% BSA and thumb as 0.1 % BSA. Various patient-reported outcomes including quality of life (QoL) were assessed using the following tools: DQLI (Dermatology Quality of Life Index), PGIC (Patient Global Impression of Change), POEM (Patient Oriented Eczema Measure), EQ-5D-5L (EQ-5D is a generic, self-administered and validated utility questionnaire where participants will rate their current health status based on the following criteria: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression), WPAI:SHP (Work Activity and Productivity Impairment Questionnaire: Specific Health Problem, version 2.0), Itch NRS, Skin Pain NRS (Numeric Rating Scale of skin pain) Short Form of PROMIS: Sleep Related Impairment (8a) and Short Form of PROMIS - Sleep Disorders (8b). To avoid bias in participants' responses to the questionnaires, all of these assessments were completed prior to any other assessments or study procedures on the day of the study visit and prior to discussions with the researcher or staff α^αζηη / ζζηζ / Β / γΐί 252 from the study site. At the baseline visit, all patient-reported outcomes were completed prior to the participant's first request for study drug. Participants were given a paper questionnaire or a handheld device (eDiary) for daily assessments. The participant was instructed to complete the diary during the specific time points required for each assessment, from the day of screening to week 8 or treatment discontinuation. Participants conducted daily assessments via diary beginning at the screening visit and all visits during the VC period: Participant rated (over the past 24 hours) the following: NRS itch: worst level of itch will register at night; Skin pain NRS: worst pain level will be recorded at night; PROMIS questionnaires; Short Form - Sleep Related Impairment (8a) will be completed at night; Short form - Sleep Disturbance (8b) will be assessed in the morning. During all VC site visits, the following were assessed: EQ-5D-5L: begins at assessment; WPAI:SHP: starts at feedback; DLQI / CDLQI: starts on Day 1; POEM: begins on Day 1; PGIC: starts in Week 2. During the LTS period the following will be evaluated: EQ-5D-5L; 253 WPAI:SHP; DLQI / CDLQI; POEM; PROMIS Short Form Sleep-Related Impairment (8a) and Short Form Sleep Disorders (8b): The DLQI is a simple 10-question validated questionnaire to measure how much the skin problem has affected the participant during the previous 7 days, as described in the SoAs (Finlay AY, Khan GK, Dermatology Life Quality Index (DLQI)- a simple practical measure for routine clinical use, Clin Exp Dermatol 1994;19:210-216.) . The participant, b 16 years or older, responded to the questionnaire with (1) a lot, (2) a lot, (3) a little, or (4) not at all. The questionnaire was analyzed under 6 headings as follows: Symptoms and feelings (Questions 1 and 2); Daily activities (Questions 3 and 4); Leisure (Questions 5 and 6); Work and school (Question 7); Personal relationships (Questions 8 and 9) ; Treatment (Question 10). CDLQI is the youth / child version of the DLQI and was completed by adolescents ages b 12 years to < 16 years. It is self-explanatory and could simply be given to the participant who was asked to complete it and who could request assistance from the parent or guardian. The questionnaire was analyzed under 6 headings as follows: Symptoms and feelings (Questions 1 and 2); Leisure (Questions 4, 5 and 6); School or vacation (Question 7); Personal relationships (Questions 3 and 8); Sleep (Question 254 9); Treatment (Question 10); Overall impression of the patient's change. The PGIC is a self-report measure of participants that reflects their belief about the effectiveness of treatment. The PGIC is a 7-point scale that represents a participant's rating of overall improvement and will be captured during site visits during the VC period (Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective results measures, J Manípulatlve Physíol Ther 2004;27:26-35). The participant will answer the following: Since the beginning of the treatment they have received in this study, their atopic dermatitis in the areas treated with the study drug: (1) has improved greatly, (2) has improved greatly, (3) has improved minimally , (4) no change, (5) minimally worse, (6) much worse, and (7) much worse. The POEM is a 7-question quality of life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days obtained as described in the SoA (Charman CR, et al. , Arch Dermatol 2004, 140:1513-1519). The EQ-5D-5L: The EQ-5D is a generic, self-administered and validated utility questionnaire where participants (adolescents and adults) rate their status Qfraznn / zznz / E / Yii 255 current health based on the following criteria (dimensions): mobility, self-care, activities, pain / discomfort, and anxiety / depression. The 5L indicates that for each dimension there are 5 levels, which are the following: no problems, mild problems, moderate problems, severe problems and extreme problems. During all study visits in the VC period (starting at screening) and at specific LTS visits (Weeks 12, 24, 36, 52 and follow-up visit), the participant was asked to indicate his or her health status during the VC period. last 7 days by checking the box next to the most appropriate statement in each of the 5 dimensions. The digits of the 5 dimensions can be combined into a 5-digit number that describes the health status of the participant (EuroQol Research Foundation. EQ-5D-5L. 2017. https: / / euroqol.org / eq-5d-instruments / eq-5d-51-about / . Accessed July 17, 2018). The WPAI:SHP v2.0 questionnaire is a validated 6-item instrument, completed during all site visits beginning at screening, during the VC period, and at specific LTS visits (Weeks 12, 24, 36, 52 and visit follow-up) that measures the effect of general health and specific symptoms on productivity at work and regular activities outside of work during the last 7 days (Reilly MC, Zbrozek AS, Dukes EM, The validity and 256 reproducibility of a work productivity and activity disabled instrument, PharmacoEconomícs 1993;4:353-365). Itch NRS is a daily patient-reported measure (24-hour recall) of the worst level of itch intensity. Participants were asked to rate the severity of itch due to their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best described their worst level of itch in the past 24 hours. Participants were given a diary in which to record the severity of their itch. Participants were instructed to complete the diary each night from the day of screening until the last application of study drug in the CV period. Skin Pain NRS is a daily patient-reported measure (24-hour recall) of the worst pain intensity level from 0 (no pain) to 10 (worst pain imaginable). Participants were asked: Please rate the pain severity of your atopic dermatitis skin changes by selecting the number that best describes your worst pain level in the past 24 hours, as described in the SoA. Participants were given a diary in which they recorded the severity of their skin pain each night, rating the worst pain in the last 24 hours. Participants were instructed to complete the diary 257 each night from the day of screening until the last application of study drug in the CV period. PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of widely used and accepted patient-reported outcome measures that have been developed with robust clinical outcome assessment development methods and are psychometrically supported. The selected PROMIS Short Form - Sleep-Related Impairment (8a) and Short Form - Sleep Disturbance (8b) questionnaires were modified to be completed by diary on a daily basis with a 24-hour recall: Short Form - Sleep-Related Impairment Sleep (8a) is collected in the evening, and the short form: sleep disorders (8b) is collected in the morning during the VC period. Beginning at Week 8 and throughout the LTS period, these were / will be conducted with a 7-day recovery period and will be completed on-site during study visits. The PROMIS Short Form – Sleep-Related Impairment questionnaire (8a) was completed in the evening during the VC period. This assessment focuses on self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and perceived functional impairments during wakefulness. 258 associated with sleep problems or altered alertness (Buysse, Sleep 2 010; 33:781-792). The questionnaire consists of 8 simple questions on a 5-point scale with a score range of 8 to 40, with higher scores indicating greater severity of sleep-related impairment. Each item asks the participant to rate the severity of the participant's sleep difficulty. The recovery period was the last 24 hours for the VC period and the last 7 days for the LTS period. The PROMIS Short Form - Sleep Disturbance questionnaire (8b) was completed in the morning during the CV period. This assessment is self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. Sleep disturbance does not focus on symptoms of specific sleep disorders and does not provide subjective estimates of the amount of sleep (e.g., total amount of sleep, time to fall asleep, amount of wakefulness during sleep; Buysse et al. . 2010). The shortened form of sleep disturbance is generic rather than disease-specific. The questionnaire is also a 5-point scale with a score range of 8 to 40, with higher scores indicating greater severity of sleep disturbance. Each element asked the 259 participant to rate the severity of the participant's sleep disturbance. The recovery period was the last 24 hours for the VC period and the last 7 days for the LTS period. VC period results In TRuE-ADl (study 303), 631 patients were randomized (vehicle, n=126; 0.75% twice daily, n=252; 1.5% twice daily, n=253); the median (range) age was 32.0 (12-85) years and 62.0% of patients were women. Seventy-three patients (11.6%) dropped out of the study. In TRuE-AD2 (study 304), 618 patients were randomized (vehicle, n=124; 0.75% twice daily, n=248; 1.5% twice daily, n=246); the median (range) age was 330 (12-85) years and 61.5% were women. Fifty-seven patients (9.2%) discontinued the study. Complete demographic data for TRuE-ADl and TRuE-AD2 are shown in Tables 10 and 11, respectively. The mean baseline itch NRS score for the TRuE-ADl and TRuE-AD2 populations pooled for the vehicle, 0.75% BID, and 1.5% BID populations was 5.15, 5.14, and 5.09, respectively. Table 10 Parameters Total Parameters Total Age Ethnicity n (%) 260 Mean (SD) 35.2 (18.15) White 431 (68.3) Median 32 (12-85) Black 140 (22.2) 12-17 n(%) 123 (19.5) Asian 32 (5.1) >=18 n (%) 508 ( 80.5) Others 28 (4.5) Sex n (%) Region n (%) Male 240 (38) North America 440 (69.7) Female 391 (62) Europe 191 (30.3) IGA at baseline n (%) EASI at ice n( %) 2 152 (24.1) <=7 318(50.4) 3 479 (75.9) >7 313(49.6) Table 11 Parameters Total Parameters Total Age Ethnicity n (%) Mean (SD) 36.4 (18.38) White 436 (70.6) Median (Min- 33 (12-85) Black 152 (24.6) 12-17 n (%) 122 (19.7) Asian 14(2.3) >=18 n(%) 496 (80.3) Other 16(2.6) Sex n(%) Region n (%) Male 238 (38.5) North America 415(67.2) α^αζηη / ζζηζ / Β / γι 261 Female 380 (61.5) Europe 203 (32.8) IGA at level Initial EASI n(%) 2 160 (25.9) <=7 302 (48.9) 3 458 (74.1) >7 316 (51.1) The efficacy population consisted of 631 patients for TRuE-ADl (all randomized patients) and 577 patients for TRuE-AD2 (vehicle, n=118; 0.75% twice daily, n=231; 1.5% twice daily, n=228). All patients who received >1 dose of treatment (all randomized patients) were included in the safety population in both studies. A summary of the primary and primary secondary efficacy endpoints for TRuEADl (Study 303) and TRuE-AD2 (Study 304) is shown in Tables 12 and 13. Table 12 Vehicle 0.75% BID 1.5% BID N 126 252 253 IGA-TS 15.1% 50% ** 53.8% ** EASI75 24.6% 56.0% ** 62.1%** ITCH4 15.4% 40.4% ** 52.2% **A PROMIS6 8b 9.5 % 21% * 22.3% * 262 PROMIS6 8a 13.2% 20.2% 21.6% αίταζηη / ζζηζ / Ε / γΐι ** ρ <0.0001, Rux vs vehicle; * p <0.01 Rux vs vehicle;Λp =0.04, 1.5% BID vs 0.75% BID Table 13 Vehicle 0.75% BID 1.5% BID N 118 231 228 IGA-TS 7.6% 39.0% ** 51.3%**M EASI75 14.4% 51.5%** 61.8% **A ITCH4 16.3% 42.7% ** 50.7% ** PROMIS6 8b 19.1% 20.7% 25.6% PROMIS6 8a 13.5% 20.0% 23.1% ** p < 0.0001, Rux vs vehicle; * p <0.01 Rux vs vehicle;Λp =0.04, 1.5% BID vs 0.75% BID In TRuE-DA 1 and TRuE-AD2, respectively, significantly more patients treated with ruxolitinib cream achieved treatment success with IGA (0.75% BID, 50.0% and 39.0%; 1.5% BID, 53.8% and 51.3%) vs. vehicle (15.1% and 7.6%, all P<0.0001) (figure 11). EASI-75 was achieved in 56.0% and 51.5% of patients applying ruxolitinib cream 0.75% twice daily, as well as 62.1% and 61.8% with 1.5% twice daily vs 24.6% % and 14.4% with vehicle (all P<0.0001) in TRuE-ADl and TRuE-AD2, respectively 263 (figure 12). In TRuEADl (study 303), Eczema Area and Severity Index scores decreased over time with a clear separation for both active treatment groups from the vehicle treatment group at week 2. In TRuE-ADl (study 303) and TRuE-AD2 (study), Eczema Area and Severity Index scores decreased over time with a clear separation for both active treatment groups from the vehicle treatment group at week 2 (see Figures 31, 32 and 33). In both studies, patients who applied ruxolitinib cream (0.75% twice daily or 1.5% twice daily) achieved statistically significant reductions in itch (NRS4) compared to vehicle at Week 8 (Figure 13; results). numbers are for patients with an initial itch NRS score > 4). In addition to achieving a sustained reduction in itch at Week 8, patients who applied ruxolitinib cream (0.75% twice daily or 1.5% twice daily) also experienced rapid reduction in itch within 1 to 2 days (Figures 14 and 15; Table 14 (TRuE-ADl; mean initial itch NRS score 6.39, 6.44 and 6.45 for vehicle, 0.75% BID and 1.5% BID, respectively); Table 15 (TRuE-AD2; mean initial itch NRS score 6.42, 6.38 and 6.38 for vehicle, 0.75% BID, and 1.5% twice a day, α^αζηη / ζζηζ / Β / γι 264 respectively); numbers are for patients with an initial itch NRS score > 4). α^αζηη / ζζηζ / Β / γΐί Table 14 Mean change from Vehicle Day NRS score 0.75% BID p-value 1.5% BID p-value N 78 156 161 1 -0.21 -0.61 -0.60 2 -0.11 -1.43 <0.0001 -1.66 <0.0001 3 -0.46 -1.81 <0.0001 -2.05 <0.0001 4 -0.38 -2.21 <0.0001 -2.45 <0.0001 5 -0.5 -2.14 <0.0001 -2.66 <0.0001 6 -0.88 -2.20 <0.0001 -2.79 <0.0001 7 -0.88 -2.33 <0.000 1 -2.88 <0.0001 14 - 1.32 -3.12 <0.0001 -3.66 <0.0001 21 -1.40 -3.38 <0.0001 -4.06 <0.0001 28 -1.49 -3.47 <0.0001 -4.46 <0.0001 35 -1.91 -3.65 <0.0001 -4.73 <0.0 001 42 -1.83 -3.51 <0.0001 - 4.52 <0.0001 49 -2.22 -3.65 <0.0001 -4.80 <0.0001 56 -2.16 -3.52 <0.0001 -4.64 <0.0001 *p value between ruxolitinib cream group and vehicle 265 Table 15 α^αζηη / ζζηζ / Β / γι Mean Change from NRS Onset Itch Score Day Vehicle 0.75% BID p-value 1.5% BID p-value N 80 157 146 1 -0.10 -0.48 0.0598 -0.60 0.0159 2 -0.10 -1.29 <0.0001 -1.42 <0.0001 3 - 0.22 -1.67 <0.0001 -1.82 <0.0001 4 -0.03 -1.90 <0.0001 -2.23 <0.0001 5 -0.33 -1.99 <0.0001 -2.25 <0.0001 6 -0.23 -2.30 <0.0001 -2.27 <0.0001 7 -0.26 -2.41 <0.0001 - 2.51 <0.0001 14 -1.22 -3.02 <0.0001 -3.36 <0.0001 21 -1.24 -3.43 <0.0001 -3.65 <0.0001 28 -1.53 ​​-3.52 <0.0001 -3.61 <0.0001 35 -1.59 -3.94 < 0.0001 -3.80 <0.0001 42 -1.59 -3.95 <0.0001 -3.87 <0.0001 49 -1.70 -3.94 <0.0001 -3.82 <0.0001 56 -1.77 -3.88 <0.0001 -3.89 <0.0001 *p value between ruxolitinib cream group and vehicle In both TRuE-DA 1 and TRuE-AD2, a significantly greater reduction in itch was observed compared to vehicle on day 2 (within 12 hours after 266 to the first application of ruxolitinib cream) for patients who received ruxolitinib cream 1.5% twice daily (Table 16 (TRuEADl) and Table 17 (TRuE-AD2), measured for the entire patient population). The mean initial itch NRS score for vehicle, 0.75% BID, and 1.5% BID for Table 16 was 5.06, 5.13, and 5.15, respectively. The mean initial itch NRS score for vehicle, 0.75% BID, and 1.5% BID for Table 17 was 5.25, 5.15, and 5.02, respectively. On day 2 (within 36 hours of the first application of ruxolitinib cream), patients achieved significantly greater itch reduction with ruxolitinib cream 0.75% twice daily in both studies. Table 16 Mean Change from NRS Itch Score of Day Vehicle 0.75% BID p-value 1.5% BID p-value N 126 252 253 1 -0.09 -0.41 0.0512 -0.48 0.0161 2 -0.03 -1.12 <0.0001 -1.27 <0.0001 3 -0.09 -1.49 <0.0001 -1.61 <0.0001 4 0.06 -1.33 <0.0001 -1.90 <0.0001 5 -0.16 -1.78 <0.0001 -2.07 <0.0001 6 -0.45 -1.81 <0.0001 -2.18 <0.0001 267 7 -0.43 -1.93 <0.0001 -2.23 <0.0001 14 -0.78 -2.60 <0.0001 -2.81 <0.0001 21 -0.98 -2.72 <0.0001 -3.08 <0.0001 28 -1.03 -2.81 <0.0001 -3.39 <0 .0001 35 -1.32 -2.99 < 0.0001 -3.69 <0.0001 42 -1.24 -2.83 <0.0001 -3.44 <0.0001 49 -1.41 -2.98 <0.0001 -3.65 <0.0001 56 -1.51 -2.97 <0.0001 -3.53 <0.0001 * p-value between ruxolitinib cream and vehicle group Table 17 Mean Change from NRS Itch Score of Day Vehicle 0.75% BID p-value 1.5% BID p-value N 118 231 228 1 -0.12 -0.35 0.1713 -0.48 0.0290 2 -0.08 -1.12 <0.0001 -1.21 <0.0001 3 -0.20 -1.42 <0.0001 -1.45 <0.0001 4 -0.02 -1.60 <0.0001 -1.81 <0.0001 5 -0.24 -1.65 <0.0001 -1.84 <0.0001 6 -0.22 -1.94 <0.0001 -1.83 <0.0001 7 -0. 24 -2.00 <0.0001 -2.07 <0.0001 14 -0.94 -2.52 <0.0001 -2.75 <0.0001 268 21 -1.00 -2.79 <0.0001 -2.95 <0.0001 28 -1.09 -2.89 <0.0001 -2.88 <0.0001 35 -1.29 -3.15 <0.0001 -3.10 <0.0001 42 -1.23 -3.21 <0.0001 -3.03 < 0.0001 49 -1.40 -3.13 < 0.0001 -3.01 <0.0001 56 -1.33 -3.04 <0.0001 -3.17 <0.0001 *p value between ruxolitinib cream group and vehicle Pooled data from the TRuE-AD1 and TRuE-AD2 studies for the mean change from baseline in daily itch NRS score are shown in Table 18 and Figure 25. The p-values ​​show that the differences for the Ruxolitinib cream 0.75% and 1.5% become significant on day 1 (within 12 hours). The mean change from baseline in daily itch NRS score at day 1 (within 12 hours) for ruxolitinib 0.75% and 1.5% cream is -0.38 and 0.48, respectively. The mean change from baseline in daily itch NRS score at day 2 (within 36 hours) for ruxolitinib 0.75% and 1.5% cream is -1.12 and -1.24, respectively. 269 Table 18 α^αζηη / ζζηζ / Β / γι Mean Change from Baseline in Daily Itch NRS Score Vehicle Day 0.75% BID p-value 1.5% BID p-value 1 -0.10 -0.38 0.0180 -0.48 0.0011 2 -0.06 -1.12 <0.0001 -1.24 <0.0001 3 -0.14 - 1.45 <0.0001 -1.53 ​​<0.0001 4 0.02 -1.72 <0.0001 -1.86 <0.0001 5 -0.20 -1.72 <0.0001 -1.96 <0.0001 6 -0.34 -1.87 <0.0001 -2.01 <0.0001 7 -0. 34 -1.97 <0.0001 -2.15 <0.0001 8 -0.53 -2.09 <0.0001 -2.30 <0.0001 9 -0.53 -2.13 <0.0001 -2.36 <0.0001 10 -0.66 -2.19 <0.0001 -2.39 <0.0001 11 -0.67 -2.17 <0.0001 -2.45 <0. 0001 12 -0.75 -2.38 < 0.0001 -2.59 <0.0001 13 -0.86 -2.46 <0.0001 -2.67 <0.0001 14 -0.86 -2.56 <0.0001 -2.78 <0.0001 15 -0.91 -2.54 <0.0001 -2.92 <0.0001 16 -1.0 0 -2.58 <0.0001 -2.97 <0.0001 17 -0.96 -2.63 <0.0001 -2.93 <0.0001 18 -0.94 -2.68 <0.0001 -3.03 <0.0001 19 -1.04 -2.64 <0.0001 -3.09 <0.0001 270 20 -1.08 -2.66 <0.0001 -3.11 <0.0001 21 -0.99 -2.75 <0.0001 -3.02 <0.0001 22 -1.09 -2.78 <0.0001 -3.18 <0.0001 23 -0.97 -2.74 <0.0001 -3.05 < 0.0001 24 -1.01 -2.78 < 0.0001 -3.05 <0.0001 25 -1.05 -2.78 <0.0001 -3.17 <0.0001 26 -0.95 -2.79 <0.0001 -3.11 <0.0001 27 -1.06 -2.75 <0.0001 -3.06 <0.0001 28 -1.0 6 -2.85 <0.0001 -3.16 <0.0001 In patients with a baseline NRS itch score >2, the number of responders achieving >2 point improvement in NRS itch score became statistically significant on day 2 (within 36 hours of first application of ruxolitinib in cream) for patients receiving 0.75% and 1.5% ruxolitinib cream twice daily (Table 19 (TRuE-ADl) and Table 20 (TRuEAD2). Table 19 Participants achieving > 2 point reduction in NRS Itch Score - Day Vehicle 0.75% BID p-value 1.5% BID p-value 1 9 of 96 (9.4%) 31 of 201 (15.4%) 0.2030 28 of 207 (13.5% ) 0.4099 2 8 of 95 (8.4%) 64 of 197 (32.5%) <0.0001 78 of 199 (39.2%) <0.0001 3 16 of 97 (16.5%) 72 of 195 (36.9%) 0.0003 91 of 199 (45.7% ) <0.0001 271 4 13 of 95 (13.7%) 96 of 199 (48.2%) <0.0001 105 of 198 (53.0%) <0.0001 5 12 of 94 (12.8%) 92 of 193 (47.7%) <0.0001 115 of 198 (58.1%) <0.0001 6 22 of 92 (23.9%) 99 of 192 (51.6%) <0.0001 121 of 203 (59.6%) <0.0001 7 19 of 93 (20.4%) 101 of 194 (52.1%) <0.0001 116 of 203 (57.4) %) <0.0001 8 20 of 91 (22.0%) 108 of 194 (55.7%) <0.0001 116 of 200 (58.0%) <0.0001 9 23 of 91 (25.3%) 115 of 188 (61.2%) <0.0001 115 of 197 (58.4%) <0.0001 10 23 of 90 (25.6%) 110 of 188 (58.5%) <0.0001 123 of 191 (64.4%) <0.0001 11 24 of 87 (27.6%) 110 of 179 (61.5%) <0.0001 121 of 187 (64.7%) <0.0001 12 24 of 89 (27.0%) 121 of 188 (64.4%) <0.0001 119 of 184 (64.7%) <0.0001 13 28 of 91 (30.8%) 119 of 193 (61.7%) < 0.0001 129 of 193 (66.8%) <0.0001 14 26 of 92 (28.3%) 124 of 189 (65.6%) <0.0001 134 of 196 (68.4%) <0.0001 QbQZnn / 77nZ / E / Yli Table 20 Participants who achieved a reduction of > 2 points in Vehicle Day NRS score 0.75% BID p-value 1.5% BID p-value 1 4 of 92 (4.3%) 30 of 174 (17.2%) 0.0032 22 of 175 (12%) 0.0447 2 7 of 91 (7.7%) 51 of 180 (28.3%) <0.0001 51 of 172 (29.7%) <0.0001 3 12 of 88 (13.6%) 59 of 174 (33.9%) 0.0004 64 of 170 (37.6%) < 0.0001 4 10 of 88 (11.4%) 59 of 166 (35.5%) <0.0001 81 of 172 (47.1%) <0.0001 5 12 of 89 (13.5%) 76 of 172 (44.2%) <0.0001 80 of 170 (47.1% ) <0.0001 6 10 of 87 (11.5%) 81 of 167 (48.5%) <0.0001 82 of 170 (48.2%) <0.0001 7 13 of 92 (14.1%) 89 of 172 (51.7%) <0.0001 94 of 175 ( 53.7%) <0.0001 272 8 13 of 90 (14.4%) 96 of 174 (55.2%) <0.0001 97 of 171 (56.7%) <0.0001 9 13 of 84 (15.5%) 94 of 170 (55.3%) <0.0001 88 of 165 (53.3%) <0.0001 10 18 of 90 (20.0%) 93 of 166 (56.0%) <0.0001 95 of 165 (57.6%) <0.0001 11 17 of 87 (20.2%) 94 of 174 (54.0%) <0.0001 94 of 167 (56.3) %) <0.0001 12 21 of 90 (23.3%) 100 of 172 (58.1%) <0.0001 104 of 164 (63.4%) <0.0001 13 20 of 86 (23.3%) 100 of 167 (59.9%) <0.0001 102 of 166 (61.4%) <0.0001 14 24 of 88 (27.3%) 105 of 170 (61.8%) <0.0001 107 of 170 (62.9%) <0.0001 In patients with a baseline NRS itch score >2, the number of responders achieving >2 point improvement in NRS itch score became statistically significant on day 2 (within 36 hours of first application of ruxolitinib in cream) for patients receiving 0.75% and 1.5% ruxolitinib cream twice daily (Table 21 (TRuE-DA and TRuE-AD2)). The difference between ruxolitinib cream 0.75% and 1.5% versus vehicle became statistically significant on day 1 (within 12 hours). Table 21 Participants who achieved a reduction of > 2 points in Vehicle Day NRS score 0.75% BID p-value 1.5% BID p-value 1 13 of 188 (0.7%) 61 of 375 (2.7%) 0.0021 50 of 382 (3.1%) 0.0300 2 15 of 186 (8.1%) 115 of 377 (30.5%) <0.0001 129 of 371 (34.8%) <0.0001 273 3 28 of 185 (15.1%) 131 of 369 (35.5%) <0.0001 155 of 369 (42.0%) <0.0001 4 23 of 183 (12.6%) 155 of 365 (42.5%) <0.0001 186 of 370 (50.3%) <0.0001 5 24 of 183 (13.1%) 168 of 365 (46.0%) <0.0001 195 of 368 (53.0%) <0.0001 6 32 of 179 (17.9%) 180 of 359 (50.1%) <0.0001 203 of 373 (54.4) %) <0.0001 7 32 of 185 (17.3%) 190 of 366 (51.9%) <0.0001 210 of 377 (55.7%) <0.0001 Qfraznn / zznz / E / Yii In patients with a baseline NRS itch score of > 4, the number of responders achieving a > 4 point improvement in NRS itch score became statistically significant on day 4 of the first ruxolitinib cream application for patients receiving received ruxolitinib cream 0.75% BID and on day 3 of the first application of ruxolitinib cream for patients who received ruxolitinib cream 1.5% BID (Table 22 (TRuE-ADl and TRuE-AD2 and Figure 26)). Table 22 Participants who achieved > 4 point reduction in Vehicle Day NRS Score 0.75% BID p-value 1.5% BID p-value 1 1 of 144 (0.7%) 8 of 291 (2.7%) 0.0807 9 of 288 (3.1%) 0.1290 2 3 of 145 (2.1%) 26 of 293 (8.9%) 0.0042 31 of 277 (11.2%) 0.0012 3 3 of 142 (2.1%) 38 of 286 (13.3%) 0.0002 44 of 276 (15.9%) <0.0001 4 4 of 142 (2.8%) 51 of 285 (17.9%) <0.0001 64 of 277 (23.1%) <0.0001 5 5 of 141 (3.5%) 55 of 285 (19.3%) <0.0001 67 of 275 (24.4%) < 0.0001 6 8 of 140 (5.7%) 62 of 279 (22.2%) <0.0001 78 of 277 (28.2%) <0.0001 274 7 10 of 142 (7.0%) 68 of 281 (24.2%) <0.0001 86 of 283 (30.4%) <0.0001 Patients achieve an IGA score of 0 or 1 at Week 2 for patients receiving ruxolitinib cream 0.75% and 1.5% twice daily in the TRuE-ADI study (Table 23). Patients achieve an IGA score of 0 or 1 at Week 2 for patients receiving ruxolitinib 1.5% cream twice daily and at Week 4 for patients receiving ruxolitinib 0.75% cream twice daily on the TRuE-AD2 study (Table 24). Table 23 Participants achieving an IGA score of 0 or 1 - Vehicle Week Number 0.75% BID p-value 1.5% BID p-value 2 8 of 126 (6.3%) 82 of 252 (32.5%) <0.0001 88 of 253 (34.8%) <0.0001 4 19 of 126 (15.1%) 134 of 252 (53.2%) <0.0001 139 of 253 (54.9%) <0.0001 8 30 of 126 (23.8%) 148 of 252 (58.7%) <0.0001 159 of 253 (62.8 %) <0.0001 Table 24 Participants achieving an IGA score of 0 or 1 - Vehicle Week Number 0.75% BID p-value 1.5% BID p-value 2 11 of 118 (9.3%) 56 of 231 (24.2%) 0.0008 79 of 228 (34.6%) < 0.0001 4 20 of 118 (16.9%) 106 of 231 (45.9%) <0.0001 120 of 228 (52.6%) <0.0001 8 19 of 118 (16.1%) 118 of 231 (51.1%) <0.0001 142 of 228 (62.3% ) <0.0001 275 Patients achieve EASI90 for patients receiving 0.75% and 1.5% ruxolitinib cream twice daily (Table 25 (TRuE-A...

Claims

CLAIMS Having described the invention as above, the following claims are claimed as property:

1. A method for treating moderate atopic dermatitis in a human patient, characterized in that it comprises administering to the skin of the human patient in need a topical formulation twice a day, wherein the topical formulation comprises 1.5% (w / w) on a freebase base of ruxolitinib, or one of its pharmaceutically acceptable salts.

2. The method according to claim 1, characterized in that the patient: is an adolescent aged > 12 to 17 years inclusive, or a male or female aged 1 to 18 years; and has been diagnosed with atopic dermatitis for at least 2 years.

3. The method in accordance with any of claims 1-2, characterized in that the patient has a Body Surface Area affected by atopic dermatitis of 10% to 20% at the start of the study.

4. The method in accordance with any of claims 1-3, characterized in that the patient has an Eczema Area and Severity Index score of > 285 16 at the start of the study.

5. The method in accordance with any of claims 1-4, characterized in that the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from the initial value.

6. The method according to any of claims 1-5, characterized in that the patient achieves a 75% improvement in the Eczema Area and Severity Index score from the initial value.

7. The method according to any of claims 1-6, characterized in that the patient achieves at least a 4-point improvement in the Numerical Rating Scale score for itching from the initial value, and wherein the patient has a score on the reference Numerical Rating Scale equal to or greater than 4.

8. The method according to any of claims 1-7, characterized in that the patient achieves: a score of 0 or 1 on the Investigator Global Assessment with an improvement of at least 2 points from the baseline value; a 4-point improvement in the itch Numerical Rating Scale 286 score from the baseline value, wherein the patient has a baseline Numerical Rating Scale score equal to or greater than 4; and a 75% improvement in the Eczema Area and Severity Index score from the baseline value.

9. The method according to any of claims 1-8, characterized in that the patient achieves: a score of 0 or 1 on the Investigator Global Assessment with an improvement of at least 2 points from the baseline value at Week 4; a 4-point improvement in the Numerical Rating Scale score for itching from the baseline value at Week 4, wherein the patient has a Numerical Rating Scale score from the baseline value equal to or greater than 4; and a 75% improvement in the Eczema Area and Severity Index score from the baseline value at Week 4.

10. The method according to any of claims 1-9, characterized in that the patient achieves: a score of 0 or 1 on the Investigator Global Assessment with an improvement of at least 2 points from the baseline value at Week 8; a 4-point improvement in the Numerical Rating Scale score for itching from the baseline value at Week 8, wherein the patient has a Numerical Rating Scale score from the baseline value equal to or greater than 4; and a 75% improvement in the Eczema Area and Severity Index score from the baseline value at Week 8.

11. The method in accordance with any of claims 1-10, characterized in that the patient achieves at least a 2-point improvement in the Numerical Rating Scale score for itching from the baseline value on day 2 of administration.

12. A method for treating atopic dermatitis in a human patient, characterized in that it comprises administering to the skin of the human patient in need a topical formulation twice daily, wherein the topical formulation comprises 1.5% (w / w) on a phosphate-free base of ruxolitinib, wherein the patient: is 12 years of age or older; has a Body Surface Area affected by atopic dermatitis of 10% to 20% at baseline; and has a score of 3 on the Investigator Global Assessment at baseline.

13. The method according to claim 12, characterized in that the patient: 288 is an adolescent aged 12 to 17 years inclusive, or a male or female aged 1 to 18 years; and has been diagnosed with atopic dermatitis for at least 2 years.

14. The method in accordance with any of claims 12-13, characterized in that the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from the initial value.

15. The method according to any of claims 12-14, characterized in that the patient achieves a 75% improvement in the Eczema Area and Severity Index score from the initial value.

16. The method according to any of claims 12-15, characterized in that the patient achieves at least a 4-point improvement in the Numerical Rating Scale score for itching from the initial value, and wherein the patient has a Numerical Rating Scale score from the initial value equal to or greater than 4.

17. The method according to any of claims 12-13, characterized in that the patient achieves: a score of 0 or 1 on the Investigator Global Assessment with an improvement of at least 2 points from the baseline value; a 4-point improvement in the Numerical Rating Scale score for itching from the baseline value, wherein the patient has a baseline Numerical Rating Scale score equal to or greater than 4; and a 75% improvement in the Eczema Area and Severity Index score from the baseline value.

18. The method according to any of claims 12-13, characterized in that the patient achieves: a score of 0 or 1 on the Investigator Global Assessment with an improvement of at least 2 points from the baseline value at Week 4; a 4-point improvement in the Numerical Rating Scale score for itching from the baseline value at Week 4, wherein the patient has a Numerical Rating Scale score from the baseline value equal to or greater than 4; and a 75% improvement in the Eczema Area and Severity Index score from the baseline value at Week 4.

19. The method according to any of claims 12-13, characterized in that the patient achieves: a score of 0 or 1 on the Investigator Global Assessment 290 with an improvement of at least 2 points from the baseline value at Week 8; a 4-point improvement in the Numerical Rating Scale score for itching from the baseline value at Week 8, wherein the patient has a Numerical Rating Scale score from the baseline value equal to or greater than 4; and a 75% improvement in the Eczema Area and Severity Index score from the baseline value at Week 8.

20. The method according to any of claims 1-19, characterized in that the topical formulation is a cream formulation.

21. A method for reducing itching in a human patient with atopic dermatitis, characterized in that it comprises administering to the skin of the human patient in need, a cream formulation twice daily, wherein the cream formulation comprises 1.5% (w / w) on a free base of ruxolitinib, or one of its pharmaceutically acceptable salts; wherein the patient achieves a statistically significant reduction in the Numerical Rating Scale score for itching from baseline within 36 hours of administration.

22. A method for treating atopic dermatitis in a human patient, characterized in that it comprises administering to the skin of the human patient in need, a cream formulation twice a day, wherein the cream formulation comprises 0.75% (w / w) on a free base of ruxolitinib, or one of its pharmaceutically acceptable salts.

23. The method according to claim 21 or 22, characterized in that the patient achieves a score of 0 or 1 on the Investigator's Global Assessment with an improvement of at least 2 points from the initial value.

24. The method according to any of claims 21-23, characterized in that the patient achieves a score of 0 or 1 on the Investigator Global Assessment with an improvement of at least 2 points from the baseline value at week 8 of administration.

25. The method according to any of claims 21-24, characterized in that the patient achieves a 75% improvement in the Eczema Area and Severity Index score from the initial value.

26. The method according to any of claims 21-25, characterized in that the patient achieves a 75% improvement in the Eczema Area and Severity Index score from baseline at week 8 of administration. 292 27. The method according to any of claims 21-26, characterized in that the patient achieves at least a 4-point improvement in the Numerical Rating Scale score for itching from the initial value.

28. The method according to any of claims 21-27, characterized in that the patient achieves at least a 4-point improvement in the Numerical Rating Scale score for itching from the initial value, and wherein the patient has a Numerical Rating Scale score from the initial value equal to or greater than 4.

29. The method according to any of claims 21-28, characterized in that the patient achieves at least a 4-point improvement in the Numerical Rating Scale score for itching from baseline at week 8 of administration, and wherein the patient has a Numerical Rating Scale score from baseline equal to or greater than 4.

30. The method according to any of claims 21-29, characterized in that the administration is maintained for at least 8 weeks.

31. The method according to any of claims 21-30, characterized in that patient 293 is 12 years of age or older.

32. The method according to any of claims 21-31, characterized in that the patient has a Body Surface Area (BSA) affected by atopic dermatitis (excluding the scalp) of 3% to 20% at the start of the study.

33. The method in accordance with any of claims 21-32, characterized in that the patient has an Investigator Global Assessment score of 2 to 3 at the start of the study.

34. A method for reducing itching in a human patient with atopic dermatitis, characterized in that it comprises administering to the skin of the human patient in need, a cream formulation twice a day, wherein the cream formulation comprises 1.5% (w / w) on a free base of ruxolitinib, or one of its pharmaceutically acceptable salts.

35. The method according to claim 34, characterized in that the patient achieves at least a 1 point reduction in the Numerical Rating Scale score for itching on day 2 of administration.

36. The method according to claims 34-35, characterized in that the patient achieves at least a 2-point reduction in the 294 Numerical Rating Scale for itching score in week 1 of administration.

37. The method according to any of claims 34-36, characterized in that the patient achieves a reduction of at least 3 points in the Numerical Rating Scale score for itching by week 3 of administration.

38. The method according to any of claims 34-37, characterized in that the patient achieves a clinically significant minimum difference in the Numerical Rating Scale for itch score within 36 hours of administration, wherein the clinically significant minimum difference in the Numerical Rating Scale for itch score is a reduction of 2 to 3 points in the Numerical Rating Scale for itch score compared to the baseline value, wherein the patient has a Numerical Rating Scale score from the baseline value equal to or greater than 2.

39. The method according to any of claims 34-38, characterized in that the patient achieves a clinically relevant improvement in the Numerical Rating Scale for itch score within 36 hours of administration, wherein the clinically relevant improvement in the Numerical Rating Scale for itch score is a reduction of > 4 points in the Numerical Rating Scale for itch score from baseline, wherein the patient has a Numerical Rating Scale score from baseline equal to or greater than 4.